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SUMMARY 
Pharmacoepidemiology has been defined as the study of the uses and the effects of 
drugs in large numbers of people and is important for the surveillance of drugs after 
marketing. With the recent movement from a reactive to a rather proactive 
pharmacovigilance, (pharmaco)epidemiological research plays an increasing role in 
basically all stages of the drug development process. Data on the disease planned to 
be treated with a new drug have to be gained which can be useful e.g. for the risk-
benefit analysis of that compound (e.g. for the comparison of rates of adverse events 
in the treated population with the disease with rates of such events in the untreated 
population with the disease). Additionally, good knowledge of diseases is valuable for 
daily clinical practice. Hence, apart from the classical drug safety studies, 
pharmacoepidemiology groups conduct more and more disease epidemiology or 
drug utilisation studies in order to learn more about the natural history of diseases. 
The aim of this thesis was to increase the knowledge of psoriasis by providing new 
information and complementing existing data. Psoriasis is a chronic inflammatory 
skin disease which is common in certain parts of the world. The gain of new insights 
into the pathogenesis of this disease has prompted the recent development of new 
therapeutic drugs, primarily biologicals, and vice versa. 
The studies of this thesis were conducted with data from the General Practice 
Research Database, which contains longitudinal primary care clinical records from 
several million patients representative of the United Kingdom population. The general 
practitioners have been trained to record information on patient demographics and 
characteristics, lifestyle factors, symptoms, medical diagnoses, referrals to hospitals 
or specialists, and therapies in a standard and anonymous way. Several hundred 
studies have been conducted using this extensively validated database.  
In the first three case-control studies, the influence of beta-blockers and other 
antihypertensives (Study 3.1), of lithium and antipsychotics (Study 3.2), and of 
thiazolidinediones and other antidiabetics (Study 3.3) on the risk of developing 
psoriasis were investigated. The study population consisted of 36,702 patients with a 
first-time psoriasis diagnosis between 1994 and 2005 and the same number of 
patients without psoriasis, matched on age, sex, index date, general practitioner, and 
history in the database. Exposure to the drug classes was evaluated taking duration 
and timing of use and potential confounding into account. In contrast to the notion in 
the literature (including standard dermatology textbooks), which was mainly based on 
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data from case reports and case series, use of beta-blockers and other 
antihypertensives did not materially alter the risk of incident psoriasis. On the 
contrary, the second study confirmed the suggestion that long-term exposure to 
lithium can induce psoriasis. Furthermore, for atypical antipsychotics, primarily 
olanzapine, a statistically significantly decreased psoriasis risk was found for current 
exposure of longer duration. This observation needs further confirmation. Small 
clinical trials had shown potential clinical benefits of thiazolidinediones on psoriasis 
symptoms. Study 3.3 additionally suggested that longer-term exposure to 
thiazolidinediones reduces the risk of developing psoriasis. The risk also tended to 
be decreased after use of metformin, however, this needs further investigation. 
Studies 3.4 to 3.6 were cohort studies with a nested case-control analysis in which 
the study population defined for Studies 3.1 to 3.3 (= cohort population) was followed 
for identification of incident diabetes mellitus (Study 3.4), myocardial infarction (MI) or 
stroke / transient ischaemic attack (TIA) (Study 3.5), and cancer (Study 3.6) in 
patients with or without psoriasis. Incidence rates (IRs) and unadjusted incidence 
rate ratios (IRRs) were calculated. In the nested case-control analysis, patients with 
the outcome of interest were matched on age, sex, and index date to four control 
patients from the cohort population, and the psoriasis history stratified by duration 
and severity (using treatment as proxy) was compared by calculating adjusted odds 
ratios (ORs). The overall diabetes IR in psoriatic patients was about 35% higher than 
in psoriasis-free patients. Psoriasis patients with intensive systemic treatment for 
their skin disease and a disease history of longer duration showed an about 2.5 times 
increased risk of diabetes compared to psoriasis-free patients. For MI and stroke / 
TIA the overall risk was not increased, but further analyses showed increased risks in 
subpopulations (e.g. severe psoriasis patients or patients <60 years of age [for MI]). 
The risk of lymphohaematopoietic or certain types of solid cancers was statistically 
significantly increased in patients with psoriasis, for solid cancers primarily in patients 
with a longer-term disease history. 
These large population-based studies further analysed existing hypotheses and 
raised new ones. The results may be valuable for healthcare professionals in their 
daily clinical practice and for pharmaceutical companies in the risk-benefit analysis of 
their drugs. Additionally, the example of the association between use of beta-
blockers and psoriasis showed that there should be no place for dogmas in medicine 
and that conclusions can be challenged. 
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ZUSAMMENFASSUNG 
Die Pharmakoepidemiologie studiert die Anwendung und Effekte von Medikamenten 
in grossen Patientenpopulationen und ist wichtig für die Arzneimittelüberwachung. 
Da diese vermehrt proaktiv (nicht nur reaktiv) handelt, spielt die 
(pharmako)epidemiologische Forschung eine immer bedeutendere Rolle in der 
Entwicklung eines Medikamentes. Die Verfügbarkeit von Daten über die zu 
behandelnde Krankheit ist z.B. wichtig für die Nutzen-Risikoanalyse eines neuen 
Medikaments (z.B. Vergleich von Nebenwirkungsraten in der behandelten 
Bevölkerung mit der Erkrankung mit Raten solcher Ereignisse in der unbehandelten 
Bevölkerung mit der Erkrankung). Ausserdem ist ein breites Wissen über 
Erkrankungen von Bedeutung für den klinischen Alltag. Pharmakoepidemiologische 
Gruppen führen deshalb neben klassischen Sicherheitsstudien zu Medikamenten 
auch Studien zur Epidemiologie von Krankheiten und Medikamentengebrauch durch. 
Das Ziel dieser Arbeit war es, das Wissen über Psoriasis durch neue Informationen 
und Ergänzung vorhandener Daten zu vergrössern. Psoriasis ist eine chronische 
inflammatorische Hauterkrankung, die in gewissen Teilen der Welt häufig vorkommt. 
Neue Erkenntnisse über den Pathomechanismus haben in letzter Zeit zur 
Markteinführung neuer Medikamente geführt (v.a. Biologika) und umgekehrt. 
Die Daten für die Studien dieser Arbeit stammten von der General Practice Research 
Database, einer Datenbank, die Hausarztdaten von mehreren Millionen Patienten in 
England enthält und repräsentativ für die Bevölkerung ist. Die Hausärzte wurden 
ausgebildet, Daten zu Demographie, Lebensstil, Diagnosen, Überweisungen und 
Therapien der Patienten anonymisiert und standardisiert zu erfassen. Mehrere 
hundert Studien wurden auf dieser validierten Datenbank bereits durchgeführt. 
In den Fall-Kontrollstudien 3.1-3.3 wurde der Einfluss von Betablockern und anderen 
Antihypertensiva (Studie 3.1), von Lithium und Antipsychotika (Studie 3.2) und von 
Glitazonen und anderen Antidiabetika (Studie 3.3) auf das Risiko, Psoriasis zu 
entwickeln, untersucht. Die Studienpopulation bestand aus 36'702 Patienten mit 
einer Erstdiagnose von Psoriasis zwischen 1994 und 2005 und 36'702 
Kontrollpatienten, die auf Alter, Geschlecht, Indexdatum, Hausarzt und Jahre auf der 
Datenbank gematcht waren. Die Medikamentenexposition wurde, stratifiziert nach 
Dauer und Zeitpunkt der Einnahme und adjustiert auf potentielle Störfaktoren, 
untersucht. Im Gegensatz zu gängigen Angaben in der Literatur (inkl. 
Standardliteratur der Dermatologie), welche v.a. auf Daten von Fallberichten und -
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serien beruhen, beeinflussten Betablocker und Antihypertensiva das Psoriasisrisiko 
nicht. Die zweite Studie hingegen bestätigte die Annahme, dass langzeitige 
Einnahme von Lithium Psoriasis induzieren kann. Ausserdem konnte für eine 
Langzeiteinnahme von atypischen Antipsychotika, v.a. Olanzapin, ein statistisch 
signifikanter protektiver Effekt gezeigt werden. Diese Beobachtung muss weiter 
bestätigt werden. Kleine klinische Studien hatten für Glitazone einen potentiellen 
Nutzen auf Psoriasissymptome gezeigt. Die Resultate der Studie 3.3 zeigten 
zusätzlich einen statistisch signifikanten protektiven Effekt unter Langzeiteinnahme 
von Glitazonen auf das Risiko, Psoriasis zu entwickeln. Auch für Metformin konnte 
eine solche Tendenz gezeigt werden, doch muss dies weiter untersucht werden. 
Die Studien 3.4 bis 3.6 waren Kohortenstudien mit integrierten Fall-Kontroll 
Analysen, in welchen die Studienpopulation (= Kohorte), welche für die Studien 3.1-
3.3 definiert worden war, beobachtet wurde, um Erstdiagnosen von Diabetes (Studie 
3.4), Myokardinfarkt (MI) oder Schlaganfall / transitorische ischämische Attacke (TIA) 
(Studie 3.5) und Krebs (Studie 3.6) in Patienten mit und ohne Psoriasis zu 
identifizieren. Inzidenzraten (IR) und Verhältnisse von IR (IRR) wurden berechnet. In 
der Fall-Kontrollstudie wurden diejenigen Patienten, die die Krankheit entwickelten, 
mit jeweils vier Kontrollpatienten aus der Kohorte, gematcht auf Alter, Geschlecht 
und Indexdatum, in Bezug auf Psoriasisanamnese stratifiziert nach Dauer und 
Schweregrad (Therapie als Proxy) verglichen und die Resultate als adjustierte Odds 
Ratios dargestellt. Die IR von Diabetes war in Psoriasispatienten ca. 35% höher als 
in Kontrollpatienten. Psoriasispatienten, die unter eher intensiver oraler Therapie für 
ihre Hauterkrankung standen und länger an Psoriasis litten, hatten ein ca. 2.5-fach 
erhöhtes Diabetesrisiko. Das Risiko, einen MI oder Schlaganfall / TIA zu erleiden, 
war in Psoriasispatienten generell nicht grösser als in der Kontrollpopulation, gewisse 
Subgruppen zeigten jedoch ein erhöhtes Risiko (z.B. schwere Psoriatiker und 
Patienten <60 Jahre alt [für MI]). Das Risiko, an lymphohämatopoietischen oder 
gewissen soliden Krebsarten zu erkranken, war statistisch signifkant höher in 
Psoriatikern, für solide Krebsarten v.a. in Patienten mit längerer Psoriasisanamnese. 
Diese grossen populationsbezogenen Studien untersuchten existierende Hypothesen 
und warfen neue auf. Die Resultate können hilfreich sein für die tägliche Arbeit von 
Personen im Gesundheitswesen und für die pharmazeutische Industrie. Ausserdem 
zeigte das Beispiel der Assoziation zwischen dem Gebrauch von Betablockern und 
Psoriasis, dass bestehendes Wissen hinterfragt werden sollte. 
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1 INTRODUCTION 
1.1 GENERAL ASPECTS OF PHARMACOEPIDEMIOLOGY 
1.1.1 Pharmacoepidemiology yesterday and today 
Pharmacoepidemiology - the word is composed of pharmaco and epidemiology - 
bridges between clinical pharmacology and epidemiology.1 It is defined as the study 
of the uses and the effects (beneficial and adverse) of drugs in large numbers of 
people1, 2 and uses methods from epidemiology which investigates the distribution of 
disease and health in human populations.2 The discipline has mainly evolved 
because drugs can also cause harm to the population. According to a prospective 
observational study in England, 6.5% of all hospital admissions were due to adverse 
drug reactions, with a fatality rate of 0.15%.3  
Pharmacoepidemiology can support regulatory bodies in their task to protect public 
health by providing safe and efficacious drugs of high quality.1 However, the 
development and marketing of drugs were not regulated strictly from the beginning. 
Disasters such as the death of 100 people from renal failure due to the elixir 
sulfanilimide dissolved in diethylene glycol (1937), the development of aplastic 
anaemia following exposure to chloramphenicol (early 1950s), and mainly the 
‘thalidomide disaster’ with a high increase in the number of babies born with 
phocomelia after maternal use of thalidomide during pregnancy (1961)1 increased 
awareness and finally resulted in today’s strict regulations with three phases of 
clinical testing before marketing of a drug and surveillance of the drug after marketing 
(figure 1.1.1). The beginning of pharmacoepidemiology dates back to the mid-1960s 
when in the United States (US) the Boston Collaborative Drug Surveillance Program 
(BCDSP) and the Johns Hopkins Hospital monitored drug use in the hospital and 
conducted cohort studies to identify risks.1, 4 Postmarketing observational studies as 
well as the collection of spontaneous reports on adverse drug reactions or events in 
the international database of the World Health Organisation (WHO) Collaborative 
Centre for International Drug Monitoring, located in Uppsala, Sweden1, 2 became 
increasingly important, mainly because adverse events which occur seldom or after 
long-term drug exposure can hardly be detected in Phase I-III clinical trials and 
because drugs may be used in different patient populations or other indications (off 
label use) after market launch.1, 2, 5 According to the rule of three the number of 
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subjects needed to detect an adverse event of a certain frequency is three times that 
of the estimated frequency, i.e. if an adverse event occurs with an estimated 
frequency of 1 / 5000, about 15,000 users would need to be observed to detect the 
event with a 95% likelihood.1, 2 
While the focus of pharmacoepidemiology may have been on the postmarketing 
phase in the past, the field is gaining more and more importance in the premarketing 
period (figure 1.1.1).1  
 
 
Figure 1.1.1 Different phases of the drug development process and pharmacoepidemiology2, 6 
 
Population-based studies on the natural history of the disease to be treated by a 
potential new agent (new chemical entity [NCE] in preclinical phase or investigational 
new drug [IND] in phases I-III) in development can provide valuable information on 
the burden and the severity of that disease and the characteristics of the patients 
(e.g. drug use, comorbidities) and give input for the choice of the indication, the 
development process (e.g. planning of interaction studies based on patients’ drug 
use), the market strategy, and also the viability of an entire project. Additionally, 
during phases II, III, and early IV, serious adverse events infrequently observed 
during clinical trials with the IND or early in the postmarketing period can be 
quantified in a population not exposed to the IND to decide if the observed events are 
in the expected range for the population expected to use the drug (= background 
incidence rates). If so, then development programs can be saved, otherwise, 
appropriate actions may be put in place more rapidly.1, 6 Such information as well as 
frequency and characteristics data of the disease to be treated with an IND are – 
according to the International Conference on Harmonisation (ICH) guideline E2E - 
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requested in the safety specification upon submission of a drug license application to 
the authorities.7 Another example where pharmacoepidemiology could have a 
supportive role is in the accelerated approval process of the Food and Drug 
Administration (FDA), the corresponding process of the European Medicines Agency 
(EMEA), the conditional marketing authorisation, or in a similar process of the 
Swissmedic in Switzerland, ‘das beschleunigte Zulassungsverfahren’. Under these 
processes, drugs for serious, debilitating, or life-threatening diseases, emergency 
situations, or for rare diseases (orphan drugs) can receive marketing authorisation 
before the usually required data have been collected or with clinical trials using 
surrogate rather than clinical endpoints.6, 8-10  
Data gained from above-mentioned epidemiological studies, which are often initiated 
by the pharmaceutical industry or regulatory bodies, are of importance for healthcare 
professionals in their daily practice. The more is known about a disease or a drug, 
the better patients can be treated. 
Hence, over the past decades and in a changing regulatory environment, 
pharmacoepidemiology has evolved from the study of adverse reactions of marketed 
drugs to a scientific discipline involved in basically all stages of the development 
process of a drug1 and provides important data on the epidemiology of diseases.  
 
1.1.2 Pharmacoepidemiology and risk management 
While the safety surveillance of drugs has been rather reactive in the past, a 
proactive pharmacovigilance is required today, and risk management is getting more 
and more important. Risk management in general is the identification and 
implementation of strategies to reduce risk to individuals and populations.6 The 
EMEA ‘guideline on risk management systems for medicinal products for human use’ 
defines such a system as a set of pharmacovigilance activities and interventions 
designed to identify, characterise, prevent, or minimise risks relating to medicinal 
products, including the assessment of the effectiveness of those interventions. The 
aim of the system is that the benefits of a drug outweigh its risks.11 It is the art and 
science of getting the right drug to the right patient at the right time.6 According to the 
EMEA guideline,11 a risk management plan (RMP) encompasses a Part I with a 
safety specification and a pharmacovigilance plan (according to the ICH E2E 
guideline) and a Part II with an evaluation of the need for risk minimisation activities 
and a risk minimisation plan if needed. A RMP may have to be submitted at any time 
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of a product’s life-cycle. Pharmacoepidemiological expertise is needed for the 
compilation, implementation, and execution of such a plan (table 1.1.1).  
 
Table 1.1.1 Risk management plan (according to EMEA guideline11) 
P A R T   I P A R T   II 
Safety specification Pharmacovigilance (PV) Plan Risk minimisation plan 
- identified risks 
- potential risks 
- missing information 
- populations potentially 
at risk 
- safety questions 
 
Tools: Apart from 
nonclinical / clinical data, 
information from disease 
epidemiology studies or 
classical pharmaco-
epidemiological studies 
could be helpful 
- Routine PV (collecting of adverse 
event reports) 
- Active surveillance 
 
Tools: sentinel sites, intensive 
monitoring schemes, prescription 
event monitoring, registries, cross-
sectional / cohort / case-control 
studies, clinical trials, disease 
epidemiology studies, drug 
utilisation studies 
Actions taken depending on  
nature and / or seriousness of risk 
(if not adequately addressed by 
PV Plan) 
 
Tools: provision of information, 
educational material, legal status 
of a medicine, control at 
pharmacy level, control of 
prescription size or validity, 
informed consent, restricted 
access programs, patient 
registries (e.g. pregnancy)  
 
Risk management is a complex field which has to constantly examine and balance 
the risks and benefits of a drug, taking into consideration data from the drug 
development process and - after the drug has reached the market - from the 
postmarketing surveillance. Hence, risk management deals on the one hand with 
efficacy data gained from randomised controlled clinical trials according to a strict 
protocol which show if an intervention can accomplish a particular outcome under 
ideal circumstances and on the other hand with (cost-)effectiveness data from mostly 
observational studies which provide information if an intervention does accomplish a 
particular outcome in the real world (figure 1.1.2).2  
 
 
Figure 1.1.2 Efficacy versus effectiveness data (adapted from a presentation by Richard Bergström at the European 
 Centre for Pharmaceutical Medicine (ECPM) course in 2007) 
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As the recent example of natalizumab (Tysabri®) - an α4-integrin-inhibitor for the 
treatment of multiple sclerosis - has shown, a risk minimisation plan can help to re-
introduce a drug on the market after withdrawal due to a serious adverse reaction. 
Natalizumab was taken from the market in 2005 only three months after market 
authorisation in the US due to suspected association with progressive multifocal 
leukoencephalopathy. With the help of the Prescribing Program TOUCHTM, the drug 
is now available on the market again. Prescribers and infusion / distribution centers 
of the drug have to be registered with and patients receiving the drug have to be 
enrolled into the program, and safety surveillance is being conducted.12 
 
1.1.3 Study designs in pharmacoepidemiology 
Epidemiological or clinical research uses a number of different study designs which 
can be separated into descriptive observational and analytical studies (figure 1.1.3).2 
According to the Oxford Centre for Evidence-based Medicine (EBM),13 results from 
randomised controlled trials provide the highest level of evidence for the evaluation of 
an intervention and case reports the lowest (apart from expert opinions). In EBM, 
clinical decisions are based on a process of systematically finding, appraising, and 
using contemporary research findings.14 The above-mentioned hierarchy of strengths 
of research designs has been defined long ago and is well known. In his article on 
observational research and randomised trials, JP Vandenbroucke15 proposed apart 
from the established hierarchy for the  evaluation of interventions the opposite 
direction of the hierarchy for  discoveries and explanations of causes of diseases 
(e.g. due to adverse effects of drugs) (figure 1.1.3). For  evaluation of interventions, 
or in other words to study intended effects of a treatment, randomisation is necessary 
due to the risk of ‘confounding by indication’, meaning the worse the prognosis, the 
more (efficacious) therapy would be given. For  discoveries and explanations of 
causes of diseases or to study unintended, unplanned, or adverse effects of an 
intervention, randomisation is often not necessary because ‘confounding by 
indication’ is seldom an issue due to the unexpectedness and unpredictability of the 
effect.15 Furthermore, randomised controlled trials are rarely used in this approach 
because randomisation is most of the time not possible, e.g. due to ethical reasons.1, 
16
 Both approaches ( and ) are necessary because without  discoveries leading 
to potentially better diagnosis, prevention, or therapy there would be nothing to  
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evaluate or to do randomised controlled trials on and without  evaluation we would 
not know if a  discovery was useful.15 
 
Descriptive observational studies 
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 Case reports 
 Case series 
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Figure 1.1.3. Design strategies in epidemiology or clinical research and two ways of classifying level 
of evidence depending on research area ( evaluation or  discovery / explanation) 2, 15, 16 
 
A frequently criticised point in observational research is the execution of multiple and 
subgroup analyses.15-17 However, these are necessary to make discoveries. Hence, 
the replication of findings with several studies of different designs, with different 
methods of data collection, and with different analyses as well as the assessment of 
the advantages and disadvantages of the individual studies is an important 
cornerstone of observational research.15 For a thorough evaluation of the available 
studies, a correct and complete reporting of observational studies is a requirement. 
Thus, an international group of epidemiologists, methodologists, statisticians, and 
editors have composed and recently published the STROBE (Strengthening the 
Reporting of Observational Studies in Epidemiology) statement, which comprises 
guidelines for the reporting of observational studies,18 similar to the CONSORT 
(Consolidated Standards of Reporting Trials) statement for randomised clinical 
trials.19 
The study designs listed in figure 1.1.3 have been described in various textbooks on 
(pharmaco)epidemiology.1, 2, 16 In this context, only a brief summary on case-control 
and cohort studies with a nested case-control analysis will be given because these 
designs were used for the studies conducted within the framework of this thesis. The 
Low 
High 
High 
Low 
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three designs are also illustrated in appendix 5.1. In theory, a hypothesis can be 
tested with both designs,16 but in practice there are unique advantages and 
disadvantages of cohort and of case-control studies (e.g. in terms of cost, time, 
efficiency, frequency or type of outcome / risk factor). However, they will not be 
discussed in this context as a lot of them do not apply for the kind of retrospective 
database research conducted in this thesis. Interested readers are referred to 
(pharmaco)epidemiological textbooks.1, 2, 16 Only one major difference between case-
control and cohort studies is emphasised at this point because it influenced the 
choice of study designs for this thesis: in case-control studies, multiple exposures / 
risk factors for a disease / an event can be studied, and cohort studies allow the 
investigation of multiple outcomes of interest after an exposure or an event / disease.  
1.1.3.1 Case-control studies1, 2, 16 
In a case-control design, the study population comprises cases who have an 
outcome (e.g. a disease) of interest and controls who do not. Controls need to 
represent the population who would have been cases had they also developed the 
disease. If matching is used as a technique to control for confounding factors, one or 
more controls who are equal with respect to the matching criteria (e.g. age, sex, 
timing etc.) will be searched for each case. The statistical power of the study 
increases with the number of controls matched to each case. The proportions of 
exposure history to risk factors (e.g. drugs) will then be compared between cases 
and controls, and the risk of developing an outcome in relation to the risk factor will 
be quantified by providing odds ratios (ORs). A relative risk (RR) (defined as the ratio 
of the incidence rate (IR) of the outcome in the exposed group to the rate in the 
unexposed group) cannot be calculated because case-control studies do not provide 
information on the IR of the disease in exposed and unexposed individuals. Hence, 
the risks are expressed as ORs (ratio of the odds of the outcome in the exposed 
group compared to the odds in the unexposed group, whereby the odds of an 
outcome is defined as the probability that the outcome does happen divided by the 
probability that it does not20). 
1.1.3.2 Cohort studies1, 2, 16 
A cohort refers to a group of people who have something in common at a defined 
point in time, i.e. in cohort studies, a group of people is studied who have not (yet) 
experienced the outcome of interest.2 In controlled cohort studies,2 subjects 
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(matched on potential confounders or not) are selected depending on the presence 
(‘cases’) or absence (‘controls’) of exposure to a particular factor. They form the 
cohort population, and this should be an inception cohort, which means that the 
‘cases’ are observed from the first exposure to that particular factor.2 The cohort is 
then followed until the subjects develop an outcome of interest, until they die, or 
follow-up / the study ends. With this design, IRs of one or several outcomes in 
patients with or without a certain exposure can be obtained, and by comparing these 
rates, incidence rate ratios (IRR) or RR can be calculated. Cohort studies are 
retrospective or prospective depending on if the outcome of interest has occurred at 
the time the investigator initiates the study.  
1.1.3.3 Nested case-control studies1, 2, 16 
For this design, a cohort population is followed for a period of time until a number of 
incident outcomes (diseases or adverse drug events) are identified. These cases and 
a sample of noncases (controls; matched or not) from the cohort are then compared 
with regard to prior exposure to a risk factor. The design is particularly interesting 
when the hypothesis to be tested is generated after the prospective cohort study has 
been initiated and upon availability of stored biologic specimens in order not to 
analyse the specimens of the whole cohort population. Furthermore, the design is 
efficient in terms of time (effort of data collection) and cost.1, 2, 16, 21 In retrospective 
database research, this design is also commonly applied with the advantage that 
adjustment for confounders which change over time is better than in cohort designs. 
The time of the diagnosis of the outcome is known, and it is the same for controls 
when matched on time.22 
 
1.1.4 Causality assessment in routine pharmacovigilance and epidemiology 
The WHO defined pharmacovigilance as the science and activities relating to the 
detection, assessment, understanding, and prevention of adverse effects or any 
other possible drug-related problems.23 Reports on suspected adverse events to a 
drug are collected in the international WHO database (chapter 1.1.1). They have to 
be accompanied by a causality assessment. For this purpose, a number of scores 
had been developed, such as the one by Naranjo et al.24 However, as they were too 
complex for routine clinical practice, the WHO provided its own score25 as 
summarised below:  
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Association  Conditions 
Certain 
 
 
- Plausible temporal relationship between drug exposure and event 
- Plausible response to withdrawal (dechallenge) 
- Recurrence of the event after rechallenge or other evidence 
- No alternative explanation for the event 
Probable - Plausible temporal relationship between drug exposure and event 
- Plausible response to withdrawal (dechallenge) 
- Alternative explanation for event unlikely 
Possible - Plausible temporal relationship between drug exposure and event 
- Other explanation for event possible 
Unlikely - None of the above-mentioned conditions 
 
Each report on an adverse drug event contributes to the generation of a possible 
signal which has to be assessed in greater detail (Examples of published case 
reports by Brauchli YB et al.26 in the appendix 5.2 or the publication list). For this 
task, pharmacoepidemiological studies are very useful. The evidence of such a study 
(or studies) to support a causal relationship between a drug exposure and an 
outcome has to be evaluated as well. AB Hill27 suggested a first model on the 
interpretation of an epidemiological study in the 1960s which was enhanced by 
Hennekens et al.16 two decades later: 
 
1. Valid statistical association (Study design)? Or due to 
a. Chance? (an unsystematic, or random, variation; quantified by statistics)1  
b. Bias? (a systematic variation, a consistent manner in which two groups are evaluated / 
treated differentially; e.g. selection bias, information bias (such as recall, interviewer 
bias))1 
c. Confounding? (an association is created or masked by a third variable which is 
independently related to the risk factor and the outcome)1 
2. If valid, can the association be judged as cause and effect? Points to consider 
a. Strong association? 
b. Biological credibility to the hypothesis? 
c. Consistency with other studies? 
d. Time sequence compatible? 
e. Evidence of a dose-response relationship? 
 
Replication of results with different methods or in different populations is important in 
pharmacoepidemiological research: In epidemiology, a relative risk of less than 2 is 
usually considered to indicate a weak association,1 but for adverse reactions of 
marketed drugs often only low risks can be detected; drugs with a high incidence of 
serious adverse reactions would have been too toxic to be marketed. The 
consistency of results from different studies is important for the evaluation of 
causality in such situations.28 
1 Introduction   General aspects of pharmacoepidemiology   
 10 
For a detailed explanation of bias and confounding, the reader is referred to a 
textbook on (pharmaco)epidemiology.1, 2, 16 
 
1.1.5 Database research 
In phase III clinical trials, between 500 and 3,000 patients are exposed to a drug in 
development. Considering the ‘rule of three’, drug effects which occur with an 
incidence lower than 1 per 1,000 can hardly be detected during the drug 
development process. Hence, after marketing, monitoring of the safety of a drug has 
to continue, and large study populations are necessary to evaluate rare adverse 
events. However, such studies are expensive, take long, and are often difficult to 
perform. For these reasons, there has been an increasing use of computerised or 
automated databases with medical care data for conducting 
pharmacoepidemiological studies.1 Databases can be classified into claims 
databases created primarily for administrative purposes to get reimbursement for 
clinical services and therapies (e.g. databases of health maintenance organisations 
(HMO); Medicaid databases from Medicare, a health insurance program funded by 
the US government; or the Health Services Databases in Saskatchewan, Canada) 
and into medical record databases in which medical records of patients are captured 
electronically (e.g. the General Practice Research Database (GPRD)29 in the United 
Kingdom (UK)). There are also combinations of the two, e.g. the PHARMO system in 
the Netherlands30 which links data from general practitioner (GP) registries with 
pharmacy and hospital data. Usually, the validity of the diagnoses is better in medical 
records as compared with claims databases while the recording of drug exposure is 
of similar completeness.1 When working with a database, it is important to know it 
very well, e.g. the structure, the way data are collected, the advantages, and the 
disadvantages.31 Below are listed some of the strengths and weaknesses of 
database research in general.1 
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Strengths Weaknesses 
- Provision of large sample size  
- Relatively inexpensive use 
- Cost of data collection can be saved 
- Can be population-based 
- No recall or interviewer bias 
- Not influenced by study question 
 
- Uncertain validity of diagnosis data 
- Possible lack of information on potential 
confounding variables (e.g. smoking, alcohol, 
body mass index (BMI), lifestyle factors etc.) 
- Continuous enrolment / disenrolment of 
members in claims databases 
- Usually only recording of diagnoses severe 
enough to come to medical attention 
- Generalisability may be an issue 
- Usually no data on compliance; data on over 
the counter drugs questionable 
 
1.1.6 Short history about the GPRD 
The studies of this thesis were conducted with data from the UK-based GPRD which 
encompasses about 5% of the UK population.1 In the UK, information on all relevant 
medical care of each patient congregates with the GP with whom the patient is 
registered. Hence, in the mid 1980s Value Added Medical Products (VAMP) Health, 
a commercial company, designed a system which allowed recording of this 
information on office computers. The company acquired GPs to participate in the 
recording of patient data and providing them anonymised as to patient identification. 
In return, they received compensation. VAMP entered into an agreement with the 
BCDSP who had experience with computerised data and evaluated the use of the 
GPRD for drug safety studies.4 In the meantime, the database has been validated 
extensively32-34 and is managed today by the UK Medicines and Healthcare products 
Regulatory Agency (MHRA).1 Up to September 2008, more than 630 epidemiological 
studies using this database have been published.35 Further information about the 
database is provided in the methods sections of the studies of this thesis, and 
interested readers are referred to review articles, which describe the database 
(including its history) in detail,31, 36-39 or to the website (www.gprd.com). 
 
1.1.7 Prescription-event monitoring and registries1, 2 
Prescription-event monitoring is another approach to drug surveillance in the 
postmarketing setting. The technique was introduced 1981 in the UK at the Drug 
Safety Research Unit (DSRU) and focuses on newly-marketed drugs. In the UK, 
practically all patients are registered with a National Health Service GP who 
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prescribes drugs which the patient collects at a pharmacy. After dispensing the drug, 
the pharmacy sends the prescription for reimbursement to a central prescription 
pricing authority which provides the DSRU with an electronic copy of the prescription. 
This process lasts until data of a cohort of about 20’000 to 30’000 patients have been 
gained. After 3-12 (usually 6) months of the first prescription for each patient, the 
DSRU sends the prescriber a questionnaire asking for any adverse events in 
connection with the drug. Information gained with this system is very useful for 
hypothesis generation, but less for hypothesis confirmation, mainly because an 
appropriate control group is lacking, and the physicians’ response rate may be low. 
 
In registries, defined events (e.g. medicine-induced cardiac arrhythmias) or product 
exposures are collected in a patient population defined by a particular disease, 
condition, or exposure. It is an organised system which uses observational study 
methods to collect uniform data. Patients are observed when they present for care.40 
Registries are mainly used for information gathering and hypothesis generation, but 
can also serve as risk minimisation tools (see RMP chapter 1.1.2). As an example, 
the clozapine registries were created to minimise the risk of agranulocytosis following 
exposure to the drug. Patients were registered, and blood tests had to be linked to 
the dispensing of clozapine. The agranulocytosis rates were 1% to 2% before the 
registry was set up in the US and 0.38% after the implementation.41 Another well-
known example is the thalidomide registry to prevent foetal exposures to the drug.42 
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1.2 PSORIASIS – SHORT OVERVIEW 
1.2.1 Introduction 
What did or do celebrities such as Winston Churchill (politician), Jossif 
Wissarionowitsch Stalin (politician), Romy Schneider (actress), Karin Holstein 
(German model), John Updike (writer), or Art Garfunkel (singer and actor) have in 
common? They all seem to (have) suffer(ed) from psoriasis.43  
Psoriasis had been described already before Christ and was later considered as a 
form of leprosy. Only in the 19th century, the disease was distinguished from leprosy 
by Ferdinand von Hebra and Robert Willan, although the latter still named certain 
occurrences of psoriasis Lepra Graecorum and Psora leprosa. The word psoriasis 
derives from the Greek psora (= to itch).43, 44 
Psoriasis is a chronic immune-mediated erythematous-squamous skin disorder. 
When applying the definition of autoimmune disease provided by Davidson A et al. ‘a 
clinical syndrome caused by the activation of T cells or B cells, or both, in the 
absence of an ongoing infection or other discernible cause’,45 psoriasis qualifies as 
an autoimmune disorder because it is characterised by T cell-mediated 
hyperproliferation of keratinocytes and inflammatory processes based on a complex 
genetic background and without an obvious cause.46 However, a definite (auto-) 
antigen has not been identified yet,47 and autoimmunity in the case of psoriasis is still 
being discussed.44  
 
1.2.2 Pathophysiology 
Until the late 1970s, the primary cause for the initiation of epidermal 
hyperproliferation in psoriasis was supposed to be an aberrant keratinocyte 
metabolism. A number of observations in the following two decades (such as 
therapeutic success with ciclosporin, which diminishes T cell proliferation and 
cytokine production, or healing of psoriatic lesions after haematopoietic stem cell 
transplantation) provided evidence for a primary role of the immune system, mainly 
the T cells, in the activation and maintenance of the disease.48 Research over the 
past years shed more and more light on the pathogenesis of the skin disorder which 
Sabat et al.48 summarised in a comprehensive review article. According to his theory, 
the onset of psoriasis is similar to an immune reaction with a sensitisation, a silent, 
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and an effector phase. In the sensitisation phase, naïve T cells are activated by 
antigen-presenting cells, the dendritic cells, which present (exogenous) antigen to the 
T cells in secondary lymphatic organs. T cells mainly of the T helper cell (Th)1 and 
Th17 lineage are generated which produce specific cytokines. After a silent phase, T 
cells and various other immune cells infiltrate the skin and activate each other as well 
as keratinocytes via mediators (e.g. interferon (IFN)-γ, interleukin (IL)-23, IL-6, IL-22, 
IL-17, IL-20, tumour necrosis factor (TNF)-α, or transforming growth factor (TGF)-α)  
which seem to play a central role in the pathogenesis of psoriasis (effector phase). 
This process leads to an increased proliferation of keratinocytes and inflammation.  
 
1.2.3 Clinical picture 
Psoriasis presents with different types of manifestation (table 1.2.1, including 
characteristics), with psoriasis vulgaris being the most common one (90%).44 This 
form usually presents with well-delineated erythematous-squamous plaques covered 
by silvery-white scales and of different thickness and dissemination44, 49, 50 and is 
usually easy to diagnose.50 Histopathologically, Munro’s microabscesses (neutrophil 
granulocytes in the subcorneal layer), spongiform pustules of Kogoj (neutrophils in 
the spinous layer), and dilatation of papillary dermal capillaries with thinning of the 
suprapapillary epidermis are quite characteristic features.50 
 
Table 1.2.1 Clinical variants of psoriasis44, 49, 51-53 
Psoriasis vulgaris (PV) or 
plaque psoriasis 
Chronic fixed type  
Persistent erythematous-squamous plaques at defined locations 
(figure 1.2.1) 
Psoriasis guttata 
Acute exanthematous type 
Raindrop-like erythematous papules over trunk and extremities (mainly 
type I psoriasis and triggered by pharyngeal streptococcal infection) 
Psoriasis inversa / 
intertriginosa  Other localisation than PV (figure 1.2.1); rare 
Psoriasis pustulosa (PP) 
Several clinical variants 
Rare; Clinically distinct from PV; mainly sterile subcorneal pustules; 
generalised form can be life-threatening (von Zumbusch psoriasis) 
Psoriatic erythroderma Primary or resulting from PV or PP; generalised, erythematous, and 
scaly integument; severe form, can be life-threatening  
Psoriatic nail changes In combination with other forms or isolated 
Psoriatic arthritis 
(5-42% of psoriasis patients) 
Mainly distal joints of toes or fingers and sacroiliacal joints, often 
enthesitis; mainly rheumatic factor negative 
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Figure 1.2.1 Common locations of psoriasis 
 
Depending on the extent of body surface involvement of less than 5%, 5-10%, or 
more than 10%, severity of psoriasis is defined as mild, moderate, or severe, 
respectively.54 Of all patients, about 75% suffer from mild to moderate disease.55 A 
variety of outcome measures have been developed and used to evaluate the severity 
of psoriasis as well as the efficacy of treatments in clinical trials. While the strength of 
the body surface area (BSA) is its ease of use, the psoriasis area and severity index 
(PASI) considers besides the skin area involvement also the degree of erythema, 
desquamation, and induration of the psoriatic plaque. Currently, this score is most 
commonly used in clinical trials for the evaluation of new therapeutic agents. 
However, psychosocial disability as an additional influencing factor on disease 
severity is gaining more and more importance, and a tool combining both, physical 
symptoms and quality of life (QoL) measurements,56 is needed. 
 
1.2.4 Treatment 
The diversity of psoriasis asks for an individualised treatment plan adapted to the 
nature / phenotype, extent, and localisation of the disease, the patient’s QoL and 
lifestyle, age, sex, comorbidities / triggering factors, compliance, and previous 
treatment. Furthermore, education of patients plays an important role.54, 57, 58 There 
are different treatment options which are adopted (as monotherapy or in 
combination) depending on disease severity (figure 1.2.2), however, they are not 
curative. Moderate to severe disease is usually treated with systemic therapy, 
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ultraviolet (UV), or psoralen and UVA (PUVA) with or without topical agents, whereas 
topical treatment is adequate for mild disease. Basic therapeutic agents are used in 
and between all acute stages across all severity grades.54 There are several good 
review articles on the treatment of psoriasis (e.g. by Menter A, et al.54, Shear NH59, 
Ashcroft DM, et al.57), and the treatment guidelines by the German Dermatology 
Society60 and the British Association of Dermatologists61 provide a very 
comprehensive overview. 
 
 
Figure 1.2.2 Treatment options depending on psoriasis severity (adapted from Ashcroft DM et al.57) 
 
1.2.5 Epidemiology 
1.2.5.1 Prevalence and incidence rates 
In most studies, the prevalence (proportion of individuals in a population who have 
the disease at a specific point in time16) of psoriasis lied somewhere between 0.6% 
and 4.8%,62 but the designs of the studies sometimes differed considerably. Higher 
and lower rates were also reported for certain regions:63 The rate is dependent on 
ethnicity (Caucasians are more affected than other races, and the disease does not 
exist in aboriginal Australians and Indians from South America 64) and geographical 
region (more common in colder northern climates than in tropical regions).63 The only 
two published population-based studies on IRs (number of new events or cases of 
disease that develop in a population of individuals at risk during a specified time 
interval16) of psoriasis provided overall annual IRs of 6 per 10,000 persons-years 
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(py)65 and 14 per 10,000 py,66 respectively. The rates peaked before the age of 40 
years and again at or after 50 years and were lowest in old patients (≥80 years). The 
annual IR was slightly higher in male than female patients, except for patients 
between 0-29 and 50-59 years of age. The female IRs peaked in the age groups 20-
29 years and 50-59 years.66 Between 1994 and 2005 the IRs were stable (figure 
1.2.3; Brauchli YB 2008. Unpublished data gained from the GPRD).  
 
 
Figure 1.2.3 Stable psoriasis incidence rates between 1994 and 2005 
 
1.2.5.2 Aetiology of psoriasis 
The aetiology of psoriasis is complex, probably resulting from an interaction between 
environmental factors and genetics. The incidence of the skin disorder is greater in 
first and second degree relatives of patients than in the general population, and the 
risk of psoriasis in monozygotic twins is two to three times higher than in dizygotic 
twins. The chromosomal locus termed psoriasis susceptibility 1 or PSORS1 (Major 
Histocompatibility Complex [MHC] region on chromosome 6) is the major genetic 
determinant, mainly the gene variant or allele Human Leucocyte Antigen (HLA) Cw6. 
Further eight linkage loci to psoriasis (PSORS1-5 and PSORS7-10) have been 
accepted by the Human Genome Nomenclature Committee, and additional ones 
have been reported. Phenotypic variants of psoriasis have shown to be genetically 
heterogeneous.44, 67 
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Epidemiologically, Henseler et al. differentiated two types of psoriasis depending on 
age of first onset.68 Type I psoriasis is characterised by age of onset before 40 years, 
by an increased risk of heritability, by a strong association with HLA, e.g. HLA Cw6, 
and by severe disease which is difficult to treat. About 75% of the patients have this 
type of psoriasis.55 Patients with type II psoriasis develop the disease after the age of 
40 years, the association with familiar genetics and HLA is smaller, and the disease 
is generally less severe.51, 68  
1.2.5.3 Psychosocial and economic burden 
Although psoriasis is seldom life-threatening (estimated 0.64 deaths per 100,000 
psoriasis patients annually in the US)69, the psychosocial burden for patients is often 
considerable, and, despite the distinction of psoriasis from leprosy in the 19th century, 
stigmatisation is still an issue. Impairment of QoL may be significant (similar or worse 
than for patients with other chronic diseases such as ischaemic heart disease, 
diabetes, or cancer)64, 70, 71 and may not always be proportional to skin 
involvement.72, 73 Hence, QoL should be considered in the definition of psoriasis 
severity44, 56, 64, 73 and should influence treatment decisions.54 Two psoriasis-specific 
QoL measures have been described, the Psoriasis Disability Index (PDI) and the 
Psoriasis Life Stress Inventory.51, 73  
Apart from the psychosocial aspect, psoriasis also carries a substantial economic 
burden, be it direct costs including expensive treatment, treatment failures, treatment 
of comorbidities or adverse events to psoriasis treatment, or hospitalisations, indirect 
costs including e.g. time not at work, or intangible costs including e.g. loss of QoL.74-
77
  
1.2.5.4 Risk factors and comorbidities 
A number of risk or triggering factors and comorbidities have been reported for 
psoriasis (table 1.2.2), however, data were mainly derived from case reports and 
case series (especially in the case of drugs reported as risk factors78-80) or from 
epidemiological studies which were cross-sectional or nonpopulation-based (but e.g. 
hospital-based). Hence, there are conflicting results in the literature (e.g. the 
association between psoriasis and cancer81, 82), and the temporal sequence of the 
association between psoriasis and the comorbidities or risk factors is often 
inconclusive.70 Neimann et al. provided a comprehensive review article on the risk 
factors and diseases associated with psoriasis.80 
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Table 1.2.2 Risk factors and comorbidities associated with psoriasis 
Risk- / Triggering factors Comorbidities 
 
 Family history and genetics44, 83, 84 
 Bacterial and viral infections, mainly 
streptococcal pharyngitis62, 85-87 
 Smoking, alcohol consumption, and 
diet / high BMI62, 66, 84, 85, 88-94  
 Drugs (mainly beta-blockers, 
lithium, antimalarials)62, 79, 85, 87, 95-98 
 Stress62, 85, 88 
 
 Diabetes and metabolic syndrome86, 99-106 
 Cardiovascular diseases (incl. hypertension 
and hyperlipidaemia)102, 103, 105, 107-112  
 Cancer86, 113-121  
 Immune-mediated inflammatory diseases 
(Crohn’s disease,122-126 multiple 
sclerosis,127-129 coeliac disease130, 131) 
 Psychiatric disorders (e.g. anxiety, 
depression)132, 133 
 Comorbidities due to treatment: 
nephrotoxicity, hepatotoxicity, non-
melanoma skin cancer59, 134-136 
 
1.2.6 Psoriasis and research 
Over the past years, research on psoriasis has been intensive, and knowledge has 
progressed considerably. In a recent commentary, MP Schön used the appropriate 
title ‘Psoriasis in the limelight: the remarkable career of an old skin disease’.137 
Psoriasis has become a model disorder for chronic inflammatory diseases137 despite 
the lack of a complete animal model.138 New insights into the pathogenesis of the 
disease allowed the identification of the mode of action of some established 
antipsoriatic therapies and the development of novel therapies (mainly biologicals), 
which in return helped in elucidating further the pathomechanism of psoriasis.137 
Driven - amongst others - by the recent development of a proactive 
pharmacovigilance in the regulatory environment (chapter 1.1.1 and 1.1.2) and the 
market launch of a number of biologicals, interest in gaining or supplementing 
information on the epidemiology of psoriasis has risen amongst healthcare providers 
and the pharmaceutical industry.  
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2 AIMS OF THE THESIS 
The major aim of this thesis was to contribute to the understanding of the natural 
history of psoriasis by providing new information on or complementing existing 
knowledge of risk or protecting factors for as well as comorbidities of psoriasis using 
data from the GPRD. Additionally, the study designs used (see introduction 1.1.3 and 
appendix 5.1) should allow a statement about the temporal sequence of the 
association between psoriasis and the factors investigated. 
 
Drugs are not well defined risk factors for the development of psoriasis due to 
knowledge being mainly based on case reports or case series. Some of the reports 
on a possible association could also have been chance findings because psoriasis is 
a common disease. Already in the 1980s, a group of researchers indicated this issue 
in the case of beta-blockers,95 but the association between this class of drugs as well 
as lithium and the induction of psoriasis has in the meantime been recorded in 
several standard dermatology textbooks (e.g. Fitzpatrick’s Dermatology in General 
Medicine, sixth edition 2003; Dermatology, Jean L Bolognia et al., 2003; 
Dermatologie und Venerologie, Braun-Falco et al., 5. Auflage, 2005). The objective 
was to study these reported associations in two large population-based case-control 
studies. Study 3.1 should investigate the association between exposure to beta-
blockers or other antihypertensives and psoriasis and Study 3.2 the association 
between exposure to lithium or antipsychotics and psoriasis. Scientifically sound 
knowledge of risk factors for a disease is important for healthcare professionals to 
make the right decisions in clinical practice and can be helpful in the evaluation of the 
pathomechanism of a disease. 
 
Small clinical trials suggested thiazolidinediones as possible treatment options for 
patients with psoriasis. However, the results were somewhat inconclusive, and data 
on the potential of the drug class to prevent the induction of the skin disorder were 
not available. Thus, the objective of Study 3.3 – also a case-control study – was to 
investigate the association between use of thiazolidinediones or other antidiabetic 
drugs and the induction of psoriasis. 
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Several studies on the association between psoriasis and comorbidities such as 
cardiovascular diseases, diabetes or metabolic syndrome, or cancer have been 
reported in the literature. However, these studies were often cross-sectional, 
nonpopulation-based, included prevalent rather than incident outcomes, or provided 
conflicting results (mainly for cancer). True incidence rates of the above-mentioned 
comorbidities in patients with psoriasis were lacking, and the temporal relationship 
between the comorbidities and psoriasis was often unclear. The objectives of Studies 
3.4 – 3.6 were to provide IRs of diabetes (Study 3.4), myocardial infarction (MI) and 
stroke / transient ischaemic attack (TIA) (Study 3.5), and cancer overall and stratified 
by type (Study 3.6) for patients with psoriasis, to compare them with a population 
without psoriasis, and to investigate the influence of psoriasis severity or duration on 
these outcomes. 
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3.1.1 Abstract 
Background: Several case reports have associated use of beta-blockers with an 
increased risk of psoriasis or psoriasiform drug eruptions. 
Objective: To study the association between use of beta-blockers and other 
antihypertensive drugs and the risk of developing a first-time diagnosis of psoriasis. 
Methods: We conducted a case-control analysis on the UK-based GPRD. We 
identified cases with an incident psoriasis diagnosis between 1994 and 2005 and 
matched them to one control patient on age, sex, general practice, calendar time 
(same index date), and years of history in the database. Conditional logistic 
regression was used to estimate adjusted ORs with 95% confidence intervals (CIs) of 
developing a first-time psoriasis diagnosis in relation to previous exposure to 
antihypertensive drugs, stratified by exposure timing (current versus past use) and 
exposure duration based on the number of prescriptions.  
Results: The study encompassed 36,702 cases with a first-time psoriasis diagnosis 
and the same number of matched controls. Adjusted ORs for current use of 1-4, 5-
19, or ≥20 prescriptions for beta-blockers, as compared with nonuse, were 0.93 (95% 
CI 0.76-1.13), 1.10 (95% CI 0.97-1.24), and 1.10 (95% CI 1.01-1.20), respectively. 
The risk estimates for current use of other antihypertensives at any exposure 
duration were all close to 1.0.  
Conclusions: This large population-based case-control analysis does not support the 
current proposition that beta-blocker use is associated with an increased risk of 
psoriasis, nor did we find evidence for a substantially altered psoriasis risk for other 
antihypertensive drugs.  
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3.1.2 Background 
Psoriasis is a common autoimmune inflammatory skin disease with an estimated 
prevalence between 0.6% and 4.8% and even higher rates for some regions.62, 63 In a 
recent study using the UK-based GPRD, Gelfand et al. reported a prevalence rate of 
1.5% in the UK.139 The disease is characterised by T cell-mediated hyperproliferation 
of keratinocytes and inflammatory processes based on a strong and complex genetic 
background.46 Various potential risk or triggering factors have been described such 
as smoking, alcohol consumption, increased BMI, trauma, infections, endocrine 
factors, stressful life events as well as exposure to drugs such as beta-blockers, 
angiotensin-converting enzyme inhibitors (ACE-inhibitors), antimalarials, nonsteroidal 
anti-inflammatory drugs (NSAIDs), lithium, interferons as well as the acute withdrawal 
of systemic or potent topical corticosteroids.62, 85, 88, 91, 95, 96 
Beta-blockers and ACE-inhibitors are widely used drugs for the treatment of 
hypertension, a disease which has been associated with psoriasis.86, 102, 103 
Numerous case series have reported a possible association between use of beta-
blockers and the induction or exacerbation of psoriasis, including case reports on 
timolol-containing eye drops. In many of these reports, the reaction was described as 
psoriasiform drug eruption rather than psoriasis, and histological testing was either 
not done or did not support a diagnosis of psoriasis.95, 96, 140-142 Due to disparate 
histological presentations, it has recently been suggested that the pathophysiology of 
drug-induced psoriasis may differ from that of idiopathic psoriasis.143 Although it was 
proposed in the 1980s that further studies were needed to explore whether use of 
beta-blockers alters the risk of psoriasis,95 such a possible association has - to our 
knowledge - not been studied in more detail.  
Even though cutaneous adverse effects of ACE-inhibitors are common (8.3% - 
58.3%),96 a possible link to psoriasis has been reported only rarely, particularly for 
captopril.96 Psoriasis and psoriasiform eruptions have also been associated with use 
of other antihypertensives such as angiotensin II (AT II) antagonists,144 calcium 
channel blockers (CCB),145 or clonidine.146 A recently published hospital-based case-
control (110 patients, 515 controls) and case-crossover study (98 patients) reported a 
possible association between use of ACE-inhibitors and an increased relative 
psoriasis risk in the case-control analysis. A suggestion of an increased risk 
associated with use of ACE-inhibitors as well as with use of beta-blockers was also 
reported in the case-crossover study.78  
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The currently available evidence on a possible association between use of 
antihypertensive drugs and psoriasis is based mainly on case reports and case 
series, and there is no consensus on the mechanism by which beta-blockers might 
induce such a reaction.143 We conducted a large population-based case-control study 
to further explore the association between use of beta-blockers or other 
antihypertensive drugs and the risk of developing a first-time diagnosis of psoriasis. 
 
3.1.3 Methods 
We conducted a matched case-control analysis within the GPRD on the risk of 
having a first-time psoriasis diagnosis in relation to previous use of beta-blockers, 
ACE-inhibitors, AT II antagonists, CCBs, diuretics, and clonidine. 
 
Data Source 
The GPRD is a large UK-based database established around 1987 which 
encompasses some five million patients who are actively enrolled with selected GPs. 
The GPs have agreed to provide data for research purposes to the GPRD. GPs have 
been trained to record medical information in a standard manner and to supply it 
anonymously. The patients enrolled in the GPRD are representative of the UK with 
regard to age, sex, geographical distribution, and annual turnover rate. The 
information recorded includes patient demographics and characteristics (e.g. age, 
sex, height, weight, smoking status), symptoms, medical diagnoses, referrals to 
consultants, hospitalisations, and all drug prescriptions, as the doctors generate 
prescriptions directly with the computer using a coded drug dictionary. Prescriptions 
contain the name of the preparation (active compound), the route of administration, 
the dose of a single unit, the number of units prescribed, and, in most instances, the 
intake regimen prescribed by the GP. Hospital discharge and referral letters are 
available for review to validate the diagnoses recorded in the computer record.31, 36 
This database, which has been described in detail31, 36 and validated extensively,34 
has been the source for numerous published epidemiological studies. Several 
studies on psoriasis using GPRD data have been published.103, 108, 115, 116, 139, 147  
The study protocol was approved by ISAC, the Independent Scientific Advisory 
Committee for MHRA database research. 
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Case definition and ascertainment 
We identified patients with a first-time diagnosis of psoriasis between 1 January 1994 
and 31 December 2005 via OXMIS (Oxford Medical Information System) and Read 
codes. We did not include patients with less than three years of active history in the 
database prior to the first-time diagnosis of psoriasis, and patients with a code for 
‘history of psoriasis’ at the index date were also not eligible.  
The validity of psoriasis diagnoses in the GPRD has been examined by Gelfand et al. 
who have published several GPRD-based studies on psoriasis.103, 108, 115, 116, 139, 147 
They showed that the epidemiology of psoriasis in the GPRD is similar to data from 
other population-based studies in the UK and that 92% of patients with a psoriasis 
code receive psoriasis therapies.115, 139 In addition, among a random sample of 100 
GPs who recorded a psoriasis code, approximately 90% confirmed the diagnosis 
after four years of follow-up.147  
 
Controls 
From the base population we identified at random one control subject per psoriasis 
case, matched on calendar time (same index date), age (same year of birth), sex, 
general practice, and years of history in the GPRD. Thus, controls were also required 
to have at least three years of active history in the GPRD. 
 
Exposure to antihypertensives 
For each case and control we assessed from the computer record the exposure 
history for beta-blockers, ACE-inhibitors, AT II antagonists, or combinations thereof, 
CCBs, diuretics, and clonidine prior to the index date. Patients were classified as 
‘current users’ if the last prescription was recorded <90 days, or as ‘past users’ if it 
was recorded ≥90 days prior to the index date. We also classified users by duration 
of use prior to the index date, using the number of prescriptions as proxy (1-4, 5-19, 
or ≥20 prescriptions for beta-blockers, ACE-inhibitors, CCBs, and diuretics and 1-9 or 
≥10 for AT II antagonists and clonidine due to lower exposure prevalence), and we 
also evaluated duration by timing of use.  
For the main analysis we created two models: first, subsequent or concurrent use of 
various antihypertensive drugs prior to the index date was possible, and we adjusted 
for such overlapping use in the multivariate model. In the second model, subjects 
were categorised into mutually exclusive groups of users of one antihypertensive 
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drug class, while combined use of antihypertensives (‘switchers’ or combined 
therapies) formed a separate group. 
 
Statistical analysis 
We conducted conditional logistic regression analyses using the SAS statistical 
software (version 9.1; SAS Institute Inc, Cary, NC, U.S.A.). We displayed relative risk 
estimates as ORs with 95% CIs. We adjusted ORs for the potential confounders age, 
sex, general practice, calendar time, and years of recorded history in the database by 
matching, and for smoking status (non, current, ex, or unknown) and BMI (<18.5, 
18.5-24.9, 25.0-29.9, ≥30 kg/m2, or unknown) in the multivariate model. The risk 
estimates were further adjusted for a history of cardiac arrhythmia, congestive heart 
failure, ischaemic heart disease, stroke/TIA, hypertension, diabetes, hyperlipidaemia, 
chronic obstructive pulmonary disease (COPD), asthma, and alcoholism, as well as 
for use of coronary vasodilatators (1-9 or ≥10 prescriptions). Potential confounding 
was further tested for a number of other covariates which were not included in the 
final model because they were not materially associated with the exposure or with 
the outcome, such as allergic skin disease, allergic rhinoconjunctivitis, atopic 
dermatitis, contact dermatitis, tonsillectomy, candidiasis/aspergillosis, cellulitis, viral 
infections, respiratory infections, hyper-/hypothyroidism, affective disorders, gout, 
epilepsy, neurosis, inflammatory bowel disease, rheumatoid arthritis, migraine, 
tremor, and use of antihistamines, benzodiazepines, beta-agonists, cardiac 
glycosides, NSAIDs, paracetamol, cyclooxygenase-2 inhibitors, lipid-lowering agents, 
selective serotonin re-uptake inhibitors (SSRI), terbinafine, levothyroxine, 
carbimazole, and antidiabetic agents.  
 
3.1.4 Results 
We identified 36,702 cases with a first-time diagnosis of psoriasis between 1 January 
1994 and 31 December 2005 and the same number of matched controls. Table 3.1.1 
displays age and sex distribution of cases and controls as well as the distribution of 
smoking status, BMI, a number of cardiovascular risk factors, and other diseases.  
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Table 3.1.1 Characteristics of case patients with psoriasis and matched controls 
Variable 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Adjusted OR* 
(95% CI) 
Sex** 
      
 Men 16,969 (46.2) 16,969 (46.2) - - 
 Women 19,733 (53.8) 19,733 (53.8) - - 
Agegroup (years)** 
      
 <20 5801  (15.8) 5801 (15.8) - - 
 20-29 4336 (11.8) 4339  (11.8) - - 
 30-39 5187 (14.1) 5187 (14.1) - - 
 40-49 5173 (14.1) 5171 (14.1) - - 
 50-59 5989 (16.3) 5997 (16.3) - - 
 60-69 5109 (13.9) 5102 (13.9) - - 
 ≥70 5107 (13.9) 5105 (13.9) - - 
Smoking status 
      
 Non smoker 13,390 (36.5) 15,594 (42.5)  1.00 (reference) 
 Current smoker 8787 (23.9) 6913 (18.8) 1.52 (1.46 - 1.58) 
 Ex smoker 4690 (12.8) 3763 (10.3) 1.46 (1.38 - 1.53) 
 Unknown 9835 (26.8) 10,432 (28.4) 1.08 (1.02 - 1.14) 
BMI (kg/m2)       
 12-18.4 523 (1.4) 574 (1.6) 0.92 (0.81 - 1.04) 
 18.5-24.9 10,244 (27.9) 10,887 (29.7) 1.00 (reference) 
 25-29.9 8330 (22.7) 7934 (21.6) 1.14 (1.09 - 1.19) 
 30-60 4881 (13.3) 3882 (10.6) 1.38 (1.31 - 1.45) 
 Unknown 12,724 (34.7) 13,425 (36.6) 0.99 (0.94 - 1.04) 
Comorbidities       
Arrhythmias 1098 (3.0) 1133 (3.1) 0.94 (0.86 - 1.03) 
CHF 713 (1.9) 673 (1.8) 0.97 (0.86 - 1.09) 
IHD 2587 (7.1) 2232 (6.1) 1.01 (0.92 - 1.10) 
Stroke/TIA 996 (2.7) 923 (2.5) 1.04 (0.94 - 1.15) 
Hypertension 5295 (14.4) 5140 (14.0) 0.98 (0.94 - 1.03) 
Diabetes 1355 (3.7) 1294 (3.5) 0.95 (0.87 - 1.03) 
Hyperlipidaemia 2169 (5.9) 1950 (5.3) 1.06 (0.99 - 1.14) 
Alcoholism 1031 (2.8) 725 (2.0) 1.34 (1.22 - 1.49) 
* Adjusted for all covariates listed in the table plus asthma, chronic obstructive pulmonary disease, and use of coronary 
vasodilatators; ** Matching variables 
Percentages may not sum to 100% due to rounding 
BMI = body mass index; CHF = congestive heart failure; IHD = ischaemic heart disease; TIA = transient ischaemic attack; OR = 
odds ratio; CI = confidence interval 
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The study population encompassed 53.8% female patients, and 41.7% were below 
the age of 40 years. Current smoking (OR 1.52, 95% CI 1.46-1.58) and obesity (BMI 
≥30 kg/m2) (OR 1.38, 95% CI 1.31-1.45) were associated with a small increased 
psoriasis risk. None of the cardiovascular diseases we tested in the analysis was 
associated with a materially altered psoriasis risk (table 3.1.1). 
Compared with the reference group of nonuse, the adjusted ORs for current use of 
the antihypertensive drug groups of interest were all close to one.  
The results of the analyses in which we evaluated duration and timing of use are 
displayed in table 3.1.2 for the first adjusted model and in table 3.1.3 for the mutually 
exclusive drug use model. In both models, most ORs were close to one. The 
adjusted ORs for current use of ≥20 beta-blocker prescriptions were 1.10 (95% CI 
1.01-1.20) in the first model and 1.13 (95% CI 0.98-1.30) in the mutually exclusive 
model.  
 
Table 3.1.2 Risk of first-time psoriasis diagnosis associated with the use of antihypertensive drugs  
Exposure 
(No of Rx) 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
ACE 
inhibitors 
 nonuse 
 current 
 1-4 
 5-19 
    ≥20 
 past 
     1-4 
     5-19 
 ≥20 
 
 
34,117 
 
158 
494 
1015 
 
418 
321 
179 
 
 
(93.0) 
 
(0.43) 
(1.35) 
(2.77) 
 
(1.14) 
(0.87) 
(0.49) 
 
 
34,212 
 
142 
473 
1045 
 
359 
282 
189 
 
 
(93.2) 
 
(0.39) 
(1.29) 
(2.85) 
 
(0.98) 
(0.77) 
(0.51) 
 
 
1.00 
 
1.12 
1.05 
0.98 
 
1.17 
1.15 
0.96 
 
 
(reference) 
 
(0.89 - 1.41) 
(0.92 - 1.19) 
(0.89 - 1.07) 
 
(1.02 - 1.35) 
(0.97 - 1.35) 
(0.78 - 1.18) 
 
 
1.00 
 
1.04 
0.95 
0.90 
 
1.04 
1.01 
0.86 
 
 
(reference) 
 
(0.82 - 1.31) 
(0.83 - 1.08) 
(0.81 - 0.99) 
 
(0.89 - 1.22) 
(0.84 - 1.20) 
(0.69 - 1.07) 
Beta-blockers 
 nonuse 
 current 
 1-4 
 5-19 
    ≥20 
 past 
     1-4 
     5-19 
 ≥20 
 
30,907 
 
212 
608 
1686 
 
2009 
753 
527 
 
(84.2) 
 
(0.58) 
(1.66) 
(4.59) 
 
(5.47) 
(2.05) 
(1.44) 
 
31,241 
 
224 
527 
1501 
 
1982 
731 
496 
 
(85.1) 
 
(0.61) 
(1.44) 
(4.09) 
 
(5.40) 
(1.99) 
(1.35) 
 
1.00 
 
0.97 
1.18 
1.16 
 
1.03 
1.05 
1.10 
 
(reference) 
 
(0.80 - 1.17) 
(1.05 - 1.33) 
(1.07 - 1.25) 
 
(0.97 - 1.10) 
(0.95 - 1.17) 
(0.97 - 1.24) 
 
1.00 
 
0.93 
1.10 
1.10 
 
0.99 
0.99 
1.03 
 
(reference) 
 
(0.76 - 1.13) 
(0.97 - 1.24) 
(1.01 - 1.20) 
 
(0.92 - 1.06) 
(0.89 - 1.10) 
(0.90 - 1.18) 
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Table 3.1.2 (cont.) 
Exposure 
(No of Rx) 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
AT II 
antagonists 
 nonuse 
 current 
 1-9 
 ≥10 
 past 
 1-9 
      ≥10 
 
 
36,225 
 
119 
250 
 
81 
27 
 
 
(98.7) 
 
(0.32) 
(0.68) 
 
(0.22) 
(0.07) 
 
 
36,277 
 
111 
221 
 
72 
21 
 
 
(98.8) 
 
(0.30) 
(0.60) 
 
(0.20) 
(0.06) 
 
 
1.00 
 
1.08 
1.14 
 
1.13 
1.30 
 
 
(reference) 
 
(0.83 - 1.40) 
(0.95 - 1.37) 
 
(0.82 - 1.56) 
(0.73 - 2.34) 
 
 
1.00 
 
1.01 
1.05 
 
1.09 
1.26 
 
 
(reference) 
 
(0.77 - 1.32) 
(0.86 - 1.28) 
 
(0.78 - 1.52) 
(0.69 - 2.28) 
CCBs 
 nonuse 
 current 
 1-4 
 5-19 
    ≥20 
 past 
 1-4 
 5-19 
 ≥20 
 
33,500 
 
135 
494 
1216 
 
683 
370 
304 
 
(91.3) 
 
(0.37) 
(1.35) 
(3.31) 
 
(1.86) 
(1.01) 
(0.83) 
 
33,755 
 
143 
444 
1146 
 
598 
328 
288 
 
(92.0) 
 
(0.39) 
(1.21) 
(3.12) 
 
(1.63) 
(0.89) 
(0.78) 
 
1.00 
 
0.96 
1.14 
1.09 
 
1.16 
1.16 
1.08 
 
(reference) 
 
(0.76 - 1.22) 
(1.00 - 1.30) 
(1.00 - 1.18) 
 
(1.04 - 1.30) 
(0.99 - 1.34) 
(0.92 - 1.28) 
 
1.00 
 
0.89 
1.02 
0.97 
 
1.06 
1.04 
0.97 
 
(reference) 
 
(0.70 - 1.13) 
(0.89 - 1.17) 
(0.88 - 1.07) 
 
(0.94 - 1.19) 
(0.88 - 1.21) 
(0.81 - 1.16) 
Clonidine 
 nonuse 
 current 
 1-9 
 ≥10 
 past 
     1-9 
     ≥10 
 
36,228 
 
23 
22 
 
389 
40 
 
(98.7) 
 
(0.06) 
(0.06) 
 
(1.06) 
(0.11) 
 
36,236 
 
25 
27 
 
368 
46 
 
(98.7) 
 
(0.07) 
(0.07) 
 
(1.00) 
(0.13) 
 
1.00 
 
0.93 
0.81 
 
1.06 
0.88 
 
(reference) 
 
(0.53 - 1.63) 
(0.46 - 1.44) 
 
(0.91 - 1.23) 
(0.57 - 1.34) 
 
1.00 
 
0.82 
0.81 
 
1.01 
0.85 
 
(reference) 
 
(0.46 - 1.45) 
(0.45 - 1.45) 
 
(0.87 - 1.18) 
(0.55 - 1.31) 
Diuretics 
 nonuse 
 current 
 1-4 
 5-19 
 ≥20 
past 
 1-4 
     5-19 
 ≥20 
 
30,949 
 
291 
828 
1981 
 
1608 
624 
421 
 
(84.3) 
 
(0.79) 
(2.26) 
(5.40) 
 
(4.38) 
(1.70) 
(1.15) 
 
31,488 
 
267 
759 
1941 
 
1366 
544 
337 
 
(85.8) 
 
(0.73) 
(2.07) 
(5.29) 
 
(3.72) 
(1.48) 
(0.92) 
 
1.00 
 
1.14 
1.15 
1.08 
 
1.23 
1.20 
1.32 
 
(reference) 
 
(0.97 - 1.35) 
(1.03 - 1.27) 
(1.01 - 1.16) 
 
(1.14 - 1.33) 
(1.07 - 1.35) 
(1.14 - 1.53) 
 
1.00 
 
1.11 
1.09 
1.05 
 
1.17 
1.16 
1.27 
 
(reference) 
 
(0.93 - 1.32) 
(0.98 - 1.22) 
(0.96 - 1.14) 
 
(1.08 - 1.27) 
(1.03 - 1.32) 
(1.09 - 1.48) 
* Adjusted for arrhythmias, congestive heart failure, chronic obstructive pulmonary disease, ischaemic heart disease, 
stroke/transient ischaemic attack, hypertension, asthma, diabetes, hyperlipidaemia, alcoholism, use of coronary vasodilatators, 
body mass index, smoking, and antihypertensives not under investigation 
Rx = prescriptions; ACE = angiotensin converting enzyme; AT = angiotensin; CCB = calcium channel blocker; OR = odds ratio; 
CI = confidence interval 
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Table 3.1.3 Risk of first-time psoriasis diagnosis associated with the use of antihypertensive drugs in 
mutually exclusive groups 
Exposure 
(No of Rx) 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
Nonuse 26,544 (72.3) 27,153 (74.0) 1.00 (reference) 1.00 (reference) 
ACE 
inhibitors 
  current 
 1-4 
 5-19 
 ≥20 
 past 
     1-4 
     5-19 
 ≥20 
 
 
23 
65 
111 
 
23 
15 
8 
 
 
 
(0.06) 
(0.18) 
(0.30) 
 
(0.06) 
(0.04) 
(0.02) 
 
 
 
17 
70 
120 
 
28 
12 
9 
 
 
 
(0.05) 
(0.19) 
(0.33) 
 
(0.08) 
(0.03) 
(0.02) 
 
 
 
1.40 
0.96 
0.99 
 
0.88 
1.29 
0.91 
 
 
 
(0.75 - 2.63) 
(0.68 - 1.35) 
(0.76 - 1.28) 
 
(0.51 - 1.53) 
(0.60 - 2.75) 
(0.35 - 2.37) 
 
 
 
1.39 
0.92 
0.96 
 
0.84 
1.29 
0.90 
 
 
 
(0.73 - 2.65) 
(0.65 - 1.32) 
(0.74 - 1.26) 
 
(0.48 - 1.47) 
(0.60 - 2.78) 
(0.34 - 2.38) 
Beta-
blockers 
 current 
 1-4 
 5-19 
 ≥20 
 past 
     1-4 
     5-19 
 ≥20 
 
 
 
106 
203 
504 
 
1248 
241 
99 
 
 
 
(0.29) 
(0.55) 
(1.37) 
 
(3.40) 
(0.66) 
(0.27) 
 
 
 
123 
188 
458 
 
1259 
261 
80 
 
 
 
(0.34) 
(0.51) 
(1.25) 
 
(3.43) 
(0.71) 
(0.22) 
 
 
 
0.89 
1.13 
1.17 
 
1.02 
0.96 
1.32 
 
 
 
(0.69 - 1.16) 
(0.92 - 1.38) 
(1.03 - 1.33) 
 
(0.94 - 1.11) 
(0.81 - 1.15) 
(0.98 - 1.78) 
 
 
 
0.86 
1.05 
1.13 
 
0.99 
0.93 
1.28 
 
 
 
(0.66 - 1.12) 
(0.86 - 1.29) 
(0.98 - 1.30) 
 
(0.91 - 1.08) 
(0.77 - 1.11) 
(0.95 - 1.74) 
AT II 
antagonists 
 current 
 1-9 
 ≥10 
 past 
     1-9 
      ≥10 
 
 
 
0 
6 
 
2 
0 
 
 
 
(0.00) 
(0.02) 
 
(0.01) 
(0.00) 
 
 
 
7 
6 
 
3 
0 
 
 
 
(0.02) 
(0.02) 
 
(0.01) 
(0.00) 
 
 
 
0.00 
1.06 
 
0.70 
NA 
 
 
 
(NA) 
(0.34 - 3.29) 
 
(0.12 - 4.24) 
(NA) 
 
 
 
0.00 
1.10 
 
0.81 
NA 
 
 
 
(NA) 
(0.35 - 3.44) 
 
(0.13 - 4.93) 
(NA) 
CCBs 
 current 
 1-4 
 5-19 
 ≥20 
 past 
     1-4 
     5-19 
 ≥20 
 
 
19 
68 
174 
 
137 
33 
24 
 
 
(0.05) 
(0.19) 
(0.47) 
 
(0.37) 
(0.09) 
(0.07) 
 
 
32 
58 
168 
 
135 
26 
28 
 
 
(0.09) 
(0.16) 
(0.46) 
 
(0.37) 
(0.07) 
(0.08) 
 
 
0.61 
1.25 
1.10 
 
1.05 
1.32 
0.92 
 
 
(0.35 - 1.09) 
(0.88 - 1.78) 
(0.89 - 1.36) 
 
(0.83 - 1.34) 
(0.79 - 2.21) 
(0.53 - 1.61) 
 
 
0.57 
1.15 
1.03 
 
0.98 
1.19 
0.90 
 
 
(0.32 - 1.01) 
(0.80 - 1.64) 
(0.83 - 1.29) 
 
(0.76 - 1.24) 
(0.71 - 2.01) 
(0.51 - 1.58) 
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Table 3.1.3 (cont.) 
Exposure 
(No of Rx) 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
Clonidine 
 current 
 1-9 
 ≥10 
 past 
     1-9 
     ≥10 
 
 
15 
8 
 
150 
7 
 
 
(0.04) 
(0.02) 
 
(0.41) 
(0.02) 
 
 
14 
12 
 
167 
16 
 
 
(0.04) 
(0.03) 
 
(0.46) 
(0.04) 
 
 
1.13 
0.74 
 
0.94 
0.45 
 
 
(0.54 - 2.35) 
(0.30 - 1.83) 
 
(0.75 - 1.17) 
(0.18 - 1.09) 
 
 
1.00 
0.78 
 
0.93 
0.43 
 
 
(0.48 - 2.10) 
(0.31 - 1.94) 
 
(0.74 - 1.17) 
(0.17 - 1.07) 
Diuretics 
 current 
 1-4 
 5-19 
 ≥20 
 past 
     1-4 
     5-19 
 ≥20 
 
 
114 
244 
481 
 
876 
203 
100 
 
 
(0.31) 
(0.66) 
(1.31) 
 
(2.39) 
(0.55) 
(0.27) 
 
 
114 
219 
481 
 
713 
168 
66 
 
 
(0.31) 
(0.60) 
(1.31) 
 
(1.94) 
(0.46) 
(0.18) 
 
 
1.08 
1.20 
1.09 
 
1.30 
1.29 
1.63 
 
 
(0.83 - 1.40) 
(0.99 - 1.44) 
(0.95 - 1.24) 
 
(1.17 - 1.44) 
(1.05 - 1.58) 
(1.19 - 2.23) 
 
 
1.09 
1.17 
1.04 
 
1.21 
1.24 
1.65 
 
 
(0.83 - 1.42) 
(0.96 - 1.41) 
(0.91 - 1.19) 
 
(1.09 - 1.34) 
(1.01 - 1.53) 
(1.20 - 2.27) 
Mixed use 4851 (13.22) 4491 (12.24) 1.16 (1.10 - 1.22) 1.09 (1.02 - 1.17) 
* Adjusted for arrhythmias, congestive heart failure, chronic obstructive pulmonary disease, ischaemic heart disease, 
stroke/transient ischaemic attack, hypertension, asthma, diabetes, hyperlipidaemia, alcoholism, use of coronary vasodilatators, 
body mass index, smoking 
Rx = prescriptions; ACE = angiotensin converting enzyme; AT = angiotensin; CCB = calcium channel blocker; OR = odds ratio; 
CI = confidence interval 
 
Neither stratification by sex nor by age (<40 vs. ≥40 years) provided evidence for 
effect modification, although exposure prevalence was low in patients below the age 
of 40 years for most antihypertensives (data not shown). 
The results of the analyses of beta-blockers stratified by physicochemical properties 
or pharmacological mechanism of action, based on the adjusted model with 
overlapping use, are displayed in table 3.1.4. Most ORs were around one. While 
other beta-blockers were not associated with an increased psoriasis risk, the 
adjusted OR for ≥20 timolol prescriptions was 2.44 (95% CI 1.16-5.14), based on 25 
exposed cases and 10 exposed controls, and 1.18 (95% CI 1.01-1.37) for users of 5-
19 atenolol prescriptions, based on 425 cases and 344 controls.  
We also stratified current users of CCBs, AT II antagonists, or ACE-inhibitors by 
physicochemical properties or pharmacological mechanism of action and by 
individual agents. We found a statistically significantly reduced psoriasis risk for use 
of ≥20 verapamil prescriptions (OR 0.33, 95% CI 0.16-0.71) and for 1-4 diltiazem 
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prescriptions (OR 0.25, 95% CI 0.07-0.93) in the mutually exlusive model and an 
adjusted OR of 1.60 (95% CI 1.02-2.51) for use of ≥10 prescriptions for the AT-II-
antagonist candesartan, while the risk estimates for individal ACE-inhibitors were 
close to one.  
 
Table 3.1.4 Risk of first-time psoriasis diagnosis associated with current beta-blocker use  
Exposure 
(No of Rx) 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Adjusted OR** 
(95% CI) 
Cardioselective* 
 1-4 
 5-19 
 ≥20 
Noncardioselective* 
 1-4 
 5-19 
 ≥20 
 
142 
491 
1351 
 
70 
117 
335 
 
(0.39) 
(1.34) 
(3.68) 
 
(0.19) 
(0.32) 
(0.91) 
 
137 
422 
1218 
 
87 
105 
283 
 
(0.37) 
(1.15) 
(3.32) 
 
(0.24) 
(0.29) 
(0.77) 
 
1.01 
1.10 
1.08 
 
0.80 
1.08 
1.18 
 
(0.79 - 1.29) 
(0.96 - 1.27) 
(0.99 - 1.19) 
 
(0.58 - 1.10) 
(0.83 - 1.42) 
(1.00 - 1.40) 
Hydrophilic* 
 1-4 
 5-19 
 ≥20 
Lipophilic* 
 1-4 
 5-19 
 ≥20 
Mixed* 
 1-4 
 5-19 
 ≥20 
 
144 
485 
1350 
 
62 
97 
242 
 
6 
26 
94 
 
(0.39) 
(1.32) 
(3.68) 
 
(0.17) 
(0.26) 
(0.66) 
 
(0.02) 
(0.07) 
(0.26) 
 
138 
415 
1209 
 
79 
82 
216 
 
7 
30 
76 
 
(0.38) 
(1.13) 
(3.29) 
 
(0.22) 
(0.22) 
(0.59) 
 
(0.02) 
(0.08) 
(0.21) 
 
1.03 
1.11 
1.10 
 
0.78 
1.15 
1.11 
 
0.69 
0.82 
1.21 
 
(0.81 - 1.31) 
(0.96 - 1.27) 
(1.00 - 1.20) 
 
(0.56 - 1.10) 
(0.85 - 1.55) 
(0.92 - 1.34) 
 
(0.22 - 2.12) 
(0.48 - 1.41) 
(0.88 - 1.65) 
* cardioselective (acebutolol, atenolol, betaxolol, bisoprolol, celiprolol, esmolol, metoprolol, nebivolol), noncardioselective 
(carteolol, carvedilol, labetalol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol); lipophilic (nebivolol, 
oxprenolol, penbutolol, propranolol), hydrophilic (acebutolol, atenolol, bisoprolol, carteolol, celiprolol, esmolol, labetalol, nadolol, 
pindolol, sotalol), or mixed (betaxolol, carvedilol, metoprolol, timolol) beta-blockers. 
** Adjusted for arrhythmias, congestive heart failure, chronic obstructive pulmonary disease, ischaemic heart disease, 
stroke/transient ischaemic attack, hypertension, asthma, diabetes, hyperlipidaemia, alcoholism, use of coronary vasodilatators, 
body mass index, smoking, antihypertensives not under investigation 
Reference: nonuse of beta-blockers 
Rx = prescriptions; OR = odds ratio; CI = confidence interval 
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We further conducted various sensitivity analyses. First, we ran the two final models 
(adjusted and mutually exclusive antihypertensive drug use) in a subgroup of case 
patients (n = 20,726) and their controls who received calcipotriol, coal tar, dithranol, 
tazarotene, or acitretin in the first year after the psoriasis diagnosis. Second, we 
restricted an analysis to psoriasis cases (n = 29,170) and their controls who did not 
have any prescription recorded for any of the five drugs mentioned above at any time 
prior to the first-time psoriasis diagnosis. Third, we ran a final model with 15,336 
cases who received drug treatment in the first year after their psoriasis diagnosis and 
who did not have any of these medications at any time prior to the first-time psoriasis 
diagnosis. Fourth, we conducted analyses restricted to psoriasis cases (n = 32,304) 
without any evidence of previous or concomitant allergic skin diseases, contact 
dermatitis, or atopic dermatitis as well as restricted to psoriasis cases (n = 35,092) 
without diagnosed skin infections prior to the index date. We ran these analyses as 
patients with other skin diseases may be more likely to be misdiagnosed with 
psoriasis. In all these subgroups, the findings related to use of antihypertensives 
remained virtually unchanged (data not shown). Fifth, guttate psoriasis is believed to 
be triggered mainly by drugs, and we therefore ran the first adjusted model in the 
subgroup of cases with a diagnosis of guttate psoriasis (n = 2866). In this analysis, 
past use of ≥20 beta-blocker prescriptions yielded an OR of 2.17 (95% CI 0.90-5.24), 
and past use of 1-4 ACE-inhibitor prescriptions yielded an OR of 3.70 (95% CI 1.20-
11.35). 
 
3.1.5 Discussion 
The findings of this large population-based case-control analysis do not support the 
current notion that use of any antihypertensives is associated with a materially 
altered risk of developing a first-time psoriasis diagnosis. We cannot make a 
statement about the association between use of these drugs and the risk of an 
exacerbation of existing psoriasis as this would require a different approach. 
Current long-term use of ≥20 beta-blocker prescriptions was associated with a 
relative risk estimate of 1.10 (95% CI 1.01-1.20). We also created more exposure 
duration categories for users of beta-blockers, but there was no evidence for an 
increasing psoriasis risk with increasing duration of use of up to ≥70 prescriptions 
(data not shown). Thus, these findings provide evidence that cumulative exposure 
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duration to beta-blockers is not a substantial risk factor for psoriasis. However, we 
cannot exclude the possibility that certain beta-blockers may be able to trigger 
psoriasiform eruptions in individual patients with a high individual susceptibility based 
on a particular genetic or metabolic predisposition. 
We did not find differences for cardioselective (β1 receptor antagonists) vs. non-
selective beta-blockers (β1 and β2 receptor antagonists), nor for hydrophilic vs. 
lipophilic agents. However, when we analysed individual beta-blockers, we found a 
substantially increased OR of 2.44 (95% CI 1.16-5.14) for current users of ≥20 timolol 
prescriptions. This finding, based on 25 exposed cases and 10 exposed controls, 
may be real, but it may also be a chance finding despite statistical significance.  
Previous reports in the literature on a possible association between beta-blockers 
and psoriasis were based mainly on case reports and case series78, 79 or on animal 
models.96 Despite several reports on psoriasiform eruptions and psoriasis following 
treatment with beta-blockers, biopsy was performed in only a few cases (propranolol, 
practolol), and when done it rarely confirmed psoriasis.95, 140, 142 In a recent review143 
it was postulated that the origin and treatment of drug-induced psoriasis was different 
from true psoriasis based on a study by Heng and Heng148 who demonstrated 
histopathological and immunohistochemical differences between true psoriasis and 
beta-blocker-induced psoriasis as well as between drug-induced and drug-
aggravated psoriasis, the latter being more similar to true psoriasis. Another group 
examined 21 patients with drug-induced rashes from practolol (14 with a psoriasiform 
eruption) and made a similar observation.141 In the 1970s it was proposed that 
practolol-induced skin lesions could be distinguished from psoriasis with careful 
clinical examination.149 The mechanism by which beta-blockers might induce or 
exacerbate psoriasis is largely unknown, even though a blockade of beta-adrenergic 
receptors resulting in a decrease of cyclic adenosine monophosphate (cAMP) and 
calcium, followed by stimulation of epidermal growth, has been proposed as a 
leading hypothesis.143 However, it is an open question why noncardioselective as 
well as cardioselective beta-blockers have both been associated with psoriasis in 
previous reports even though the predominant adrenergic receptor in epidermal 
keratinocytes is the β2-subtype. In addition, the wide latency ranges which were 
reported between the start of use of a beta-blocker therapy and the onset of a 
psoriatic skin eruption (several days up to 26 months in patients without a history of 
psoriasis) do not necessarily support a causal relation.95, 96 
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For ACE inhibitors and AT II antagonists there are only few case reports in the 
literature on a possible induction of psoriasis with a typical psoriasiform histology and 
with cessation of symptoms after discontinuation of the therapy.96, 144 A recent study 
suggested that patients with an ACE gene genotype of low ACE-activity, which 
seems often to occur in patients with familial psoriasis, were more susceptible to the 
onset of psoriasis.150 The results of our study do not support the notion of a 
substantially altered psoriasis risk for users of ACE-inhibitors or AT II antagonists, but 
again we cannot exclude the possibility that individual patients with a particular 
susceptibility may develop such reactions while taking an ACE-inhibitor.  
A small hospital-based case-control study of 150 patients hospitalised for psoriasis or 
psoriasiform eruptions and 150 controls was done to investigate a possible 
association between CCB use and psoriasis. A significantly increased OR was 
observed for CCB use, with a median latency between initiation of therapy and onset 
of the disease of 28 months (range 4-143 months).145 In our study we did not find an 
increased risk, but a slightly reduced risk for short-term use of diltiazem and long-
term use of verapamil. This observation may be a chance finding, or it may reflect a 
pharmacological effect by some CCBs on psoriasis, e.g. via an anti-inflammatory 
effect which has been described in several articles.151, 152  
Previous literature suggests an increased prevalence of cardiovascular risk factors 
(such as diabetes, hypertension, and hyperlipidaemia) as well as other 
cardiovascular diseases in patients with psoriasis.86, 102, 103, 108, 112 In our study we did 
not find an increased prevalence of such diseases in patients with psoriasis prior to 
the first psoriasis diagnosis, but patients with psoriasis may develop such diseases 
after the onset of psoriasis. Neimann et al. reported a higher prevalence of diabetes, 
hypertension, hyperlipidaemia, smoking, and obesity in patients with psoriasis, with a 
higher prevalence of these diseases with increasing psoriasis severity.103 In addition, 
Gelfand et al. documented an increased risk of MI in patients with psoriasis, 
particularly in younger patients with severe psoriasis.108 It is conceivable that lifestyle, 
antipsoriatic medication (e.g. potent corticosteroids) as well as the inflammatory 
process of the disease itself may increase the risk of cardiovascular diseases in 
patients with psoriasis. We found a significantly higher prevalence of smokers and 
obese subjects among patients with psoriasis at the time of the first diagnosis, as 
previously described in the literature.88 
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We explored the association between use of antihypertensive drugs and the risk of 
developing a first-time diagnosis of psoriasis. Thus, we cannot exclude the possibility 
that some of these agents may cause a worsening or exacerbation of pre-existing 
psoriasis. It was postulated that any drug that can cause skin eruptions can also 
exacerbate psoriasis as a result of a Koebner reaction.85   
A limitation of our study is the fact that we cannot exclude the possibility of a certain 
degree of diagnosis misclassification, leading to the inclusion of psoriasis cases who 
in fact did not have a first-time diagnosis of psoriasis because other previous skin 
eruptions may have been misdiagnosed. Gelfand et al. studied psoriasis in previous 
GPRD-based studies, and their validation procedures documented that the psoriasis 
diagnoses are generally of high validity in the GPRD.115, 139, 147 In addition, we 
conducted various sensitivity analyses to improve the validity of our study, which left 
the findings virtually unchanged. Another limitation is the fact that the exposure 
prevalence of antihypertensives among patients below the age of 40 years is low, 
and that our conclusions are therefore mainly based on patients above the age of 40 
years. Thus, we cannot exclude the possibility that antihypertensives may have a 
different effect on younger age groups with type I psoriasis. 
Although we tested a large number of potential confounding factors and included the 
most relevant ones in our model, we cannot exclude the possibility that other 
unknown confounders or biases may have affected our results to some degree. 
In summary, the present population-based case-control study is, to our knowledge, 
the largest study so far to explore a possible association between use of beta-
blockers or other antihypertensives and the risk of developing psoriasis. The findings 
provide evidence that use of beta-blockers or other antihypertensives does not 
substantially alter the risk of developing a first-time psoriasis diagnosis.  
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3.2.1 Abstract 
Background: Observations in controlled trials and case reports have linked lithium 
exposure to induction or exacerbation of psoriasis. A causal relationship between 
lithium exposure and incident psoriasis has been questioned, and observational 
studies are lacking. 
Methods: We conducted a case-control analysis using the UK-based GPRD to study 
the association between use of lithium or antipsychotics and the risk of developing an 
incident psoriasis diagnosis. We identified cases with an incident psoriasis diagnosis 
between 1994 and 2005, and controls were matched to cases on age, sex, general 
practice, calendar time, and years of history in the database. We used conditional 
logistic regression to estimate the risk of developing a first-time psoriasis diagnosis in 
relation to previous exposure to lithium and antipsychotic drugs, stratified by 
exposure timing and duration. We calculated ORs with 95% CI adjusted for smoking, 
BMI, and additional potential confounders. 
Results: We identified 36,702 incident psoriasis cases and the same number of 
matched controls. Compared with nonuse, current use of 5 prescriptions for lithium 
or atypical antipsychotics yielded adjusted ORs of 1.68 (95% CI 1.18-2.39, p <0.01) 
and 0.76 (95% CI 0.55-1.06, p = 0.11), respectively. The OR for olanzapine was 0.50 
(95% CI 0.28-0.89, p = 0.02). 
Conclusions: Long-term use of lithium was associated with a small increase in risk of 
incident psoriasis. There was a suggestion of a possible reduced psoriasis risk 
associated with the use of atypical antipsychotics, mainly olanzapine, a finding which 
needs further evaluation.  
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3.2.2 Background 
Psoriasis is a chronic inflammatory skin disease with an estimated prevalence 
ranging between 0.6% and 4.8%62 depending on region or ethnicity.63 Psoriasis has a 
considerable impact on a patient’s QoL.44, 62 The disease is characterised by T cell-
mediated hyperproliferation of keratinocytes and inflammatory processes. Naïve T 
cells are converted to T cells of the Th1 and Th17 lineage in secondary lymphatic 
organs which produce cytokines such as IL-22, IFN-γ, TNF-β and IL-6, IL-17, IL-22, 
respectively. These and other immune cells infiltrate the skin and activate each other 
and the keratinocytes via the previously mentioned cytokines and additional ones 
(such as TNF-α, IL-20, IL-23, TGF-α), which sustains an inflammatory process.48 A 
variety of potential risk or triggering factors have been described such as smoking, 
alcohol consumption, BMI, trauma, infections, stressful life events, endocrine factors, 
diet, or exposure to drugs. Among the drugs, beta-blockers, lithium, and antimalarial 
drugs have been associated with psoriasis, but there have also been reports for 
NSAIDs, ACE-inhibitors, interferons, SSRIs, benzodiazepines, and the acute 
withdrawal of systemic or potent topical corticosteroids.62, 85, 87, 88, 91, 95, 96 
Lithium was introduced in the 1960s for the treatment of bipolar disorders. In the 
1970s the first case reports on exacerbation or induction of psoriasis emerged, 
although the latter seems to be less common.87, 95 In controlled trials, 3.4% to 45% of 
lithium-exposed patients developed cutaneous reactions, mainly acne and 
psoriasis.153 The latency period has been reported to be relatively long, on average 
20 weeks for exacerbation and 48 weeks for induction of psoriasis. However, the 
hypothesis that lithium increases the risk of developing psoriasis has not been fully 
accepted.87, 154 Some reports have described patients with psoriasisform dermatitis 
rather than true psoriasis, and the mechanism of lithium action on psoriasis is still 
under discussion.87, 97 We therefore decided to study the association between lithium 
exposure and new-onset psoriasis in a large population-based case-control analysis, 
similar to a recent analysis on the use of beta-blockers and psoriasis.155  
With the exception of three reports on induction or exacerbation of psoriasis after 
exposure to olanzapine,156, 157 we could not find any published reports of a potential 
association between other antipsychotics and psoriasis. Stressful life events have 
been reported to trigger psoriasis,88 and the prevalence of psychiatric diseases, 
mainly depression and anxiety, is high in psoriatic patients.132  
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As, to our knowledge, no large population-based study has been published 
investigating the association between antipsychotic exposure and the risk of 
developing an incident psoriasis diagnosis, we investigated the role of antipsychotics 
and lithium exposure in a case-control analysis. 
 
3.2.3 Methods 
We conducted a matched case-control analysis within the UK-based GPRD to 
investigate the risk of developing a first-time psoriasis diagnosis in relation to 
previous use of lithium, phenothiazines, butyrophenones, atypical antipsychotics, or 
other antipsychotic drugs. 
 
Data Source 
The GPRD is a large UK-based database established around 1987 which 
encompasses some five million patients who are actively enrolled with selected GPs. 
The GPs have agreed to provide data for research purposes to the GPRD. GPs have 
been trained to record medical information in a standard manner and to supply it 
anonymously. The patients enrolled in the GPRD are representative of the UK in age, 
sex, geographic distribution, and annual turnover rate. The information recorded 
includes patient demographics and characteristics (e.g. age, sex, height, weight, and 
smoking status), symptoms, medical diagnoses, referrals to consultants, and 
hospitalisations. Because the physicians generate drug prescriptions directly with the 
computer using a coded drug dictionary, all prescriptions including the name of the 
preparation (active compound), the route of administration, the dose of a single unit, 
the number of units prescribed and, in most instances, the intake regimen are 
recorded. The database has been described in detail elsewhere36, 38 and validated 
extensively.34 It has been the source for numerous published epidemiological studies 
including several studies on psoriasis. 
The study protocol was approved by ISAC for MHRA database research. 
 
Case definition and ascertainment 
We identified patients with a first-time diagnosis of psoriasis between 1 January  
1994 and 31 December 2005 via OXMIS and Read codes. Patients with less than 
three years of active history in the database prior to the first-time diagnosis of 
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psoriasis and those with a code for ‘history of psoriasis’ at the index date were 
excluded.  
The validity of psoriasis diagnoses in the GPRD is high, 115, 139, 147 and we thus 
included all patients with a recorded psoriasis diagnosis in the main analysis. In 
addition, we conducted a number of sensitivity analyses in patients with definitive and 
incident psoriasis who fulfilled stringent treatment requirements as was done in 
previous GPRD-based studies on psoriasis.155, 158  
 
Controls 
From the base population we randomly identified one control subject per psoriasis 
case, matched on calendar time (same index date), age (same year of birth), sex, 
general practice, and years of history in the GPRD. Thus, the controls were also 
required to have at least three years of active history in the GPRD. 
 
Exposure to lithium and antipsychotics 
From the computer record, we assessed exposure to lithium, phenothiazines, 
butyrophenones, atypical antipsychotics, and other antipsychotics prior to the index 
date for cases and controls. Patients were classified as ‘current users’ if the last 
prescription was recorded <90 days, or as ‘past users’ if it was recorded ≥90 days 
prior to the index date. We also classified users by duration of use prior to the index 
date, based on the number of prescriptions (1-2, 3-14, or ≥15 prescriptions for 
phenothiazines or 1-4 or ≥5 for the other drug classes). Finally, we combined 
duration and timing of use into one exposure variable.  
We conducted two main analyses: in the first model, patients could have been 
exposed to lithium or various antipsychotics subsequently or concurrently prior to the 
index date, and we adjusted for such overlapping use in the multivariate model. In 
the second model, subjects were categorised into mutually exclusive groups of users 
of lithium or one antipsychotic drug class, whereas combined use of lithium or 
antipsychotics (“switchers” or concurrent therapies) formed a separate group. 
 
Statistical analysis 
We conducted conditional logistic regression analyses using the SAS statistical 
software (version 9.1; SAS Institute Inc, Cary, NC, U.S.A.) to calculate relative risk 
estimates as ORs with 95% CI. We controlled for the potential confounders age, sex, 
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general practice, calendar time, and years of recorded history in the database by 
matching, and we further adjusted the ORs for smoking status (non, current, ex, or 
unknown) and BMI (<18.5, 18.5-24.9, 25.0-29.9, ≥30 kg/m2, or unknown) in the 
multivariate model. The risk estimates were additionally adjusted for a history of 
atopic and contact dermatitides, hypothyroidism, and neurotic or affective disorders 
and for use of NSAIDs, SSRIs, and benzodiazepines. A variety  of other covariates 
were tested for potential confounding but were not included in the final model 
because they were not materially associated with the exposure or with the outcome, 
such as allergic skin disease, ischaemic heart disease, urticaria / angio-oedema, 
hypertension / hypotension, hyperlipidaemia, hyperthyroidism, skin infections, 
alcoholism, diabetes, epilepsia, rheumatoid arthritis, cancer, intestinal anti-
inflammatory agents, use of mono-amine re-uptake inhibitors, mono-amine oxidase 
inhibitors, or other antidepressives. 
 
3.2.4 Results 
We identified 36,702 cases with a first-time psoriasis diagnosis between 1994 and 
2005 and the same number of matched controls. Table 3.2.1 displays the age and 
sex distribution of cases and controls and the distribution of smoking status, BMI, and 
additional parameters. 
Of the newly diagnosed psoriasis patients, 53.8% were women and 46.2% men, and 
41.8% were younger than 40 years. Current smoking (OR 1.51, 95% CI 1.45-1.57, p 
<0.0001), obesity (BMI ≥30 kg/m2; OR 1.33, 95% CI 1.26-1.40, p <0.0001), and 
current exposure to ≥5 prescriptions of NSAIDs (OR 1.36. 95% CI 1.26-1.46, p 
<0.0001) were associated with an increased relative psoriasis risk. Furthermore, 
cases had a higher prevalence of first-time diagnoses of affective or neurotic 
disorders around the index date (table 3.2.1). 
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Table 3.2.1: Characteristics of case patients with psoriasis and matched controls 
Variable 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Adjusted OR* 
(95% CI) 
Sex** 
      
 Men 16,969 (46.2) 16,969 (46.2) - - 
 Women 19,733 (53.8) 19,733 (53.8) - - 
Agegroup (years)** 
      
 <40 15,324  (41.8) 15,327 (41.8) - - 
 40-59 11,162 (30.4) 11,168  (30.4) - - 
 ≥60 10,216 (27.8) 10,207 (27.8) - - 
Smoking status 
      
 Non smoker 13,390 (36.5) 15,594 (42.5)     1.00 (reference) 
 Current smoker 8787 (23.9) 6913 (18.8) 1.51 (1.45 - 1.57) 
 Ex smoker 4690 (12.8) 3763 (10.3) 1.46 (1.39 - 1.54) 
 Unknown 9835 (26.8) 10,432 (28.4) 1.09 (1.03 - 1.16) 
BMI (kg/m2)       
 12-18.4 523 (1.4) 574 (1.6) 0.92 (0.81 - 1.04) 
 18.5-24.9 10,244 (27.9) 10,887 (29.6)   1.00 (reference) 
 25-29.9 8330 (22.7) 7934 (21.6) 1.12 (1.07 - 1.17) 
 30-60 4881 (13.3) 3882 (10.6) 1.33 (1.26 - 1.40) 
 Unknown 12,724 (34.7) 13,425 (36.6) 0.99 (0.94 - 1.04) 
Comorbidities       
Atopic dermatitis 2092 (5.7) 1042 (2.8) 2.10 (1.94 - 2.28) 
Contact dermatitis 1439 (3.9) 903 (2.5) 1.52 (1.39 - 1.65) 
Hypothyroidism 1130 (3.1) 908 (2.5) 1.21 (1.11 - 1.33) 
Neurotic disorder 5463 (14.9) 4851 (13.2) 1.07 (1.02 - 1.13) 
recent Dx 129 (0.4) 59 (0.2) 2.20 (1.60 - 3.03) 
past Dx 5334 (14.5) 4792 (13.1) 1.06 (1.01 - 1.11) 
Affective disorder 5887 (16.0) 5116 (13.9) 1.11 (1.05 - 1.17) 
recent Dx 147 (0.4) 72 (0.2) 1.94  (1.45 - 2.61) 
past Dx 5740 (15.6) 5044 (13.7) 1.09  (1.03 - 1.15) 
Drug exposure (current long-term use) 
NSAID 2290 (6.2) 1768 (4.8) 1.36  (1.26 - 1.46) 
SSRI 413 (1.1) 361 (1.0) 0.93  (0.80 - 1.09) 
Benzodiazepines 947 (2.6) 773 (2.1) 1.14  (1.03 - 1.27) 
* Adjusted for all covariates listed in the table plus drug exposure categories not listed in the table; ** Matching variables 
BMI = body mass index; NSAID = nonsteroidal anti-inflammatory drug; SSRI = selective serotonin re-uptake inhibitor; Dx = 
Diagnosis; Recent = 0-60 days before index date; Past = >60 days; OR = odds ratio; CI = confidence interval 
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Compared with the reference group of nonuse, the adjusted OR for any use of lithium 
(not stratified by duration or timing) was 1.59 (95% CI 1.00-2.51, p = 0.048) in the 
mutually exclusive model and 1.27 (95% CI 0.97-1.65, p = 0.08) in the model 
adjusted for concurrent or subsequent use of antipsychotic study drugs. We then 
assessed the risk estimates of developing psoriasis associated with lithium and other 
study drugs stratified by duration and timing, again in two separate models. As 
compared with nonuse of lithium, the ORs for current use of ≥5 lithium prescriptions 
were 1.68 (95% CI 1.18-2.39, p <0.01) in the model adjusted for use of antipsychotic 
study drugs and 2.19 (95% CI 1.15-4.18, p = 0.02) in the mutually exclusive drug use 
model. The results from these two models are displayed in detail in tables 3.2.2 and 
3.2.3 and the ORs stratified by age and sex in table 3.2.4.   
For current users of ≥5 prescriptions for atypical antipsychotics, the psoriasis risk 
tended to be decreased, mainly in male and younger patients; olanzapine mainly 
accounted for this relative risk reduction (tables 3.2.2 – 3.2.4). For butyrophenones 
(94% haloperidol use), there was a suggestion of a decreased psoriasis risk for past 
users but not for current users (tables 3.2.2 / 3.2.3). For phenothiazines and other 
antipsychotics, most ORs were around one.  
 
Table 3.2.2 Risk of first-time psoriasis diagnosis associated with the use of antipsychotic drugs  
Exposure 
(No of Rx) 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
Lithium 
 nonuse 
 current 
 1-4 
 ≥5 
 past 
     1-4 
     ≥5 
 
36,561 
 
3 
92 
 
21 
25 
 
(99.6) 
 
(0.01) 
(0.25) 
 
(0.06) 
(0.07) 
 
36,594 
 
3 
53 
 
22 
30 
 
(99.7) 
 
(0.01) 
(0.14) 
 
(0.06) 
(0.08) 
 
1.00 
 
1.00 
1.73 
 
0.97 
0.84 
 
(reference) 
 
(0.20 - 4.96) 
(1.24 - 2.43) 
 
(0.53 - 1.76) 
(0.50 - 1.43) 
 
1.00 
 
1.09 
1.68 
 
0.93 
0.78 
 
(reference) 
 
(0.21 - 5.59) 
(1.18 - 2.39) 
 
(0.50 - 1.74) 
(0.45 - 1.36) 
Atypical anti-
psychotics 
 nonuse 
 current 
 1-4 
 ≥5 
 past 
     1-4 
     ≥5 
 
 
36,547 
 
15 
73 
 
38 
29 
 
 
(99.6) 
 
(0.04) 
(0.20) 
 
(0.10) 
(0.08) 
 
 
36,519 
 
17 
89 
 
37 
40 
 
 
(99,5) 
 
(0.05) 
(0.24) 
 
(0.10) 
(0.11) 
 
 
1.00 
 
0.88 
0.82 
 
1.03 
0.73 
 
 
(reference) 
 
(0.44 - 1.77) 
(0.60 - 1.12) 
 
(0.65 - 1.62) 
(0.45 - 1.17) 
 
 
1.00 
 
0.98 
0.76 
 
0.91 
0.71 
 
 
(reference) 
 
(0.48 - 2.02) 
(0.55 - 1.06) 
 
(0.57 - 1.46) 
(0.43 - 1.16) 
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Table 3.2.2 (cont.) 
Exposure 
(No of Rx) 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
Butyro- 
phenones 
 nonuse 
 current 
 1-4 
 ≥5 
 past 
 1-4 
 ≥5 
 
 
36,584 
 
9 
25 
 
56 
28 
 
 
(99.7) 
 
(0.02) 
(0.07) 
 
(0.15) 
(0.08) 
 
 
36,550 
 
11 
23 
 
86 
32 
 
 
(99.6) 
 
(0.03) 
(0.06) 
 
(0.23) 
(0.09) 
 
 
1.00 
 
0.82 
1.09 
 
0.65 
0.88 
 
 
(reference) 
 
(0.34 - 1.97) 
(0.62 - 1.92) 
 
(0.47 - 1.91) 
(0.53 - 1.45) 
 
 
1.00 
 
0.72 
0.98 
 
0.59 
0.78 
 
 
(reference) 
 
(0.29 - 1.81) 
(0.54 - 1.75) 
 
(0.42 - 0.84) 
(0.45 - 1.35) 
Phenothia-
zines 
 nonuse 
 current 
 1-2 
 3-14 
 ≥15 
 past 
 1-2 
 3-14 
 ≥15 
 
 
31,935 
 
148 
133 
231 
 
3276 
829 
150 
 
 
(87.0) 
 
(0.40) 
(0.36) 
(0.63) 
 
(8.93) 
(2.26) 
(0.41) 
 
 
32,330 
 
149 
110 
204 
 
3027 
750 
132 
 
 
(88.1) 
 
(0.41) 
(0.30) 
(0.56) 
 
(8.25) 
(2.04) 
(0.36) 
 
 
1.00 
 
1.01 
1.24 
1.16 
 
1.11 
1.14 
1.17 
 
 
(reference) 
 
(0.81 - 1.27) 
(0.96 - 1.60) 
(0.96 - 1.41) 
 
(1.05 - 1.17) 
(1.03 - 1.26) 
(0.92 - 1.49) 
 
 
1.00 
 
0.90 
1.14 
1.05 
 
1.05 
1.04 
1.02 
 
 
(reference) 
 
(0.71 - 1.14) 
(0.88 - 1.48) 
(0.86 - 1.28) 
 
(1.00 - 1.11) 
(0.94 - 1.16) 
(0.80 - 1.31) 
Other typical 
antipsychotic 
 nonuse 
 current 
 1-4 
 ≥5 
 past 
 1-4 
 ≥5 
 
 
36,299 
 
11 
43 
 
270 
79 
 
 
(98.9) 
 
(0.03) 
(0.12) 
 
(0.74) 
(0.22) 
 
 
36,322 
 
10 
35 
 
251 
84 
 
 
(98.7) 
 
(0.03) 
(0.10) 
 
(0.68) 
(0.23) 
 
 
1.00 
 
1.10 
1.23 
 
1.08 
0.94 
 
 
(reference) 
 
(0.47 - 2.59) 
(0.79 - 1.92) 
 
(0.91 - 1.29) 
(0.69 - 1.28) 
 
 
1.00 
 
1.04 
1.20 
 
0.94 
0.89 
 
 
(reference) 
 
(0.44 - 2.48) 
(0.76 - 1.91) 
 
(0.78 - 1.13) 
(0.65 - 1.23) 
* Adjusted for atopic dermatitis, contact dermatitis, hypothyroidism, neurotic and affective disorders, use of nonsteroidal anti-
inflammatory drugs, selective serotonin re-uptake inhibitors, benzodiazepines, body mass index, smoking, and antipsychotics 
not under investigation; Rx = prescriptions; OR = odds ratio; CI = confidence interval 
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Table 3.2.3: Risk of first-time psoriasis diagnosis associated with the use of antipsychotic drugs in 
mutually exclusive groups 
Exposure 
(No of Rx) 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
Nonuse 31,430 (85.6) 31,802 (86.7) 1.00 (reference) 1.00 (reference) 
Lithium 
  current 
 1-4 
 ≥5 
 past 
     1-4 
     ≥5 
 
 
2 
31 
 
7 
10 
 
 
(0.01) 
(0.08) 
 
(0.02) 
(0.03) 
 
 
0 
14 
 
6 
11 
 
 
(0.00) 
(0.04) 
 
(0.02) 
(0.03) 
 
 
NA 
2.25 
 
1.21 
0.93 
 
 
NA 
(1.20 - 4.23) 
 
(0.40 - 3.59) 
(0.39 - 2.18) 
 
 
NA 
2.19 
 
0.97 
0.95 
 
 
NA 
(1.15 - 4.18) 
 
(0.31 - 3.03) 
(0.40 - 2.27) 
Atypical anti-
psychotics 
 current 
 1-4 
 ≥5 
 past 
     1-4 
     ≥5 
 
 
 
10 
41 
 
17 
15 
 
 
 
(0.03) 
(0.11) 
 
(0.05) 
(0.04) 
 
 
 
9 
60 
 
20 
22 
 
 
 
(0.02) 
(0.16) 
 
(0.05) 
(0.06) 
 
 
 
1.14 
0.69 
 
0.86 
0.69 
 
 
 
(0.46 - 2.82) 
(0.46 - 1.03) 
 
(0.45 - 1.64) 
(0.36 - 1.34) 
 
 
 
1.13 
0.65 
 
0.74 
0.66 
 
 
 
(0.45 - 2.86) 
(0.43 - 0.98) 
 
(0.38 - 1.43) 
(0.34 - 1.29) 
Butyro-
phenones 
 current 
 1-4 
 ≥5 
 past 
 1-4 
 ≥5 
 
 
 
6 
12 
 
18 
6 
 
 
 
(0.02) 
(0.03) 
 
(0.05) 
(0.02) 
 
 
 
10 
11 
 
37 
8 
 
 
 
(0.03) 
(0.03) 
 
(0.10) 
(0.02) 
 
 
 
0.61 
1.12 
 
0.49 
0.77 
 
 
 
(0.22 - 1.68) 
(0.49 - 2.53) 
 
(0.28 - 0.87) 
(0.27 - 2.21) 
 
 
 
0.52 
1.02 
 
0.44 
0.78 
 
 
 
(0.18 - 1.48) 
(0.45 - 2.35) 
 
(0.25 - 0.80) 
(0.26 - 2.30) 
Phenothiaz. 
 current 
 1-2 
 3-14 
 ≥15 
 past 
     1-2 
     3-14 
 ≥15 
 
 
148 
126 
178 
 
3249 
752 
118 
 
 
(0.40) 
(0.34) 
(0.48) 
 
(8.85) 
(2.05) 
(0.32) 
 
 
148 
95 
163 
 
2996 
695 
101 
 
 
(0.40) 
(0.26) 
(0.44) 
 
(8.16) 
(1.89) 
(0.28) 
 
 
1.02 
1.36 
1.12 
 
1.11 
1.11 
1.21 
 
 
(0.81 - 1.29) 
(1.04 - 1.78) 
(0.91 - 1.39) 
 
(1.05 - 1.17) 
(1.00 - 1.23) 
(0.92 - 1.58) 
 
 
0.91 
1.25 
1.01 
 
1.06 
1.01 
1.04 
 
 
(0.72 - 1.15) 
(0.95 - 1.64) 
(0.81 - 1.26) 
 
(1.00 - 1.12) 
(0.91 - 1.13) 
(0.79 - 1.37) 
Other typical 
antipsychotic 
 current 
 1-4 
 ≥5 
 past 
     1-4 
     ≥5 
 
 
 
7 
31 
 
178 
38 
 
 
 
(0.02) 
(0.08) 
 
(0.48) 
(0.10) 
 
 
 
8 
26 
 
171 
39 
 
 
 
(0.02) 
(0.07) 
 
(0.47) 
(0.11) 
 
 
 
0.90 
1.23 
 
1.07 
0.99 
 
 
 
(0.33 - 2.48) 
(0.73 - 2.07) 
 
(0.86 - 1.32) 
(0.63 - 1.55) 
 
 
 
0.82 
1.07 
 
0.88 
0.88 
 
 
 
(0.29 - 2.27) 
(0.63 - 1.83) 
 
(0.71 - 1.10) 
(0.56 - 1.40) 
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Table 3.2.3 (cont.) 
Exposure 
(No of Rx) 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
Mixed use 272 (0.74) 250 (0.68) 1.12 (0.94 - 1.33) 0.95 (0.79 - 1.14) 
* Adjusted for atopic dermatitis, contact dermatitis, hypothyroidism, neurotic and affective disorders, use of nonsteroidal anti-
inflammatory drugs, selective serotonin re-uptake inhibitors, benzodiazepines, body mass index, and smoking 
Rx = prescriptions; OR = odds ratio; CI = confidence interval 
 
 
Table 3.2.4 Odds ratios for current use of ≥5 prescriptions for lithium or atypical antipsychotics 
compared with nonuse, stratified by age and sex (exposure not in mutually exclusive groups) 
 
Cases No (%) Controls No (%) Adjusted OR* (95% CI) 
p-value effect 
modification 
Lithium 
       
Age (years) 
        
<40 9 (0.06) 12 (0.08) 0.71 (0.27 - 1.84) 
≥40 83 (0.39) 41 (0.19) 1.97 (1.33 - 2.91) <0.005 
<60 49 (0.19) 30 (0.11) 1.53 (0.94 - 2.47) 
≥60 43 (0.42) 23 (0.23) 1.83 (1.08 - 3.12) ns 
Sex 
       
Men 31 (0.18) 24 (0.14) 1.37 (0.78 - 2.40) 
Women 61 (0.31) 29 (0.15) 1.92 (1.21 - 3.06) ns 
Atypical 
antipsychotics 
       
Age (years) 
       
<40 18 (0.12) 36 (0.23) 0.45 (0.24 - 0.82) 
≥40 55 (0.26) 53 (0.25) 1.02 (0.68 - 1.53) <0.01 
<60 42 (0.16) 70 (0.26) 0.54 (0.36 - 0.81) 
≥60 31 (0.30) 19 (0.19) 1.63 (0.89 - 2.99) <0.05 
Sex 
       
Men 34 (0.20) 54 (0.32) 0.62 (0.39 - 0.98) 
Women 39 (0.20) 35 (0.18) 1.01 (0.62 - 1.65) ns 
Active 
substance 
       
Olanzapine 20 (0.05) 35 (0.10) 0.50 (0.28 - 0.89)  
* Adjusted for atopic dermatitis, contact dermatitis, hypothyroidism, neurotic and affective disorders, use of nonsteroidal anti-
inflammatory drugs, selective serotonin re-uptake inhibitors, benzodiazepines, body mass index, smoking, and antipsychotics 
not under investigation 
OR = odds ratio; CI = confidence interval; ns = not significant  
Number of patients (for calculation of proportions): cases / controls 
Age <40: 15,324 / 15,327; ≥40: 21,378 / 21,375; Age <60: 26,486 / 26,495; ≥60: 10,216 / 10,207; men: 16,969 / 16,969; 
women: 19,733 / 19,733; total: 36,702 / 36,702 
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We conducted various sensitivity analyses. First, we ran the two final models 
(adjusted and mutually exclusive use of lithium or antipsychotics) in a subgroup of 
case patients with high validity of the psoriasis diagnosis (n = 20,726) defined as 
those who received calcipotriol, coal tar, dithranol, tazarotene, or acitretin in the first 
year after the psoriasis diagnosis. Second, to increase the likelihood of detecting 
incident psoriasis, we restricted an analysis to psoriasis cases (n = 29,170) who did 
not have any prescriptions recorded for any of the five drugs mentioned previously 
(calcipotriol, coal tar, dithranol, tazarotene, or acitretin) at any time prior to the first-
time psoriasis diagnosis. Third, we combined these two requirements and ran an 
analysis which encompassed 15,336 case patients. Fourth, we conducted a number 
of analyses restricted to patients who did not have certain skin diseases ([1] without 
allergic skin disease or contact or atopic dermatitis, [2] without skin infections, and [3] 
without any of the diagnoses mentioned previously) before their psoriasis diagnosis 
because their conditions may have been more likely to have been misdiagnosed as 
psoriasis. In all these subgroups, the findings related to use of lithium or 
antipsychotics remained virtually unchanged (data not shown).  
 
3.2.5 Discussion 
The findings of this large population-based case-control analysis support the 
hypothesis that long-term use of lithium increases the risk of developing a first-time 
psoriasis diagnosis.  
Psoriasis has been associated with substantial psychiatric comorbidity such as 
stress,88 anxiety, or depression, but the temporal association between these 
disorders is inconclusive.132 We found an increased psoriasis risk for patients with a 
first psychiatric diagnosis within 60 days prior to the psoriasis diagnosis date. The 
use of SSRIs87, 159, 160 and benzodiazepines78, 87 has been associated with psoriasis 
in case reports or one small observational study or both; we did not find a suggestion 
of an increased psoriasis risk for current long-term use of SSRIs or benzodiazepines.  
Aside from beta-blockers, lithium is one of the drugs most commonly associated with 
triggering or inducing psoriasis. However, both for beta-blockers and lithium, 
observations are mainly based on case reports and case series, and the causal 
association between drug use and development of the disease has been 
questioned.87 In a recent case-control analysis using data from the same database, 
we found no evidence for a substantially altered psoriasis risk for users of beta-
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blockers.155 The current study, however, provides evidence that long-term (≥5 
prescriptions) therapy with lithium increases the risk of developing psoriasis.  
Although the two most commonly reported skin reactions possibly related to the use 
of lithium were acne and psoriasis in case reports and controlled trials, there have 
been few studies exploring the histology of such skin reactions.87, 95, 96 Furthermore, 
the reaction has not always been dose-related,87 and it has been suspected that 
some of the reports were psoriasiform drug eruptions rather than true psoriasis.87, 95-
97
 However, elevated lithium plasma concentrations have been reported for psoriasis 
patients without any treatment history with this compound, originating possibly from 
the lithosphere or mineral water springs, and the clinical picture of lithium-associated 
psoriasis is very similar to idiopathic psoriasis without different histological findings.95, 
97
 Although various possible mechanisms have been described to explain how lithium 
may induce or exacerbate psoriasis, the exact mechanism is not known, and it has 
even been suggested that the mechanisms for regular and lithium-induced psoriasis 
may not be the same.143, 161  
In a small interview-based study, the authors found a higher incidence of cutaneous 
reactions (only two cases with psoriasis) after exposure to lithium, but only in female 
patients. Furthermore, the only two patients in this study who developed psoriasis 
after exposure to lithium were older than 50 years.154 These observations are 
supported by our data which suggest an increased risk mainly in female patients 
older than 40 years (where a test for interaction by sex did not reach statistical 
significance). As the lithium mechanism on psoriasis is largely unknown, it is difficult 
to interpret these observations. Increased skin consciousness of women and patients 
≥40 years of age may be a possible explanation. The age effect could also be 
explained by the reported heterogeneity of psoriasis, that is, psoriasis type I with 
early onset (<40 years of age) and type II with late onset (≥40 years of age).68 
We also observed a reduced relative risk of developing a first-time psoriasis 
diagnosis for current users of ≥5 prescriptions of atypical antipsychotics, whereby 
olanzapine primarily accounted for the reduced psoriasis risk observed for atypical 
antipsychotics. This may be explained by an effect of antipsychotics on cytokines,162 
which play a major role in the pathomechanism of psoriasis.  
Sex differences in pharmacokinetic properties and adverse effect profiles have been 
described for atypical antipsychotics.163 Although the test for interaction by sex did 
not reach statistical significance in our study, there was evidence for a possibly 
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reduced psoriasis risk for men using atypical antipsychotics, a finding which may 
deserve attention in future studies.   
We cannot exclude the possibility of some misclassification of outcome, that is, some 
people classified as cases may not have psoriasis. Gelfand et al. reported a high 
validity of psoriasis diagnoses in the GPRD.115, 139, 147 In our study, we conducted 
various sensitivity analyses which left the findings virtually unchanged suggesting 
that misclassification does not account for our findings.  
Although we tested a large number of potential confounding factors and included the 
most relevant ones in our model, we cannot exclude the possibility that other 
unknown confounders or biases may have affected our results to some degree. As 
stress has been reported to be a risk factor for psoriasis, it is possible that a stressful 
psychiatric crisis may be responsible for the induction of psoriasis rather than the 
treatment with lithium. However, this does not seem to be likely because we would 
then expect to see an increased psoriasis risk also for short-term lithium users, which 
was not the case, and we may also expect an increased risk for other classes of 
antipsychotics, which we did not see. Furthermore, our analysis was adjusted for 
diagnosed affective and neurotic disorders. 
As we explored the association between use of lithium and antipsychotic drugs and 
the risk of developing a first-time diagnosis of psoriasis, we cannot make a statement 
about the effect of lithium exposure on the risk of exacerbation of pre-existing 
psoriasis.  
In summary, we explored the association between the use of lithium or antipsychotics 
and the risk of new-onset psoriasis in this, to the best of our knowledge, first large 
population-based case-control analysis. The findings provide further evidence that 
the use of lithium may increase the risk of developing a first-time psoriasis diagnosis, 
particularly with long-term exposure. Furthermore, the suggested protective effect of 
long-term olanzapine use on psoriasis risk has not been reported so far and merits 
further investigation. 
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3.3.1 Abstract 
Background: Small clinical trials suggest that thiazolidinediones may exert a 
beneficial effect on skin lesions of patients with psoriasis. Little is known about other 
classes of antidiabetic drugs and the psoriasis risk.  
Objective: We sought to study the association between use of thiazolidinediones, 
sulfonylureas, biguanides, or acarbose and the risk of developing a first-time 
diagnosis of psoriasis. 
Methods: We conducted a case-control analysis on the UK-based GPRD. We 
identified patients with an incident psoriasis diagnosis from 1994 to 2005 and 
matched one control subject to each patient on age, sex, general practice, calendar 
time, and years of history in the database. Conditional logistic regression was used to 
estimate the ORs with 95% CIs of developing a first-time psoriasis diagnosis in 
relation to previous exposure to antidiabetic drugs, stratified by exposure timing and 
duration of use and adjusted for a variety of potential confounders. 
Results: We identified 36,702 patients with a first-time psoriasis diagnosis and the 
same number of matched control subjects. As compared with no use, the adjusted 
ORs for current use of 1 to 4 prescriptions or ≥5 prescriptions for thiazolidinediones 
were 1.01 (95% CI 0.34-3.01) and 0.33 (95% CI 0.16-0.66), respectively. Current use 
of ≥15 prescriptions for metformin or sulfonylureas yielded adjusted ORs of 0.77 
(95% CI 0.62-0.96) and 1.07 (95% CI 0.88-1.31), respectively. 
Limitations: The findings are based on a small number of patients exposed to 
thiazolidinediones (100 in total, 48 current users of ≥5 prescriptions). 
Conclusions: The findings of this large observational study provide further evidence 
for a potentially beneficial effect of thiazolidinediones on psoriasis. While current 
long-term use of metformin was also associated with a suggestion of a reduced 
psoriasis risk, no such effect was seen for use of other oral antidiabetics. 
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3.3.2 Background 
Psoriasis is a common autoimmune skin disease with an estimated prevalence 
between 0.6% and 4.8% or even higher for certain regions.62, 63 In a recent study on 
the GPRD, Gelfand et al.139 reported a prevalence rate of 1.5% in the UK. The 
disease is characterised by T cell-mediated hyperproliferation of keratinocytes and 
inflammatory processes based on a complex genetic background.46 
Thiazolidinediones, also called peroxisome proliferator-activated receptor (PPAR)-γ 
agonists because of their action at the nuclear hormone receptor PPAR-γ, are 
relatively new drugs for the treatment of type 2 diabetes mellitus. The 
thiazolidinediones pioglitazone, rosiglitazone, and troglitazone have anti-
inflammatory and antiproliferative effects in malignant and nonmalignant human cells 
including keratinocytes.164 Human keratinocytes express messenger RNA and 
protein for the nuclear hormone receptor PPAR-γ. Furthermore, PPAR-γ messenger 
RNA expression was found in human peripheral blood T lymphocytes, and it could be 
shown that PPAR-γ ligands inhibited IL-2 production in a dose-dependent manner.165, 
166
 IL-2 plays an essential role in controlling T cell proliferation, an early step in the 
pathogenesis of psoriasis.167 An important role of PPAR-γ in immunoregulation was 
proposed, even though some of the anti-inflammatory effects of thiazolidinediones 
may be independent from PPAR-γ.168, 169 
Potential clinical benefits of thiazolidinediones were documented in small open-label 
studies on up to 10 patients with psoriasis164, 165, 170 and in a prospective, 
randomised, double-blind study involving 45 patients exposed to pioglitazone and 25 
patients exposed to placebo, in which a dose-dependent beneficial effect of 
pioglitazone on psoriasis symptoms was observed.171 In addition, rosiglitazone at 2, 
4, or 8 mg/d showed some improvement of psoriasis symptoms in individual patients, 
even though the overall effects did not differ significantly from placebo in two larger 
double-blind placebo-controlled studies conducted by the manufacturer.172 The 
authors of a recent review article emphasised that neither the potential clinical 
effectiveness of this drug class in psoriasis, nor a possible mechanism of action are 
fully understood yet.173 
Little information is available on the association between other classes of oral 
antidiabetic drugs and psoriasis. Psoriasiform drug eruptions have been reported in 
two cases, one related to the biguanide metformin and one to the sulfonylurea 
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glibenclamide.174, 175 On the other hand, two patients were described in the 1970s 
whose psoriasis improved while being treated with the biguanide phenformin.176  
To our knowledge no studies have been published exploring the association between 
use of thiazolidinediones and risk of developing an incident psoriasis diagnosis. We, 
therefore, conducted a large population-based case-control study to evaluate the 
association between use of thiazolidinediones or other oral antidiabetics and the risk 
of developing a first-time psoriasis diagnosis.   
 
3.3.3 Methods 
We conducted a matched case-control analysis to explore the risk of developing a 
first-time psoriasis diagnosis in relation to a prevalent diabetes diagnosis and to 
previous use of thiazolidinediones, the biguanide derivative metformin, sulfonylureas, 
or acarbose within the GPRD. 
 
Data Source: GPRD 
The GPRD is a large UK-based database established around 1987 that 
encompasses some five million patients who are enrolled with selected GPs. The 
GPs have agreed to provide data for research purposes to the GPRD and receive a 
small fee for their service. GPs have been trained to record medical information in a 
standard manner and to supply it anonymously. Data are collected on a daily basis, 
independent of any potential study question. Practice-based measures are applied to 
derive the practice up-to-standard. The patients enrolled in the GPRD are 
representative for the UK with regard to age, sex, geographic distribution, and annual 
turnover rate. The information recorded includes patient demographics and 
characteristics (e.g. age, sex, height, weight, smoking status), symptoms, medical 
diagnoses, referrals to consultants, hospitalisations, and all drug prescriptions 
because the doctors generate prescriptions directly with the computer using a coded 
drug dictionary. Prescriptions contain the name of the preparation (active compound), 
the route of administration, the dose of a single unit, the number of units prescribed, 
and, in most instances, the intake regimen prescribed by the GPs. Hospital discharge 
and referral letters are available for review to validate the diagnoses recorded in the 
computer record.31, 36, 37, 177 This database, which has been described in detail 
elsewhere31, 37 and validated extensively,32-34 has been the source for numerous 
published epidemiological studies. Studies on psoriasis using GPRD data have been 
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published recently.103, 108, 115, 116, 139, 147 For the current study, we selected all patients 
from active general practices that were up-to-standard in the study period.  
The study protocol was approved by ISAC for MHRA database research.  
 
Case definition and ascertainment 
We identified patients with a first-time diagnosis of psoriasis between 1 January 1994 
and 31 December 2005 via OXMIS or Read codes. Patients with less than three 
years of active history in the database before the first-time diagnosis of psoriasis and 
patients with a code for history of psoriasis were not included.  
The validity of psoriasis diagnoses in the GPRD has been examined by Gelfand et 
al.108, 115, 116, 139, 147 and Neimann et al.103 who have recently published several GPRD-
based studies on psoriasis. They have shown that the epidemiology of psoriasis in 
the GPRD is similar to data from other population-based studies in the UK and that 
92% of patients with a psoriasis code receive psoriasis therapies.115, 139 In addition, 
among a random sample of 100 GPs who recorded a diagnostic code for psoriasis, 
approximately 90% confirmed the diagnosis after four years of follow-up.147  
 
Control subjects 
We identified at random one control subject per patient with psoriasis, matched on 
calendar time (same index date), age (same year of birth), sex, general practice, and 
years of history in the GPRD. Thus, control subjects were also required to have at 
least three years of active history in the GPRD. 
 
Exposure to oral antidiabetics 
For each patient and control subject we assessed from the computer record the 
exposure to thiazolidinediones, metformin, sulfonylureas, and acarbose before the 
index date. Patients were classified as current users of a study drug if the last 
prescription was recorded within 89 days prior to the index date or as past users if 
the last prescription was recorded ≥90 days before the index date. We also assessed 
the duration of use before the index date, using the number of prescriptions as proxy 
(1-4, 5-14, or ≥15 prescriptions for sulfonylureas and metformin and 1-4 or ≥5 
prescriptions for thiazolidinediones and acarbose; we used two categories only for 
the latter two because of a smaller number of users). In addition, we also classified 
3 Psoriasis project  Thiazolidinediones, other antidiabetics and psoriasis 
 62 
participants according to a combination of number of prescriptions and timing of the 
last prescription. 
For the main analysis we created a model in which we compared use of oral 
antidiabetic drugs with nonusers, whereby use of more than one oral antidiabetic 
drug before the index date was possible. We adjusted for such sequential or 
concurrent use of various antidiabetics in the multivariate model. In addition, we also 
ran a model in which participants were categorised into mutually exclusive groups of 
users of thiazolidinediones only, sulfonylureas only, metformin only, acarbose only, 
or any combination of these antidiabetics (switchers or combined use) and compared 
them with nonusers of any antidiabetic drugs. However, as the number of exposed 
patients with thiazolidinediones or acarbose was small, this model was only used as 
sensitivity analysis to confirm findings of the main analysis. 
 
Statistical analysis 
We conducted conditional logistic regression analyses using statistical software 
(SAS, version 9.1, SAS Institute Inc, Cary, NC, U.S.A.). We displayed relative risk 
estimates as OR with 95% CI. We adjusted ORs for the potential confounders age, 
sex, practice, calendar time, and years of recorded history in the database by 
matching, and for smoking status (non, current, ex, or unknown) and BMI (<18.5, 
18.5-24.9, 25.0-29.9, ≥30 kg/m2, or unknown) in the multivariate model. Additional 
potential confounders were tested in univariate analyses; if they were statistically 
significantly associated with psoriasis they were entered in the final model in which 
we explored the association between antidiabetic drug use and psoriasis. If they 
changed the relative risk estimate of interest by 10% or more, they were part of the 
final model. Thus, the risk estimates were further adjusted for a history of diagnosed 
atopic dermatitis, skin infections, other infections such as candidiasis, aspergillosis, 
cellulitis, abscess, lymphadenitis, or empyema, affective disorders, ischaemic heart 
disease, hyperlipidaemia, use of terbinafine (1-4 or ≥5 prescriptions), use of 
antimycotics (1 or ≥2 prescriptions), use of coronary vasodilators (1-9 or ≥10 
prescriptions), use of prandial glucose regulators (glinides, 1-4 or ≥5 prescriptions), 
and use of insulin (current 1-9 or ≥10 prescriptions, past 1-9 or ≥10 prescriptions). 
Potential confounding was also tested for a number of other covariates that were not 
included in the final model because they were not materially associated with the 
exposure or the outcome, such as allergic skin disease, allergic rhinoconjunctivitis, 
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asthma, congestive heart failure, contact dermatitis, urticaria and/or angio-oedema, 
hypertension, stroke/TIA, tonsillectomy, respiratory infections, viral infections, hyper- 
or hypothyroidism, alcoholism, gout, epilepsy, neurosis, inflammatory bowel disease, 
rheumatoid arthritis, COPD, use of various antidepressants, antihistamines, 
benzodiazepines, beta-agonists, cardiac glycosides, NSAIDs, paracetamol, 
cyclooxygenase-2-inhibitors, lipid-lowering agents, levothyroxine, carbimazole, 
antihypertensive agents, antibiotics, or antivirals.   
 
3.3.4 Results 
We identified 36,702 patients with a first-time diagnosis of psoriasis between 1 
January 1994 and 31 December 2005 and the exact same number of matched 
control subjects. Table 3.3.1 displays the age and sex distribution and the distribution 
of smoking status, BMI, and various comorbidities of patients and control subjects. 
The study population encompassed 53.8% women, and 41.7% of patients were 
younger than 40 years at the time of the diagnosis. Current smoking was associated 
with a statistically significantly increased psoriasis risk (OR 1.52, 95% CI 1.46-1.58), 
as was a BMI ≥30 kg/m2 (OR 1.34, 95% CI 1.27-1.41), as compared with the 
reference group of non smokers and patients of normal weight, respectively.  
 
Table 3.3.1 Characteristics of case patients with psoriasis and matched controls 
Variable 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Adjusted OR* 
(95% CI) 
Sex** 
      
 Men 16,969 (46.2) 16,969 (46.2) - - 
 Women 19,733 (53.8) 19,733 (53.8) - - 
Agegroup (years)** 
      
 <20 5801  (15.8) 5801 (15.8) - - 
 20-29 4336 (11.8) 4339  (11.8) - - 
 30-39 5187 (14.1) 5187 (14.1) - - 
 40-49 5173 (14.1) 5171 (14.1) - - 
 50-59 5989 (16.3) 5997 (16.3) - - 
 60-69 5109 (13.9) 5102 (13.9) - - 
 ≥70 5107 (13.9) 5105 (13.9) - - 
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Table 3.3.1 (cont.) 
Variable 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
OR adjusted* 
(95% CI) 
Smoking status 
      
 Non smoker 13,390 (36.5) 15,594 (42.5) 1.00 (reference) 
 Current smoker 8787 (23.9) 6913 (18.8) 1.52 (1.46 - 1.58) 
 Ex smoker 4690 (12.8) 3763 (10.3) 1.44 (1.36 - 1.52) 
 Unknown 9835 (26.8) 10,432 (28.4) 1.11 (1.04 - 1.17) 
BMI (kg/m2)       
 12-18.4 523 (1.4) 574 (1.6) 0.94 (0.83 - 1.06) 
 18.5-24.9 10,244 (27.9) 10,887 (29.7) 1.00 (reference) 
 25-29.9 8330 (22.7) 7934 (21.6) 1.13 (1.08 - 1.18) 
 30-60 4881 (13.3) 3882 (10.6) 1.34 (1.27 - 1.41) 
 Unknown 12,724 (34.7) 13,425 (36.6) 1.00 (0.95 - 1.05) 
Comorbidities       
IHD 2587 (7.1) 2232 (6.1) 1.00 (0.91 - 1.09) 
Hyperlipidaemia 2169 (5.9) 1950 (5.3) 1.05 (0.98 - 1.13) 
Atopic dermatitis 2092 (5.7) 1042 (2.8) 2.06 (1.90 - 2.23) 
Infections 11,068 (30.2) 9153 (24.9) 1.21 (1.17 - 1.25) 
   Skin infections  10,450 (28.5) 7388 (20.1) 1.46 (1.41 - 1.52) 
Affective disorder 5931 (16.2) 5158 (14.1) 1.10 (1.05 - 1.15) 
* Adjusted for all covariates listed in the table plus use of coronary vasodilatators, terbinafine, antimycotics, prandial glucose 
regulators, and insulin; ** Matching variables 
Percentages may not sum to 100% due of rounding 
BMI = body mass index; IHD = ischaemic heart disease; OR = odds ratio; CI = confidence interval 
 
Table 3.3.2 displays the prevalence of treated and untreated diabetes in patients with 
psoriasis and control subjects. The relative risk estimates of developing psoriasis 
among users of sulfonylureas or acarbose were close to one (data not shown). On 
the other hand, we found adjusted ORs of 0.44 (95% CI 0.25-0.78) and 1.00 (95% CI 
0.49-2.05) for current and past thiazolidinedione use, respectively, as compared with 
nonuse. The ORs for current and past biguanide use were 0.82 (95% CI 0.69-0.97) 
and 0.70 (95% CI 0.52-0.94), respectively. 
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Table 3.3.2 Prevalence of treated or untreated diabetes before the index date 
 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
No diabetes 35,347 (96.3) 35,408 (96.5) 1.00 (reference) 1.00 (reference) 
Diabetes 
 No treatment 
 Treatment 
  oral only 
  insulin only 
  combination 
1355
368
987
640
171
176
(3.69) 
(1.00) 
(2.69) 
(1.74) 
(0.47) 
(0.48) 
1294
313
981
648
188
145
(3.53) 
(0.85) 
(2.67) 
(1.77) 
(0.51) 
(0.40) 
1.05
1.18
1.01
0.99
0.91
1.22
(0.97 - 1.14) 
(1.01 - 1.37) 
(0.92 - 1.11) 
(0.89 - 1.11) 
(0.74 - 1.12) 
(0.98 - 1.53) 
0.89 
1.01 
0.85 
0.83 
0.83 
0.95 
(0.81 - 0.96) 
(0.86 - 1.18) 
(0.77 - 0.93) 
(0.74 - 0.93) 
(0.67 - 1.02) 
(0.75 - 1.20) 
* Adjusted for atopic dermatitis, skin infections, infections such as candidiasis, aspergillosis, cellulitis, abscess, lymphadenitis, 
and empyema, use of terbinafine and antimycotics, affective disorders, ischaemic heart disease, hyperlipidaemia, use of 
coronary vasodilatators, body mass index, and smoking; OR = odds ratio; CI = confidence interval 
 
Table 3.3.3 displays the results for duration combined with timing of use. The 
adjusted OR for current use of ≥5 thiazolidinedione prescriptions compared with no 
use was 0.33 (95% CI 0.16-0.66), and for current use of ≥15 metformin prescriptions 
compared with no use the OR was 0.77 (95% CI 0.62-0.96). Further stratification of 
current thiazolidinedione users of ≥5 prescriptions by individual drug yielded adjusted 
ORs of 0.29 (95% CI 0.13-0.66; based on 8 exposed patients and 29 control 
subjects) for rosiglitazone and of 0.45 (95% CI 0.13-1.60; based on 4 exposed 
patients and 7 control subjects) for pioglitazone.  
 
Table 3.3.3 Risk of first-time psoriasis diagnosis associated with use of antidiabetics  
Exposure 
(No of Rx) 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
Thiazoli-
dinediones 
 nonuse 
 current 
 1-4 
 ≥5 
 past 
     1-4 
     ≥5 
 
 
36,662 
 
8 
12 
 
9 
11 
 
 
(99.9) 
 
(0.02) 
(0.03) 
 
(0.02) 
(0.03) 
 
 
36,642 
 
7 
36 
 
6 
11 
 
 
(99.8) 
 
(0.02) 
(0.10) 
 
(0.02) 
(0.03) 
 
 
1.00 
 
1.14 
0.33 
 
1.50 
1.02 
 
 
(reference) 
 
(0.41 - 3.15) 
(0.17 - 0.64) 
 
(0.53 - 4.23) 
(0.44 - 2.35) 
 
 
1.00 
 
1.01 
0.33 
 
1.21 
0.93 
 
 
(reference) 
 
(0.34 - 3.01) 
(0.16 - 0.66) 
 
(0.41 - 3.60) 
(0.38 - 2.31) 
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Table 3.3.3 (cont.)  
Exposure 
(No of Rx) 
Cases No (%) 
(n = 36,702) 
Controls No (%) 
(n = 36,702) 
Unadjusted OR 
(95% CI) 
Adjusted OR* 
(95% CI) 
Biguanides 
 nonuse 
 current 
 1-4 
 5-14 
 ≥15 
   past 
   1-4 
 5-14 
 ≥15 
 
36,127 
 
54 
107 
280 
 
53 
29 
52 
 
(98.4)  
 
(0.15) 
(0.29) 
(0.76) 
 
(0.14) 
(0.08) 
(0.14) 
 
36,115 
 
51 
101 
283 
 
50 
40 
62 
 
(98.4)  
 
(0.14) 
(0.28) 
(0.77) 
 
(0.14) 
(0.11) 
(0.17) 
 
1.00 
 
1.05 
1.06 
0.99 
 
1.06 
0.73 
0.84 
 
(reference) 
 
(0.72 - 1.54) 
(0.81 - 1.39) 
(0.84 - 1.17) 
 
(0.72 - 1.56) 
(0.45 - 1.17) 
(0.58 - 1.21) 
 
1.00 
 
0.87 
0.86 
0.77 
 
0.88 
0.66 
0.58 
 
(reference) 
 
(0.58 - 1.31) 
(0.64 - 1.15) 
(0.62 - 0.96) 
 
(0.57 - 1.36) 
(0.39 - 1.11) 
(0.37 - 0.91) 
Sulfonyl-
ureas 
 nonuse 
 current 
 1-4 
 5-14 
 ≥15 
 past 
 1-4 
 5-14 
 ≥15 
 
 
36,064 
 
41 
74 
311 
 
61 
37 
114 
 
 
(98.3)  
 
(0.11) 
(0.20) 
(0.85) 
 
(0.17) 
(0.10) 
(0.31) 
 
 
36,090 
 
35 
79 
296 
 
41 
52 
109 
 
 
(98.3)  
 
(0.10) 
(0.22) 
(0.81) 
 
(0.11) 
(0.14) 
(0.30) 
 
 
1.00 
 
1.17 
0.94 
1.05 
 
1.49 
0.71 
1.05 
 
 
(reference) 
 
(0.74 - 1.83) 
(0.68 - 1.29) 
(0.90 - 1.24) 
 
(1.00 - 2.21) 
(0.47 - 1.09) 
(0.81 - 1.36) 
 
 
1.00 
 
1.13 
0.92 
1.07 
 
1.50 
0.72 
1.24 
 
 
(reference) 
 
(0.71 - 1.82) 
(0.66 - 1.29) 
(0.88 - 1.31) 
 
(0.98 - 2.30) 
(0.45 - 1.15) 
(0.87 - 1.76) 
Acarbose 
 nonuse 
 current 
 1-4 
 ≥5 
 past 
 1-4 
 ≥5 
 
36,654 
 
4 
14 
 
16 
14 
 
(99.9) 
 
(0.01) 
(0.04) 
 
(0.04) 
(0.04) 
 
36,645 
 
6 
10 
 
25 
16 
 
(99.8) 
 
(0.02) 
(0.03) 
 
(0.07) 
(0.04) 
 
1.00 
 
0.67 
1.38 
 
0.65 
0.88 
 
(reference) 
 
(0.19 - 2.36) 
(0.61 - 3.10) 
 
(0.34 - 1.21) 
(0.43 - 1.79) 
 
1.00 
 
0.59 
1.33 
 
0.58 
0.86 
 
(reference) 
 
(0.15 - 2.22) 
(0.56 - 3.16) 
 
(0.29 - 1.14) 
(0.40 - 1.87) 
* Adjusted for atopic dermatitis, skin infections, infections such as candidiasis, aspergillosis, cellulitis, abscess, lymphadenitis, 
and empyema, use of terbinafine and antimycotics, affective disorders, ischaemic heart disease, hyperlipidaemia, use of 
coronary vasodilatators, use of insulin and prandial glucose regulators, body mass index, smoking, and antidiabetics not under 
investigation 
Rx = prescriptions; OR = odds ratio; CI = confidence interval 
 
Stratification of the final model by age (<40 vs. ≥40 years) did not suggest effect 
modification, whereby the number of exposed subjects in the younger age group was 
rather low. Stratification by sex yielded an OR of 0.20 (95% CI 0.07-0.59) for female 
and of 0.49 (95% CI 0.19-1.25) for male current users of ≥5 thiazolidinedione 
prescriptions (P >.1). Current metformin exposure of ≥15 prescriptions yielded an 
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adjusted OR of 0.56 (95% CI, 0.41-0.76) for male and of 1.10 (95% CI 0.80-1.51) for 
female participants (P <.05). 
We further conducted various sensitivity analyses. First, we ran the final model in a 
subgroup of 20,726 patients (and their control subjects) who were treated with 
calcipotriol, coal tar, dithranol, tazarotene, or acitretin in the first year after their 
psoriasis diagnosis, a pharmacologically treated subgroup of psoriasis patients who 
were likely to have a confirmed psoriasis diagnosis. The adjusted ORs for current 
users of ≥5 thiazolidinedione or ≥15 metformin prescriptions were 0.28 (95% CI 0.11-
0.73; based on 6 exposed patients and 22 control subjects) and 0.71 (95% CI 0.54-
0.95; based on 159 exposed patients and 168 control subjects), respectively. 
Second, we restricted an analysis to 29,170 patients with psoriasis (and their control 
subjects) who did not have any prescriptions recorded for any of the five medications 
mentioned above at any time before the first-time psoriasis diagnosis. The date of the 
first-time recording of a disease such as psoriasis in a large primary care database is 
unlikely to be the exact date of the first disease manifestation; the onset of the 
disease and, therefore, the correct index date occurred in reality some time before. 
Thus, to reduce the risk of including patients with a long-term psoriasis history, only 
patients without evidence of previous treatment were eligible for this analysis. The 
adjusted ORs for current use of ≥5 prescriptions for thiazolidinediones or ≥15 
prescriptions for metformin were 0.42 (95% CI 0.19-0.92; based on 10 exposed 
patients and 25 control subjects) and OR 0.78 (95% CI 0.61-1.01; based on 192 
exposed patients and 208 control subjects), respectively. Third, we ran the final 
model in 15,336 patients with psoriasis (and their control subjects) who had both 
received treatment with calcipotriol, coal tar, dithranol, tazarotene, or acitretin in the 
first year after their psoriasis diagnosis and did not have any of these drugs at any 
time before the index date. In this subgroup, current use of ≥5 thiazolidinedione 
prescriptions or ≥15 metformin prescriptions yielded adjusted ORs of 0.50 (95% CI 
0.17-1.53; based on 5 exposed patients and 12 control subjects) and 0.68 (95% CI 
0.48-0.97; based on 96 exposed patients and 113 control subjects), respectively.  
Fourth, we ran the final model in 18,798 patients with psoriasis (and their control 
subjects) whose index date was in the year 2000 or thereafter, i.e., when all 
antidiabetics of interest were on the market. Current use of ≥5 thiazolidinedione 
prescriptions or ≥15 metformin prescriptions yielded adjusted ORs of 0.30 (95% CI 
0.15-0.60; based on 12 exposed patients and 36 control subjects) and 0.84 (95% CI 
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0.64-1.10; based on 206 exposed patients and 188 control subjects), respectively. 
Finally, we conducted another model in patients with diabetes only whose index date 
was in the year 2000 or later, which yielded closely similar results (adjusted OR for 
current use of ≥5 thiazolidinedione prescriptions 0.45, 95% CI 0.25 – 0.81). 
 
3.3.5 Discussion 
The findings of this large population-based case-control analysis support the 
hypothesis of a possible beneficial effect of thiazolidinediones in psoriasis in patients 
with an existing diabetes diagnosis, as previously observed in small clinical trials.  
We found a statistically significantly decreased risk of developing a first-time 
psoriasis diagnosis in current users of ≥5 thiazolidinedione prescriptions (reflecting a 
treatment duration of approximately one year), suggesting a possible effect of this 
drug class on the risk of developing psoriasis. While previous studies investigated a 
possible effect of thiazolidinediones as therapeutic agents for patients with manifest 
psoriasis, we conducted the (to our knowledge) first published retrospective case-
control study on the association between use of these drugs and the risk of 
developing a first-time psoriasis diagnosis.  
There are few and inconclusive data on a possible association between use of 
metformin and psoriasis in the literature because potentially beneficial and negative 
drug effects have been described.174, 176 We found a suggestion of a reduced risk for 
current metformin use of ≥15 prescriptions of 0.77 (95% CI 0.62-0.96), whereas the 
OR for past use of ≥15 prescriptions was even lower (0.58, 95% CI 0.37-0.91). While 
the crude ORs of both current and past longer-term use of metformin were around 
one, the risk estimates decreased below one after adjusting for BMI, use of other oral 
antidiabetics, and smoking. Metformin is often used in overweight diabetics and often 
in combination with other antidiabetics such as thiazolidinediones. The OR for current 
use of ≥15 prescriptions for metformin users only in the model in which we used 
mutually exclusive exposure groups was also 0.73 (95% CI 0.52-1.04), based on 69 
exposed patients and 71 control subjects. However, the low OR of past use of ≥15 
prescriptions for metformin is not easy to explain. Possible explanations are a chance 
finding or a causal association with a metformin effect lasting beyond the actual 
exposure. As opposed to the similar thiazolidinedione findings in both men and 
women, we found different relative risks for male or female metformin users, with an 
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OR below one only for male users. To our knowledge there are no studies published 
in the literature on the mechanism by which biguanides might affect psoriasis. 
However, thiazolidinediones and biguanides share a common effect on the 
adenosine 5’-monophosphate-activated protein kinase that was hypothesised to be 
dysregulated in patients with the metabolic syndrome (insulin resistance, obesity, and 
a predisposition to hypertension, dyslipidaemia, pancreatic β-cell dysfunction, type 2 
diabetes mellitus, and premature atherosclerosis).178 Findings of a possible anti-
inflammatory effect seem to be inconclusive.179  
Diabetes has been associated with psoriasis in several hospital- and population-
based studies86, 102-106 with a higher diabetes prevalence in patients with severe 
psoriasis103 possibly as a result of therapy with corticosteroids105 or chronic 
inflammation and the production of pro-inflammatory cytokines.106 In the current 
study population, the diabetes prevalence was not higher in patients with psoriasis at 
the time of the first psoriasis diagnosis as compared with control subjects without 
psoriasis. On the contrary, diabetes treated with certain oral antidiabetics was 
associated with a lower psoriasis risk.  
Our study population included patients and control subjects between 1994 and 2005, 
thus also a time period in which thiazolidinediones, in contrast to sulfonlyureas, 
metformin, and other oral antidiabetics, were not yet available on the market. In 
addition, we did not restrict our study to diabetics only. We, therefore, ran a 
sensitivity analysis in which we restricted the study to patients and control subjects 
with diabetes and to those with index date in the year 2000 or thereafter. The 
association between use of thiazolidinediones or other oral antidiabetics and the risk 
of developing psoriasis remained virtually unchanged.  
A limitation of our study is that there were only 48 patients who were current users of 
thiazolidinediones with 5 or more prescriptions recorded (0.065% of the study 
population) and only 63 current users in total. This led to analyses with limited power, 
particularly after stratification into subgroups. Future studies in the GPRD and in 
other databases will have more power because use of thiazolidinediones is 
increasing. Nevertheless, the observed reduced psoriasis risk associated with current 
use of thiazolidinediones is an intriguing finding that reached statistical significance 
despite the rather low exposure prevalence. 
Another limitation is the fact that there may be some misclassification of diagnosis, 
leading to the inclusion of patients who did not have psoriasis. In addition, the index 
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date for chronic diseases without acute onset is often not precisely recorded in large 
databases, leading to a certain degree of exposure misclassification. However, 
Gelfand et al.115, 139, 147 used the GPRD to study patients with psoriasis in previous 
studies, and their validation procedure documented that psoriasis diagnoses in the 
GPRD are in general of high validity. We conducted various sensitivity analyses to 
improve the validity of our findings; the risk estimates in these analyses were closely 
similar to the ones seen in the entire case-control set. In addition, our analyses are 
based on GP-recorded prescriptions, but not on the patients’ actual drug intake, 
which is of course not known. 
We further tested a large number of potential confounders and included the most 
relevant ones in our model, but, as in all observational studies, we cannot exclude 
the possibility that unidentified confounders or biases may have distorted the results 
to some degree. We did not have information on smoking status and BMI for 
approximately a third of all patients and control subjects. Including a category of 
missing values in an analysis can introduce distortion if this parameter is indeed a 
confounder of the main exposure – outcome association. In this case, however, 
neither smoking nor BMI confounded the association between use of 
thiazolidinediones and the risk of developing psoriasis, as we explored in several 
sensitivity analyses, and so the issue of some missing smoking and BMI values is not 
relevant. We further ran a model restricted to those patients and controls subjects 
with known values only, which left the result unchanged. 
Furthermore, we were not in a position to explore the risk of antidiabetic drug use on 
psoriasis in patients without diabetes because the antidiabetic drugs are currently 
used only in patients with diabetes. 
In summary, this population-based case-control study provides evidence that use of 
thiazolidinediones may reduce the risk of developing a psoriasis diagnosis. These 
findings are consistent with previous observations from small randomised studies in 
which patients with psoriasis benefited from therapy with thiazolidinediones. These 
findings and the somehow inconclusive findings for metformin need to be confirmed 
by further studies to learn more about the effect of oral antidiabetics on psoriasis and 
to further elucidate the possible mechanism of antidiabetic drugs on psoriasis.  
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3.4.1 Abstract 
Background: Cross-sectional studies, mostly in hospitalised patients, reported a 
possible positive association between psoriasis and diabetes mellitus. However, 
information on the temporal relation is scarce, and incidence rates of new-onset 
diabetes mellitus in patients with psoriasis are lacking. 
Objective: To assess and compare incidence rates of new-onset diabetes mellitus 
between patients with psoriasis and a comparison group without psoriasis and to 
explore the role of psoriasis severity and BMI. 
Methods: We conducted a follow-up study with a nested case-control analysis within 
the UK-based GPRD. The study population consisted of patients with a first-time 
diagnosis of psoriasis between 1994 and 2005 and a matched group of psoriasis-free 
patients. We used psoriasis duration and treatment as proxy for disease severity, and 
we applied conditional logistic regression to obtain ORs with 95% CIs. 
Results: Within the study population of 65,449 patients we identified 1061 incident 
cases of diabetes mellitus. Of these, 59% had a history of psoriasis, yielding a crude 
IRR of 1.36 (95% CI 1.20-1.53). The adjusted OR for patients with ≥2 years disease 
duration and >2 prescriptions per year for oral psoriasis treatment was 2.56 (95% CI 
1.11-5.92). In an analysis restricted to patients with normal BMI, the adjusted OR 
was 2.02 (95% CI 1.31-3.10). 
Conclusions: In this large observational study the risk of incident diabetes mellitus 
was increased for patients with psoriasis as compared with a psoriasis-free 
comparison group. The risk increased with psoriasis duration and severity and was 
not driven by high BMI alone.  
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3.4.2 Background 
Psoriasis is an immune-mediated inflammatory skin disease with an estimated 
prevalence of 1.5% in the UK.139 The prevalence varies across geographical regions 
of the world.63 The disease is characterised by T cell-mediated hyperproliferation of 
keratinocytes and inflammatory processes based on a complex genetic background. 
After activation of naïve T cells by antigen-presenting cells, effector/memory T cells 
mainly of the Th1 and Th17 lineage are generated which produce cytokines such as 
IL-22, INF-γ, and TNF-β and IL-6, IL-17, and IL-22, respectively. These cytokines, 
which seem to play a central role in the pathogenesis of psoriasis, can activate 
keratinocytes directly or via macrophages/dendritic cells leading to increased 
proliferation of keratinocytes as well as production of other cytokines (e.g. TNF-α) 
and growth factors which sustain the inflammatory processes.48 This inflammation is 
thought to be a reason for an increased cardiovascular risk in patients with psoriasis 
as is thought to be the case for other diseases with systemic inflammation such as 
rheumatoid arthritis or lupus erythematosus.180 Other possible reasons for an altered 
cardiovascular risk associated with psoriasis are an increased prevalence of smoking 
and high BMI.88 Previous studies on comorbidities of psoriasis reported an increased 
prevalence of diabetes mellitus among patients with psoriasis86, 102 including one 
study in which the effect was restricted to women.86 TNF-α is involved in the 
pathogenesis of psoriasis and has been shown to induce insulin resistance, and 
inflammatory processes have also been hypothesised to play a role in the 
pathogenesis of diabetes mellitus.181-183 One cross-sectional study in patients with a 
BMI <30 kg/m2 did not provide evidence for a material difference in insulin secretion 
or sensitivity between patients with psoriasis and healthy controls, but a subanalysis 
related psoriasis duration with decreased insulin sensitivity, and the authors of 
another study described the metabolic state in patients with psoriasis to be shifted 
towards insulin resistance.184, 185 In addition, several epidemiological studies86, 99, 101-
106
 reported an increased prevalence of diabetes mellitus or metabolic syndrome 
(including central obesity, atherogenic dyslipidaemia, hypertension, and glucose 
intolerance) in patients with psoriasis. However, all of the studies were cross-
sectional, and most of them involved hospitalised patients. Furthermore, diabetes 
mellitus was the primary outcome of interest in only one of these studies.105  
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It was the aim of the present study to elucidate further the association between 
psoriasis and the risk of developing new-onset diabetes mellitus in a large 
population-based observational study.  
 
3.4.3 Methods  
We conducted a matched follow-up study and a nested case-control analysis to 
quantify the risk of new-onset diabetes mellitus in patients with psoriasis and to 
compare it with that in a matched population without psoriasis. 
 
Data source 
We used the GPRD, a large UK-based database established around 1987 which 
encompasses some five million patients who are actively enrolled with selected GPs. 
The GPs have agreed to provide data for research purposes to the GPRD. GPs have 
been trained to record medical information in a standard manner and to supply it 
anonymously. The patients enrolled in the GPRD are representative of the UK with 
regard to age, sex, geographical distribution, and annual turnover rate. The 
information recorded includes patient demographics and characteristics (e.g. age, 
sex, height, weight, smoking status), symptoms, medical diagnoses, referrals to 
consultants, hospitalisations, and all drug prescriptions, as the doctors generate 
prescriptions directly with the computer using a coded drug dictionary. Prescriptions 
contain the name of the preparation (active compound), the route of administration, 
the dose of a single unit, the number of units prescribed, and, in most instances, the 
intake regimen prescribed by the GP. This database, which has been described in 
detail elsewhere31, 37 and validated extensively,32-34 has been the source for 
numerous epidemiological studies published in peer-reviewed journals.  
The study protocol was approved by ISAC for the UK MHRA database research. 
 
Study population 
The study population consisted of all patients with a first-time diagnosis of psoriasis 
between 1 January 1994 and 31 December 2005 and of a comparison group of the 
exact same number of patients free of psoriasis, matched on calendar time (date of 
the psoriasis diagnosis), age (same year of birth), sex, general practice, and years of 
history in the GPRD. We excluded patients with less than three years of history in the 
database prior to the first-time diagnosis of psoriasis (or the corresponding date in 
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the comparison group). In previous GPRD-based studies on psoriasis, Gelfand et al. 
documented a high validity of psoriasis diagnoses in the GPRD,115, 139, 147 and we 
therefore included all patients with a recorded psoriasis diagnosis in the analyses.  
 
Follow-up and identification of incident diabetes cases 
From the study population we excluded all patients with a prevalent diagnosis of 
diabetes mellitus as well as of cancer or human immunodeficiency virus (HIV) prior to 
the psoriasis diagnosis (or the corresponding date in the comparison group). We then 
followed all patients until they developed a first-time diagnosis of diabetes mellitus, 
died, or follow-up in the medical record ended, whichever came first. The date of the 
diagnosis of diabetes mellitus will subsequently be referred to as ‘index date’. Cases 
with diabetes mellitus were included in the analyses if they had a first-time diabetes 
mellitus code recorded plus at least one prescription for an antidiabetic drug such as 
insulin, sulfonylureas, biguanides, thiazolidinediones, acarbose, glinides, or guar gum 
within 30 days prior to or at any time after the first-time diagnosis of diabetes mellitus. 
In addition, patients with a recorded diagnosis of diabetes mellitus who did not 
receive any drug treatment but who were started on a diet were included. We 
excluded potential cases who did not fulfil these criteria as well as those who 
received antidiabetic drugs more than 30 days prior to the first recorded diagnosis of 
diabetes mellitus, as they were considered to be prevalent rather than incident. We 
applied these criteria for inclusion or exclusion of potential cases of diabetes mellitus 
after having manually reviewed a random sample of computer profiles of potential 
cases of diabetes mellitus.  
 
Nested case-control analysis 
To each case patient with an incident diagnosis of diabetes mellitus we matched at 
random up to four control patients from the study population on age (same year of 
birth), sex, and calendar time (same index date, i.e. the date when the case 
developed diabetes mellitus). We applied the same exclusion criteria to controls as 
we did to cases.  
We compared the prevalence of diagnosed psoriasis prior to the index date between 
cases of diabetes mellitus and controls and stratified patients with psoriasis by 
severity of disease, thereby taking into account 1) duration of psoriasis (<2 versus ≥2 
years), 2) psoriasis treatment (no treatment, topical treatment only [emollients, 
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salicylic acid, calcipotriol, coal tar, dithranol or tazarotene preparations, or 
corticosteroids] and/or UV/oral treatment [azathioprine, ciclosporin, methotrexate, 
acitretin, hydroxyurea, mycophenolate mofetil, or UV/PUVA therapy]) and (3) 
intensity of psoriasis treatment (no treatment, ≤4 versus >4 prescriptions per year for 
topical treatment, ≤2 versus >2 prescriptions per year for oral treatment).  
 
Statistical analysis 
In the follow-up analysis we assessed person-time for all patients in the study 
population from the date of first psoriasis diagnosis (or the corresponding date in the 
comparison group) until a patient developed diabetes mellitus, died, or follow-up in 
the medical record ended. We assessed the crude IR of a first-time diagnosis of 
diabetes mellitus among patients with or without psoriasis, stratified by age and sex 
as well as a crude IRR with 95% CI.  
In the nested case-control analysis we conducted conditional logistic regression 
analyses using the SAS statistical software (version 9.1; SAS Institute Inc, Cary, NC, 
U.S.A.). We displayed relative risk estimates as OR with 95% CI. The analyses were 
controlled for the potential confounders age, sex, and calendar time by matching. We 
further adjusted the ORs for smoking status (non, current, ex, unknown) and BMI 
(<18.5, 18.5-24.9, 25.0-29.9, ≥30 kg/m2, unknown) in the multivariate model, as well 
as for hyperlipidaemia (diagnosis or antihyperlipidaemic treatment recorded), 
hypertension, use of oral steroids (1-4 or ≥5 prescriptions), and previous infections 
(candidiasis/aspergillosis, cellulitis). We also tested potential confounding for a 
number of other covariates which were not included in the final model because they 
were not materially associated with the exposure or the outcome, such as ischaemic 
heart disease, congestive heart failure, arrhythmias, cerebrovascular diseases, 
arterial thrombosis, venous thrombosis, renal failure, schizophrenia, affective 
disorders, skin infections, respiratory/chest infections, viral infections, and use of 
aspirin, NSAIDs, antipsychotics, SSRIs, oral contraceptives, and oestrogens. 
 
3.4.4 Results 
The initial study population consisted of 73,404 patients, 36,702 with psoriasis and 
36,702 psoriasis-free patients in the matched comparison group (16,969 [46.2%] 
men and 19,733 [53.8%] women). Patients with psoriasis were more likely to be 
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current (23.9% vs. 18.8%) or ex smokers (12.8% vs. 10.3%), and they tended to 
have a higher BMI (22.7% vs. 21.6% with BMI 25-29.9 kg/m2 and 13.3% vs. 10.6% 
with BMI ≥30 kg/m2) prior to the first-time psoriasis diagnosis than patients in the 
comparison group without psoriasis. 
 
Incidence rates of diabetes in the person-time analysis 
After the exclusion of patients with prevalent diabetes mellitus, cancer, or HIV, the 
remaining study population consisted of 65,449 patients (32,593 cases and 32,856 
controls). Within this population we identified 1061 cases with an incident diagnosis 
of diabetes mellitus of whom 626 (59%) had a history of psoriasis and 435 (41%) did 
not. The IR for diabetes mellitus was 4.06 (95% CI 3.75-4.39) per 1000 py in patients 
with psoriasis and 2.98 (95% CI 2.72-3.28) per 1000 py in the comparison group 
without psoriasis, yielding a crude IRR of 1.36 (95% CI 1.20-1.53) for patients with 
psoriasis compared with the comparison group. The crude IRs and IRRs, stratified by 
age and sex, are displayed in table 3.4.1. 
 
Table 3.4.1 Incidence rates and incidence rate ratios of diabetes mellitus stratified by age and sex 
 Person-years Cases IR / 1000 py  (95% CI) IRR  (95% CI) 
Psoriasis (P) 154,316.1 626 4.06 (3.75 - 4.39) 1.36 (1.20 - 1.53) 
No psoriasis (NP) 145,783.8 435 2.98 (2.72 - 3.28)   
Sex 
  
  
  
Men  P 71,084.7 332 4.67 (4.20 - 5.20) 1.23 (1.04 - 1.44) 
          NP 66,270.5 252 3.80 (3.36 - 4.30)   
Women P 83,231.3 294 3.53 (3.15 - 3.96) 1.53 (1.28 - 1.83) 
             NP 79,513.4 183 2.30 (1.99 - 2.66)   
Age (years) 
  
  
  
  0-29 P 40,246.0 18 0.45 (0.28 - 0.71) 2.75 (1.24 - 6.13) 
          NP 36,928.7  6 0.16 (0.07 - 0.35)   
30-59 P 70,072.0 237 3.38 (2.98 - 3.84) 1.33 (1.09 - 1.61) 
          NP 65,861.4 168 2.55 (2.19 - 2.97)   
60-79 P 37,008.4 330 8.92 (8.01 - 9.93) 1.43 (1.21 - 1.69) 
          NP 36,312.4 226 6.22 (5.47 - 7.09)   
80+    P 6989.7 41 5.87 (4.33 - 7.95) 1.12 (0.71 - 1.75) 
          NP 6681.5 35 5.24 (3.77 - 7.28)   
P = psoriasis; NP = no psoriasis; IR = incidence rate; py = person-years; CI = confidence interval; IRR = incidence rate ratio 
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Nested case-control analysis 
The nested case-control analysis encompassed 1061 incident cases of diabetes 
mellitus and 4244 matched control patients. The background characteristics of cases 
and controls are displayed in table 3.4.2.  
 
Table 3.4.2 Background characteristics of diabetes cases and controls in the nested case-control 
analysis 
Variable 
Cases No (%) 
(n = 1061) 
Controls No (%) 
(n = 4244) 
Adjusted OR* 
(95% CI) 
Smoking status 
      
 Non smoker 479 (45.2) 1937 (45.6) 1.00 (reference) 
 Current smoker 197 (18.6) 948 (22.3) 0.97 (0.79 - 1.20) 
 Ex smoker 271 (25.5) 826 (19.5) 1.10 (0.90 - 1.34) 
 Unknown 114 (10.7) 533 (12.6) 1.11 (0.82 - 1.51) 
BMI (kg/m2)       
 12-18.4 2 (0.2) 49 (1.2) 0.47 (0.11 - 1.99) 
 18.5-24.9 97 (9.1) 1304 (30.7) 1.00 (reference) 
 25-29.9 320 (30.2) 1398 (32.9) 3.10 (2.41 - 3.99) 
 30-60 476 (44.9) 619 (14.6) 9.95 (7.68 - 12.89) 
 Unknown 166 (15.6) 874 (20.6) 2.53 (1.87 - 3.43) 
Comorbidities       
Hypertension 494 (46.6) 1151 (27.1) 1.93 (1.64 - 2.28) 
Hyperlipidaemia without 
treatment 
59 (5.6) 206 (4.9) 1.05 (0.75 - 1.47) 
Hyperlipidaemia with 
treatment 
230 (21.7) 477 (11.2) 2.13 (1.72 - 2.64) 
Infections 419 (39.5) 1331 (31.4) 1.25 (1.06 - 1.47) 
*Adjusted for all covariates listed in the table plus use of systemic corticosteroids 
BMI = body mass index; OR = odds ratio; CI = confidence interval  
Infections include: cellulitis, candidiasis, and aspergillosis 
 
As compared with patients without psoriasis, the relative risk estimate (OR) of 
developing diabetes mellitus associated with psoriasis was 1.31 (95% CI 1.13-1.51), 
adjusted for smoking status, BMI, hypertension, hyperlipidaemia, infections, and use 
of systemic steroids. We found increasing ORs with increasing psoriasis severity, 
based on assessments of treatment type and duration (<2 vs. ≥2 years) prior to the 
index date. An additional stratification of the duration of psoriasis prior to the index 
date into categories of <2, 2 to <4, or ≥4 years yielded increasing adjusted ORs with 
increasing psoriasis duration of 1.24 (95% CI 1.03-1.51), 1.26 (95% CI 1.01-1.59), 
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and 1.43 (95% CI 1.16-1.76), respectively. The OR for patients with a history of 
psoriasis of ≥2 years who received >2 prescriptions per year for oral psoriasis 
treatment was 2.56 (95% CI 1.11-5.92), as compared with those without psoriasis 
(table 3.4.3).  
 
Table 3.4.3 Diabetes risk and psoriasis stratified by severity, nested case-control analysis 
 
Cases No (%) 
(n = 1061) 
Controls No (%) 
(n = 4244) 
Adjusted OR* 
(95% CI) 
No Psoriasis 435 (41.0) 2154 (50.8) 1.00 (reference) 
Psoriasis 626 (59.0) 2090 (49.2) 1.31 (1.13 - 1.51) 
 Short-term disease  
(<2 years) 
238 (22.4) 866 (20.4) 1.24 (1.03 - 1.51) 
 Long-term disease 
 (≥2 years) 
388 (36.6) 1224 (28.8) 1.35 (1.14 - 1.60) 
 Untreated psoriasis 32 (3.0) 132 (3.1) 1.20 (0.77 - 1.87) 
Short-term 20 (1.9) 83 (2.0) 1.10 (0.64 - 1.90) 
Long-term 12 (1.1) 49 (1.2) 1.41 (0.69 - 2.86) 
 Topical treatment 572 (53.9) 1909 (45.0) 1.30 (1.12 - 1.51) 
Short-term 216 (20.4) 773 (18.2) 1.27 (1.04 - 1.55) 
Long-term 356 (33.5) 1136 (26.8) 1.33 (1.11 - 1.58) 
Low intensity 333 (31.4) 1212 (28.6) 1.20 (1.01 - 1.43) 
High intensity 239 (22.5) 697 (16.4) 1.47 (1.21 - 1.80) 
Long-term/high  90 (8.5) 202 (4.8) 1.71 (1.27 - 2.32) 
intensity       
 Oral treatment  
 (+/- topical) 
22 (2.1) 49 (1.1) 1.61 (0.90 - 2.88) 
Short-term 2 (0.2) 10 (0.2) 0.55 (0.11 - 2.76) 
Long-term 20 (1.9) 39 (0.9) 1.98 (1.06 - 3.70) 
Low intensity 7 (0.7) 22 (0.5) 1.40 (0.55 - 3.60) 
High intensity 15 (1.4) 27 (0.6) 1.77 (0.86 - 3.66) 
Long-term/high       
intensity 13 (1.2) 18 (0.4) 2.56 (1.11 - 5.92) 
*Adjusted for body mass index, smoking, hypertension, hyperlipidaemia, infections, and use of oral corticosteroids 
OR = odds ratio; CI = confidence interval 
 
We further analysed the role of BMI and hyperlipidaemia in the association of 
psoriasis and diabetes mellitus risk. As compared with patients without psoriasis and 
with normal BMI, the risk of developing diabetes mellitus was substantially elevated 
for overweight (BMI ≥25 kg/m2) patients without psoriasis (adjusted OR 7.04, 95% CI 
4.86-10.19), and the point estimate was even slightly higher for overweight patients 
with psoriasis (OR 8.27, 95% CI 5.75-11.90). In order to distinguish between the role 
of BMI and the role of psoriasis on the risk of developing diabetes mellitus, we 
restricted an analysis to patients with normal BMI. Among them, the diabetes mellitus 
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risk was increased twofold for patients with psoriasis (OR 2.02, 95% CI 1.31-3.10) as 
compared with patients without psoriasis. As compared with patients without 
psoriasis and without hyperlipidaemia, the adjusted relative risk estimate of 
developing diabetes mellitus for patients with both psoriasis and hyperlipidaemia was 
2.23 (95% CI 1.74-2.85) (table 3.4.4).  
 
Table 3.4.4 Diabetes risk and psoriasis, role of body mass index and hyperlipidaemia 
 
Cases No (%) 
(n = 1061) 
Controls No (%) 
(n = 4244) 
Adjusted OR* 
(95% CI) 
Psoriasis and BMI (kg/m2) 
      
BMI <25 NP 35  (3.3) 732 (17.3) 1.00 (reference) 
 P 64 (6.03) 621 (14.6) 2.02 (1.31 - 3.10) 
BMI ≥25 NP 327 (30.8) 949 (22.4) 7.04 (4.86 - 10.19) 
 P 469 (44.2) 1068 (25.2) 8.27 (5.75 - 11.90) 
Psoriasis and Hyperlipidaemia 
      
No hyperlipidaemia NP 328 (30.9) 1841 (43.4) 1.00 (reference) 
No hyperlipidaemia P 444 (41.9) 1720 (40.5) 1.33 (1.12 - 1.57) 
Hyperlipidaemia NP 107 (10.1) 313 (7.4) 1.80 (1.35 - 2.39) 
Hyperlipidaemia P 182 (17.2) 370 (8.7) 2.23 (1.74 - 2.85) 
* Adjusted for body mass index (BMI) or hyperlipidaemia, smoking, hypertension, infections, and use of oral corticosteroids 
Number of cases / controls in the model with BMI do not sum up to the total number of cases / controls as patients with 
unknown BMI are not in analysis.; NP = no psoriasis; P = psoriasis; OR = odds ratio; CI = confidence interval 
 
Stratification by age <60 and ≥60 years yielded similar risk estimates of developing 
diabetes mellitus (OR 1.31, 95% CI 1.03-1.68 and OR 1.26, 95% CI 1.05-1.52, 
respectively), and the ORs after stratification by sex were 1.17 (95% CI 0.96-1.41) for 
male and 1.54 (95% CI 1.23-1.94) for female patients with psoriasis, as compared 
with those without psoriasis. 
In an additional analysis, we stratified cases of diabetes mellitus into type I and type 
II diabetes mellitus (type I diabetes mellitus was defined either by a diagnostic code 
for type I and/or by treatment with insulin only). We found a higher prevalence of type 
I diabetes mellitus in younger patients with psoriasis and a higher prevalence of type 
II diabetes mellitus in older patients. About two-thirds of the patients with type I 
diabetes mellitus had a history of psoriasis (table 3.4.5). Only two of the patients with 
type I diabetes mellitus had oral psoriasis treatment (data not shown). 
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Table 3.4.5 Prevalence of psoriasis in patients with type I or type II diabetes mellitus stratified by age 
  
Type I diabetes mellitus 
(n = 32) 
Type II diabetes mellitus 
(n = 1029) 
 
Psoriasis 
(n / %) 
No Psoriasis 
(n / %) 
Psoriasis 
(n / %) 
No Psoriasis 
(n / %) 
Age (years) 
        
 0-29 11 (34.4) 4 (12.5) 7 (0.7) 2 (0.2) 
 30-39 3 (9.4) 3 (9.4) 17 (1.7) 14 (1.4) 
 40-49 1 (3.1) 0 (0.0) 72 (7.0) 50 (4.9) 
 50-59 0 (0.0) 0 (0.0) 144 (14.0) 101 (9.8) 
 60-69 5 (15.6) 1 (3.1) 197 (19.1) 128 (12.4) 
 70-79 1 (3.1) 1 (3.1) 127 (12.3) 96 (9.3) 
 ≥80 0 (0.0) 2 (6.3) 41 (4.0) 33 (3.2) 
Total 21 (65.6) 11 (34.4) 605 (58.8) 424 (41.2) 
 
3.4.5 Discussion 
The findings of this large population-based study suggest that the risk of developing 
diabetes mellitus is slightly increased in patients with psoriasis as compared with 
patients without psoriasis. The risk estimates were highest for patients with psoriasis 
with a longer psoriasis history who regularly received systemic treatment, possibly 
reflecting greater disease severity. 
Unlike in previous cross-sectional studies, we were in a position to distinguish 
between prevalent diabetes mellitus and new-onset diabetes mellitus after the first 
psoriasis diagnosis. The overall diabetes mellitus incidence rate in the psoriasis-free 
comparison group (3 per 1000 py) is similar to the findings of another GPRD-based 
study reporting an IR of 3.3 / 1000 py186 and slightly higher than the IR of 2.2 / 1000 
py in a study from the Netherlands.187 As previously reported,187 we also observed an 
age-dependent increase in the diabetes mellitus incidence rate which again 
decreased in the highest age groups. In our study population the diabetes mellitus IR 
overall was higher than in the psoriasis-free comparison group, reaching a peak 
(8.92 per 1000 py) in patients aged 60 to 79 years. The rates were slightly higher 
among men than women, which is also consistent with previous literature.186 When 
we compared the diabetes mellitus IR between patients with or without psoriasis, the 
IRR was highest for patients <30 years of age, most likely driven by cases with type I 
diabetes mellitus which tends to be increased in young patients with psoriasis. In a 
subgroup analysis encompassing 32 patients with type I diabetes mellitus, 11 
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(34.4%) had psoriasis and were <30 years of age, as compared with four (12.5%) 
without psoriasis below 30 years of age. Like psoriasis, type I diabetes mellitus is 
considered to be an autoimmune disease mediated by Th1 helper T cells, and the 
two diseases may share mechanistic characteristics.188 
In the nested case-control analysis, the prevalence of psoriasis was slightly higher 
among cases of diabetes mellitus than among controls (adjusted OR 1.31, 95% CI 
1.13-1.51), and a BMI above 25 kg/m2 as well as comorbidities related to the 
metabolic syndrome were also more common in cases with diabetes mellitus than in 
controls. The slightly increased relative diabetes mellitus risk associated with 
psoriasis was similar to findings from previous studies in nonhospitalised patients 
and from cross-sectional designs.103, 105 Another cross-sectional study in hospitalised 
patients found an OR of 2.48 (95% CI 1.70-3.61), however, the result was not 
adjusted for BMI.106 We compared the diabetes prevalence prior to the first-time 
psoriasis diagnosis in a previous analysis and did not find a substantial difference 
between patients with psoriasis and the comparison group without psoriasis.158  
After stratification by psoriasis duration and type of treatment we found higher ORs 
for patients with a longer history of psoriasis and / or oral treatment, both markers of 
disease severity. The authors of another cross-sectional analysis on the GPRD who 
also used pharmacological treatment as a marker for disease severity reported an 
OR for diabetes mellitus of 1.62 (95% CI 1.30-2.01)103 for patients with psoriasis 
using oral treatment, a similar finding to our OR of 1.61 (95% CI 0.90-2.88), and 
another study also reported increasing diabetes mellitus ORs with increasing 
psoriasis severity (defined by type of treatment).105 In our study population, the 
diabetes mellitus risk for patients with psoriasis who received intensive topical 
treatment and had a longer disease duration was 1.71 (95% CI 1.27-2.32), and it was 
2.56 (95% CI 1.11-5.92) for patients with intensive oral treatment and longer disease 
duration.   
As methotrexate has been shown to increase progression of diabetes mellitus in a 
randomised trial189 and as ciclosporin has been associated with hyperglycaemia and 
acitretin with alterations in glucose tolerance,190 we conducted several sensitivity 
analyses to explore the role of pharmacological treatment on the risk of developing 
diabetes mellitus. In a model restricted to patients with psoriasis without recorded 
use of oral treatment, the relative risk of developing diabetes mellitus remained 
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higher for psoriasis patients (adjusted OR 1.31, 95% CI 1.11-1.57) with a longer-term 
psoriasis history. 
The herein reported association between the chronic inflammatory skin disease 
psoriasis and diabetes mellitus may support the notion that insulin resistance, 
diabetes mellitus, and the metabolic syndrome are triggered by chronic inflammation, 
i.e. that they are associated with a cytokine-mediated activation of innate 
immunity.191 C-reactive protein (CRP), a sensitive marker of inflammation, as well as 
other inflammatory mediators have been related to insulin sensitivity as well as to 
BMI.192, 193 Cytokines (e.g. IL-1, IL-6, and TNF-α) stimulate hepatic production of 
acute-phase proteins, such as CRP,191, 192 which is also supposed to be increased in 
mild and severe psoriasis.194 The beneficial effect of thiazolidinediones in both 
diabetes mellitus and psoriasis158 additionally supports the link via inflammation 
between the two diseases, as these substances are supposed to have anti-
inflammatory properties. 195 
Our study has several limitations. In large observational studies one can never rule 
out a certain degree of misclassification which may have led to the inclusion of cases 
of psoriasis or of cases of diabetes mellitus who in fact did not have such a 
diagnosis. However, in previous GPRD-based studies on psoriasis, Gelfand et al.115, 
139, 147
 documented a high validity of this diagnosis. In order to reduce the likelihood 
of including cases of diabetes mellitus who did not have an incident diagnosis of 
diabetes mellitus, we applied a stringent previously defined algorithm and reviewed a 
large sample of case profiles so that we were confident that misclassification was not 
a major issue in this study. Nevertheless, it is possible that high blood glucose was 
detected by chance or due to increased medical attention in some cases, and that in 
some instances the index date may not have been accurate, or the person may not 
have had diabetes mellitus. The number of patients with psoriasis who were exposed 
to oral treatment is rather low in our study population. As this subgroup reflects 
patients with the highest disease severity, we do not have much information on this 
subgroup; most patients with psoriasis in our study population had mild to moderate 
psoriasis. In addition, it is possible that our classification of disease severity which 
was based on drug treatment is not always accurate, as patients may have received 
some treatment on an irregular basis by the dermatologist, and this may not have 
been recorded for all patients by the GP. 
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Although we tested for a large number of potential confounding factors and included 
the most relevant ones in our model, we cannot exclude the possibility that unknown 
confounders or biases may have affected our results to some degree. 
Particularly BMI is a strong risk factor for type II diabetes mellitus, and patients with 
psoriasis have been shown to have higher BMI. Thus, BMI is likely to confound the 
association between psoriasis and the risk of diabetes mellitus. We therefore 
adjusted the various models for BMI and ran sensitivity analyses to distinguish further 
between the role of BMI and of psoriasis as risk factors for new-onset diabetes 
mellitus. Nevertheless, we cannot rule out the possibility that a certain proportion of 
misclassified or missing BMI values may have led to some residual confounding. 
There was, however, substantial evidence from these various analyses that the 
association between psoriasis and an increased diabetes mellitus risk remained 
independent of BMI.  
In conclusion, this is, to the best of our knowledge, the first study which explored the 
association between incident psoriasis and the risk of developing an incident 
diagnosis of diabetes mellitus. In our study population patients with psoriasis were at 
an increased risk of developing new-onset diabetes mellitus, and there was a 
suggestion that the risk increased with psoriasis severity and duration. Finally, the 
risk of developing a diagnosis of diabetes mellitus did not seem to be explained by 
high BMI alone. 
 
 
 
 
   
 
 
3.5 PSORIASIS AND RISK OF INCIDENT MYOCARDIAL INFARCTION, STROKE, OR 
TRANSIENT ISCHAEMIC ATTACK: AN INCEPTION COHORT STUDY WITH A 
NESTED CASE-CONTROL ANALYSIS 
 
 
 
 
Yolanda B. Brauchli1, Susan S. Jick 2, Montserrat Miret3, Christoph R. Meier 1,2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology and Toxicology, University 
Hospital Basel, Switzerland;  2Boston Collaborative Drug Surveillance Program, Boston University 
School of Medicine, 11 Muzzey Street, Lexington, MA 02421, U.S.A; 3Merck Serono International S.A., 
Geneva, Switzerland 
 
 
 
Br J Dermatol 2009 (Epub ahead of print) 
 
3 Psoriasis project  Psoriasis and risk of incident MI, stroke, or TIA 
 86 
3.5.1 Abstract 
Background: Systemic inflammation may increase the risk for cardiovascular 
diseases in psoriasis patients, but data on this risk in patients with early psoriasis are 
scarce.  
Objective: To assess and compare the risk of developing incident MI, stroke, or TIA 
between an inception cohort of psoriasis patients and a psoriasis-free population. 
Methods: We conducted an inception cohort study with a nested case-control 
analysis within the UK-based GPRD. The study population encompassed 36,702 
patients with a first-time recorded diagnosis of psoriasis between 1994 and 2005, 
matched 1:1 to psoriasis-free patients. We assessed crude IRs and applied 
conditional logistic regression to obtain ORs with 95% CIs.  
Results: Overall, the IRs of MI (n = 449), stroke (n = 535), and TIA (n = 402) were 
similar among patients with or without psoriasis. However, the adjusted OR of 
developing MI for psoriasis patients aged <60 years was 1.66 (95% CI 1.03-2.66) 
compared with patients without psoriasis, while the OR for patients aged ≥60 years 
was 0.99 (95% CI 0.77-1.26). The adjusted ORs of developing MI for patients of all 
ages with ≤2 or >2 prescriptions/year for oral psoriasis treatment were 2.48 (95% CI 
0.69-8.91) and 1.39 (95% CI 0.43-4.53), respectively, with a similar finding for stroke 
and TIA.   
Conclusions: The risk of developing a cardiovascular outcome was not materially 
elevated for patients with early psoriasis overall. In subanalyses, however, there was 
a suggestion of an increased (but low absolute) MI risk for psoriasis patients aged 
<60 years, mainly for those with severe disease. 
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3.5.2 Background 
Psoriasis, a disease with an estimated prevalence of 1.5% in the UK,139 is 
characterised by T cell-mediated hyperproliferation of keratinocytes on a complex 
genetic background. Pro-inflammatory Th1 and Th17 cytokines such as IL-22, IFN-γ, 
TNF-β, IL-6, and IL-17 play a central role in the pathogenesis together with other 
cytokines (e.g. TNF-α, IL-20, IL-23, and TGF-α).48 Increased levels of the acute-
phase CRP were reported in mild and severe psoriasis.194 Atherosclerosis, a main 
risk factor for MI, ischaemic stroke, and TIA, is also an inflammatory process driven 
by Th1 cells with a predominance of pro-inflammatory cytokines.196 Atherosclerosis 
has been associated with psoriasis in recent observational studies,105, 197, 198 and 
chronic systemic inflammatory processes are thought to be a possible reason for the 
increased cardiovascular risk seen in patients with other systemic inflammatory 
diseases such as rheumatoid arthritis or lupus erythematosus.180, 199 In addition, 
smoking, metabolic syndrome, high BMI, alcohol consumption,88, 101, 200 and a pro-
atherogenic lipoprotein profile112, 201, 202 may also increase the risk for cardiovascular 
diseases in psoriatic patients. Hospital-based studies reported a higher prevalence of 
cardiovascular diseases in psoriatic patients, particularly in those with severe disease 
activity at young age.102, 111, 203 Whereas population-based outpatient studies from the 
1980s did not or only partially support these findings,86, 120 recent observational 
studies provided evidence for an increased prevalence of diabetes, hypertension, 
hyperlipidaemia, obesity, and smoking103, 110 as well as of MI108, 110 in psoriatic 
patients, mainly with severe disease. In one of the studies,108 a cohort study on the 
GPRD conducted by Gelfand et al., the increased MI risk was independent from 
other cardiovascular risk factors. However, a history of MI prior to start of observation 
could not have been determined completely in that study because patients who 
already had a diagnosis of psoriasis at registration in the GPRD were included in the 
study cohort.108  
One study showed an increased mortality from cerebrovascular diseases for patients 
hospitalised for psoriasis, a finding which was not accompanied by an increased 
mortality from cardiovascular events (MI, stroke, and pulmonary embolism) in 
outpatients.111 Recently, two groups reported a slightly increased risk of stroke in 
outpatient psoriatic patients.107, 109, 110 
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It was the aim of the present study to investigate the reported association between 
psoriasis and MI, stroke, or TIA using primary care data from the UK and applying a 
slightly different study design from that used in the earlier reports. 
 
3.5.3 Methods  
We conducted a matched follow-up study with a nested case-control analysis to 
quantify the risk of an incident MI, stroke, or TIA diagnosis in patients after a first-time 
recorded psoriasis diagnosis and to compare it with a matched population without 
psoriasis. 
 
Data source 
We used the GPRD, a large UK-based database established around 1987 which 
encompasses some five million patients who are actively enrolled with selected GPs. 
The GPs have agreed to provide data for research purposes to the GPRD. GPs have 
been trained to record medical information in a standard manner and to supply it 
anonymously. The patients enrolled in the GPRD are representative of the UK with 
regard to age, sex, geographic distribution, and annual turnover rate. The information 
recorded includes patient demographics and characteristics (e.g. age, sex, height, 
weight, smoking status), symptoms, medical diagnoses, referrals to consultants, 
hospitalisations, and all drug prescriptions, as the doctors generate prescriptions 
directly with the computer using a coded drug dictionary. This database, which has 
been described in detail elsewhere31, 37 and validated extensively,32-34 has been the 
source for numerous epidemiological studies published in peer-reviewed journals.  
The study protocol was approved by ISAC for MHRA database research. 
 
Study population 
The study population consisted of all patients with a first-time recorded diagnosis of 
psoriasis between 1 January 1994 and 31 December 2005 and of a comparison 
group of the same number of psoriasis-free patients, matched to psoriasis patients 
on calendar time (date of the psoriasis diagnosis), age (same year of birth), sex, 
general practice, and years of history in the GPRD. We excluded patients with <3 
years of history in the database prior to the first-time psoriasis diagnosis (or the 
corresponding date in the comparison group). We included all patients with a 
recorded psoriasis diagnosis in the analyses, as we did in previous GPRD-based 
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studies on psoriasis.155, 158  
 
Follow-up and identification of MI, stroke, and TIA 
From the study population we excluded all patients with a history of ischaemic heart 
disease or cerebrovascular diseases, cancer, or HIV prior to the psoriasis diagnosis 
(or the corresponding date in the comparison group). We then followed all patients 
until they developed a first-time diagnosis of MI, stroke, or TIA, they died, or follow-up 
in the medical record ended. The date of the MI, stroke, or TIA diagnosis will be 
subsequently referred to as the ‘index date’. We validated all potential cases with a 
recorded code for incident MI, stroke, or TIA using a computer-based algorithm and 
manual computer profile review, thereby focusing on newly started pharmacological 
therapies after the cardiovascular diagnosis, on hospitalisations, and on referrals to 
identify eligible first-time cases of interest and to classify stroke cases into 
haemorrhagic, thrombotic, or unspecified stroke, or into cases with TIA. This 
validation process was done blinded as to whether the cases had psoriasis or not.   
 
Nested case-control analysis 
To each case patient with an MI, stroke, or TIA diagnosis identified in the follow-up 
part we matched at random up to four control patients from the study population on 
age (same year of birth), sex, and calendar time (same index date, i.e. the date when 
the case developed MI or stroke/TIA). We applied the same exclusion criteria to 
controls as we did to cases.  
We compared the prevalence of diagnosed psoriasis prior to the index date between 
cases with a cardiovascular outcome and their matched controls, and we stratified 
psoriasis patients by duration of psoriasis (<2 vs. ≥2 years) and treatment (no 
treatment, topical treatment only [emollients, salicylic acid, calcipotriol, coal tar, 
dithranol or tazarotene preparations, or corticosteroids] and/or UV/oral treatment 
[azathioprine, ciclosporin, methotrexate, acitretin, hydroxyurea, mycophenolate 
mofetil, or UV/PUVA therapy]). Treatment was used as a proxy for severity of 
psoriasis whereby prescription of at least one oral preparation or UV therapy 
classified for severe disease. We further stratified patients by treatment intensity (no 
treatment, ≤4 vs. >4 prescriptions/year for topical treatment, ≤2 vs. >2 
prescriptions/year for oral treatment).  
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Statistical analysis 
In the follow-up part we assessed person-time for all patients in the study population 
from the date of first psoriasis diagnosis (or the corresponding date in the 
comparison group) until a patient developed an outcome of interest, died, or follow-
up in the medical record ended. We assessed crude IRs of a first-time MI, stroke, or 
TIA diagnosis among patients with or without psoriasis, stratified by age and sex, and 
we calculated a crude IRR with 95% CI.  
In the nested case-control analysis we conducted conditional logistic regression 
analyses using the SAS statistical software (version 9.1; SAS Institute Inc, Cary, NC, 
U.S.A.), displaying relative risk estimates as ORs with 95% CIs. The analyses 
controlled for the potential confounders age, sex, and calendar time by matching. We 
further adjusted the ORs for smoking status (non, current, past, unknown) and BMI 
(<18.5, 18.5-24.9, 25.0-29.9, ≥30 kg/m2, unknown) in the multivariate model as well 
as for hyperlipidaemia, diabetes, hypertension, other cardiac diseases (congestive 
heart failure, arrhythmia), and affective disorders. Depression has been reported to 
increase the risk of coronary heart disease204 and stroke,205 and psychiatric 
disorders, including depression, seem to be fairly common in patients with 
psoriasis.132 In addition, we adjusted the analyses of MI for acute chest infections 
(<30 days before index date) as well as for use of oral steroids (last prescription <90 
or ≥90 days before index date) because acute respiratory tract infections206 and use 
of oral corticosteroids207 have been associated with MI and infections (primarily 
streptococcal throat infections) with psoriasis.87 Additionally, patients with psoriasis 
may be less likely to receive oral corticosteroids due to fear of potential corticosteroid 
dependence and exacerbation of psoriasis upon withdrawal.95 The analyses of stroke 
and TIA were further adjusted for a history of ischaemic heart disease, use of 
acetylsalicylic acid and nonsteroidal anti-inflammatory drugs (last prescription <90 or 
≥90 days before index date), alcoholism, and epilepsy. The latter three factors have 
been reported to alter the risk of stroke.208-210 We also evaluated the effects of other 
covariates for potential confounding, which were not included in the final model 
because they were not materially associated with either the exposure or the 
outcome. 
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3.5.4 Results 
The initial study population encompassed 73,404 patients, 36,702 with psoriasis and 
36,702 matched psoriasis-free patients (16,969 [46.2%] men and 19,733 [53.8%] 
women). Psoriasis patients were more likely to be current smokers (23.9% vs. 
18.8%) and overweight (22.7% vs. 21.6% with BMI 25-29.9 kg/m2 and 13.3% vs. 
10.6% with BMI ≥30 kg/m2) than patients in the comparison group. The mean time of 
follow-up was 4.6 years. 
 
Incidence rates of myocardial infarction in the person-time analysis 
After excluding patients with a history of ischaemic heart disease, cancer, or HIV, the 
remaining study population consisted of 63,639 patients (31,568 cases and 32,071 
controls). Within this population we identified 449 cases with an incident MI 
diagnosis, of whom 238 (53%) had a history of psoriasis. The overall IR for MI was 
1.58 (95% CI 1.39 – 1.79) / 1000 py in patients with psoriasis, and the crude IRR was 
1.07 (95% CI 0.89 – 1.29) (table 3.5.1).  
 
Table 3.5.1 Incidence rates and incidence rate ratios of myocardial infarction 
Outcome Group Events 
Person-
years 
IR/1000 py (95% CI) IRR (95% CI) 
MI 
       
 Psoriasis All 238 150,972.2 1.58 (1.39 - 1.79) 1.07 (0.89 - 1.29) 
 Men 151 68,503.1 2.20 (1.88 - 2.58) 1.06 (0.84 - 1.33) 
 Women 87 82,469.0 1.05 (0.86 - 1.30) 1.09 (0.80 - 1.48) 
 Age 0-29 0 40,383.7 NA NA NA NA 
 Age 30-59 76 70,212.8 1.08 (0.86 - 1.35) 1.99 (1.37 - 2.88) 
 Age 60-80+ 162 40,375.7 4.01 (3.44 - 4.68) 0.92 (0.75 - 1.14) 
 No Psoriasis All 211 143,231.5 1.47 (1.29 - 1.69) 1.0  
 Men 135 64,707.2 2.09 (1.76 - 2.47) 1.0  
 Women 76 78,524.3 0.97 (0.77 - 1.21) 1.0  
 Age 0-29 1 37,068.7 0.03 (0.00 - 0.15) 1.0  
 Age 30-59 36 66,180.7 0.54 (0.39 - 0.75) 1.0  
 Age 60-80+ 174 39,982.1 4.35 (3.75 - 5.05) 1.0  
MI = myocardial infarction; IR = incidence rate; IRR = incidence rate ratio; CI = confidence interval; py = person-year; age in 
years; Reference group: patients in the same age and / or sex group without psoriasis 
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Incidence rates of stroke and TIA in the person-time analysis 
After excluding patients with a history of cerebrovascular diseases, cancer, or HIV, 
the remaining study population consisted of 66,139 patients (32,930 cases and 
33,209 controls). Within this population we identified 535 cases with an incident 
stroke diagnosis (327 thrombotic, 69 haemorrhagic, 139 unspecified), of whom 264 
(49%) had psoriasis, and 402 cases with an incident TIA diagnosis, of whom 205 
(51%) had psoriasis. The crude IRs and IRRs are displayed in table 3.5.2.   
 
Table 3.5.2 Incidence rates and incidence rate ratios of stroke and transient ischaemic attack 
Outcome Group Events 
Person-
years 
IR/1000 py (95% CI) IRR (95% CI) 
Stroke 
       
 Psoriasis All 264 156,492.8 1.69 (1.50 - 1.90) 0.92 (0.77 - 1.09) 
 Men 135 72,208.3 1.87 (1.58 - 2.21) 1.02 (0.80 - 1.31) 
 Women 129 84,284.5 1.53 (1.29 - 1.82) 0.83 (0.65 - 1.05) 
 Age 0-29 1 40,392.1 0.02 (0.00 - 0.14) NA NA 
 Age 30-59 37 71,800.5 0.52 (0.37 - 0.71) 0.75 (0.49 - 1.16) 
 Age 60-80+ 226 44,300.3 5.10 (4.48 - 5.81) 0.98 (0.81 - 1.18) 
 No Psoriasis All 271 147,287.7 1.84 (1.63 - 2.07) 1.0  
 Men 123 67,279.2 1.83 (1.53 - 2.18) 1.0  
 Women 148 80,008.5 1.85 (1.58 - 2.17) 1.0  
 Age 0-29 0 37,076.6 NA NA NA NA 
 Age 30-59 46 67,094.7 0.69 (0.51 - 0.91) 1.0  
 Age 60-80+ 225 43,116.3 5.22 (4.58 - 5.94) 1.0  
TIA 
       
 Psoriasis All 205 156,492.8 1.31 (1.14 - 1.50) 0.98 (0.81 - 1.19) 
 Men 92 72,208.3 1.27 (1.04 - 1.56) 0.88 (0.66 - 1.18) 
 Women 113 84,284.5 1.34 (1.12 - 1.61) 1.07 (0.82 - 1.40) 
 Age 0-29 0 40,392.1 NA NA NA NA 
 Age 30-59 28 71,800.5 0.39 (0.27 - 0.56) 1.14 (0.66 - 1.97) 
 Age 60-80+ 177 44,300.3 4.00 (3.45 - 4.63) 0.99 (0.80 - 1.22) 
 No Psoriasis All 197 147,287.7 1.34 (1.16 - 1.54) 1.0  
 Men 97 67,279.2 1.44 (1.18 - 1.76) 1.0  
 Women 100 80,008.5 1.25 (1.03 - 1.52) 1.0  
 Age 0-29 0 37,076.6 NA NA NA NA 
 Age 30-59 23 67,094.7 0.34 (0.23 - 0.51) 1.0  
 Age 60-80+ 174 43,116.3 4.04 (3.48 - 4.68) 1.0  
TIA = transient ischaemic attack; IR = incidence rate; IRR = incidence rate ratio; CI = confidence interval; py = person-year; age 
in years; Reference group: patients in the same age and / or sex group without psoriasis 
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Nested case-control analysis – MI 
The nested case-control analysis encompassed the 449 incident MI cases and 1796 
matched controls (table 3.5.3).  
 
Table 3.5.3 Characteristics of myocardial infarction cases and controls in the nested case-control 
analysis 
Variable 
Cases No (%) 
(n = 449) 
Controls No (%) 
(n = 1796) 
Adjusted OR* 
(95% CI) 
Smoking status 
      
 Non smoker 154 (34.3) 822 (45.8) 1.00 (reference) 
 Current smoker 142 (31.6) 363 (20.2) 2.21 (1.68 - 2.90) 
 Ex smoker 97 (21.6) 378 (21.0) 1.30 (0.96 - 1.76) 
 Unknown 56 (12.5) 233 (13.0) 1.50 (0.97 - 1.76) 
BMI (kg/m2)       
 12-18.4 9 (2.0) 19 (1.1) 1.93 (0.82 - 4.54) 
 18.5-24.9 113 (25.2) 500 (27.8) 1.00 (reference) 
 25-29.9 157 (35.0) 620 (34.5) 1.11 (0.84 - 1.47) 
 30-60 77 (17.1) 258 (14.4) 1.20 (0.84 - 1.72) 
 Unknown 93 (20.7) 399 (22.2) 1.07 (0.74 - 1.53) 
Comorbidities       
Hyperlipidaemia without  24 (5.4) 76  (4.2) 1.35 (0.82 - 2.22) 
treatment       
Hyperlipidaemia with  64 (14.3) 174 (9.7) 1.41 (0.99 - 2.02) 
treatment       
Hypertension 177 (39.4) 555 (30.9) 1.41 (1.11 - 1.78) 
Diabetes without 
treatment 
10 (2.2) 30 (1.7) 1.30 (0.61 - 2.76) 
Diabetes with treatment 49 (10.9) 108 (6.0) 1.75 (1.18 - 2.59) 
CHF, arrhythmia 64 (14.3) 172  (9.6) 1.52 (1.08 - 2.12) 
Acute infection 17 (3.8) 33  (1.8) 1.82 (0.97 - 3.42) 
Affective disorder 109 (24.3) 322 (17.9) 1.31 (1.01 - 1.71) 
*Adjusted for all covariates listed in the table and use of oral corticosteroids 
BMI = body mass index; OR = odds ratio; CI = confidence interval; CHF = congestive heart failure 
 
Compared with patients without psoriasis, the adjusted OR of developing MI for 
patients with psoriasis was 1.14 (95% CI 0.93-1.41). Compared with patients without 
psoriasis, the OR for patients with psoriasis who received ≤2 prescriptions/year for 
oral psoriasis treatment tended to be higher (OR 2.48, 95% CI 0.69-8.91) than for 
those who received >2 prescriptions/year (OR 1.39, 95% CI 0.43-4.53) (table 3.5.4), 
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although these estimates are relatively imprecise as shown by the rather wide 95% 
CIs. 
The risk estimates of developing MI associated with psoriasis were similar between 
men (OR 1.10, 95% CI 0.85-1.43) and women (OR 1.19, 95% CI 0.82-1.71). 
Stratification by age yielded higher ORs for patients aged <60 years (OR 1.66, 95% 
CI 1.03-2.66) than for those ≥60 years of age (OR 0.99, 95% CI 0.77-1.26) (table 
3.5.4). When we further stratified patients <60 years of age by psoriasis treatment, 
the adjusted ORs were 2.64 (95% CI 0.85-8.20) for those without treatment, 1.48 
(95% CI 0.91-2.41) for those with topical, and 11.3 (95% CI 1.54-82.8) for those with 
oral treatment. This latter risk estimate was based on only 4 cases and 3 controls. 
 
Table 3.5.4 Psoriasis and myocardial infarction risk stratified by age, sex, duration, and severity, in the 
nested case-control analysis 
 
Cases No (%) 
(n = 449) 
Controls No (%) 
(n = 1796) 
Adjusted OR* 
(95% CI) 
No Psoriasis 211 (47.0) 912 (50.8) 1.00 (reference) 
Psoriasis 238 (53.0) 884 (49.2) 1.14 (0.93 - 1.41) 
 <60 years 76 (16.9) 227 (12.6) 1.66 (1.03 - 2.66) 
 ≥60 years 162 (36.1) 657 (36.6) 0.99 (0.77 - 1.26) 
Short-term disease  98 (21.8) 367 (20.4) 1.15 (0.87 - 1.51) 
(<2 years)       
 Women 37 (8.2) 108 (6.0) 1.43 (0.88 - 2.33) 
 Men 61 (13.6) 259 (14.4) 0.97 (0.69 - 1.38) 
Long-term disease 140 (31.2) 517 (28.8) 1.14 (0.89 - 1.47) 
(≥2 years)       
 Women 50 (11.2) 208 (11.6) 1.04 (0.67 - 1.61) 
 Men 90 (20.0) 309 (17.2) 1.21 (0.89 - 1.65) 
Untreated psoriasis 11 (2.4) 53 (2.9) 0.98 (0.49 - 1.96) 
 <60 years 6 (1.3) 17 (0.9) 2.64 (0.85 - 8.20) 
 ≥60 years 5 (1.1) 36 (2.0) 0.55 (0.21 - 1.46) 
Topical treatment 219 (48.8) 811 (45.2) 1.14 (0.92 - 1.41) 
 <60 years 66 (14.7) 207 (11.5) 1.48 (0.91 - 2.41) 
 ≥60 years 153 (34.1) 604 (33.7) 1.02 (0.80 - 1.30) 
 Low intensity 135 (30.1) 490 (27.3) 1.17 (0.91 - 1.50) 
 High intensity 84 (18.7) 321 (17.9) 1.09 (0.82 - 1.46) 
Oral treatment  8 (1.8) 20 (1.1) 1.78 (0.74 - 4.28) 
(+/- topical)       
 <60 years 4 (0.9) 3 (0.2) 11.27 (1.54 - 82.77) 
 ≥60 years 4 (0.9) 17 (0.9) 0.86 (0.24 - 3.08) 
 Low intensity 4 (0.9) 7 (0.4) 2.48 (0.69 - 8.91) 
 High intensity 4 (0.9) 13 (0.7) 1.39 (0.43 - 4.53) 
* Adjusted for body mass index, smoking, hyperlipidaemia, hypertension, diabetes, other cardiac diseases, affective disorders, 
acute infections, and use of oral corticosteroids 
OR = odds ratio; CI = confidence interval 
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Nested case-control analysis – stroke and TIA 
This analysis encompassed 535 incident stroke cases (61% thrombotic, 13% 
haemorrhagic, 26% unspecified) and 2137 matched controls, and 402 incident TIA 
cases and 1604 matched controls, respectively (tables 3.5.5 and 3.5.6).  
 
Table 3.5.5 Characteristics of stroke cases and controls in the nested case-control analysis 
Variable 
Cases No (%) 
(n = 535) 
Controls No (%) 
(n = 2137) 
Adjusted OR* 
(95% CI) 
Smoking status 
      
 Non smoker 223 (41.7) 1050 (49.1) 1.00 (reference) 
 Current smoker 135 (25.2) 364 (17.0) 1.84 (1.41 - 2.40) 
 Ex smoker 112 (20.9) 484 (22.7) 1.02 (0.78 - 1.35) 
 Unknown 65 (12.2) 239 (11.2) 1.48 (1.01 - 2.18) 
BMI (kg/m2)       
 12-18.4 13 (2.4) 34 (1.6) 1.28 (0.63 - 2.59) 
 18.5-24.9 170 (31.8) 623 (29.2) 1.00 (reference) 
 25-29.9 141 (26.4) 701 (32.8) 0.69 (0.53 - 0.89) 
 30-60 100 (18.7) 353 (16.5) 0.85 (0.62 - 1.16) 
 Unknown 111 (20.7) 426 (19.9) 1.00 (0.73 - 1.38) 
Comorbidities       
Hyperlipidaemia without  24 (4.5) 87 (4.1) 0.99 (0.61 - 1.62) 
treatment       
Hyperlipidaemia with  92 (17.2) 300 (14.0) 0.87 (0.63 - 1.20) 
treatment       
Hypertension 248 (46.4) 731 (34.2) 1.60 (1.29 - 1.98) 
Diabetes without treatment 18 (3.4) 44 (2.1) 1.67 (0.93 - 3.02) 
Diabetes with treatment 61 (11.4) 168 (7.9) 1.31 (0.93 - 1.84) 
CHF, arrhythmia 121 (22.6) 317 (14.8) 1.60 (1.23 - 2.09) 
Affective disorder 117 (21.9) 430 (20.1) 1.00 (0.78 - 1.29) 
IHD 134 (25.1) 419 (19.6) 0.96 (0.72 - 1.28) 
Epilepsy 16 (3.0) 20 (0.94) 3.83 (1.82 - 8.02) 
Alcoholism 25 (4.7) 55 (2.6) 1.57 (0.92 - 2.70) 
*Adjusted for all covariates listed in the table and use of oral nonsteroidal anti-inflammatory drugs or acetylsalicylic acid  
BMI = body mass index; CHF = congestive heart failure; IHD = ischaemic heart disease; OR = odds ratio, CI = confidence 
interval 
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Table 3.5.6 Characteristics of transient ischaemic attack cases and controls in the nested case-control 
analysis 
Variable 
Cases No (%) 
(n = 402) 
Controls No (%) 
(n = 1604) 
Adjusted OR* 
(95% CI) 
Smoking status 
      
 Non smoker 202 (50.2) 792 (49.4) 1.00 (reference) 
 Current smoker 71 (17.7) 289 (18.0) 1.08 (0.78 - 1.49) 
 Ex smoker 92 (22.9) 340 (21.2) 0.99 (0.73 - 1.34) 
 Unknown 37 (9.2) 183 (11.4) 0.85 (0.52 - 1.37) 
BMI (kg/m2)       
 12-18.4 9 (2.2) 29 (1.8) 1.64 (0.73 - 3.71) 
 18.5-24.9 117 (29.1) 485 (30.2) 1.00 (reference) 
 25-29.9 114 (28.4) 518 (32.3) 0.78 (0.58 - 1.05) 
 30-60 83 (20.6) 239 (14.9) 1.09 (0.77 - 1.54) 
 Unknown 79 (19.7) 333 (20.8) 1.12 (0.76 - 1.64) 
Comorbidities       
Hyperlipidaemia without  21 (5.2) 83 (5.2) 1.04 (0.62 - 1.75) 
treatment       
Hyperlipidaemia with  83 (20.7) 201 (12.5) 1.29 (0.90 - 1.85) 
treatment       
Hypertension 194 (48.3) 557 (34.7) 1.59 (1.25 - 2.03) 
Diabetes without treatment 12 (3.0) 36 (2.2) 1.03 (0.52 - 2.05) 
Diabetes with treatment 44 (11.0) 98 (6.1) 1.34 (0.89 - 2.02) 
CHF, arrhythmia 81 (20.2) 226 (14.1) 1.28 (0.94 - 1.75) 
Affective disorder 102 (25.4) 280 (17.5) 1.52 (1.15 - 2.02) 
IHD 116 (28.9) 310 (19.3) 1.08 (0.79 - 1.47) 
Epilepsy 10 (2.5) 17 (1.1) 2.38 (1.04 - 5.44) 
Alcoholism 14 (3.5) 43 (2.7) 1.03 (0.53 - 1.99) 
*Adjusted for all covariates listed in the table and use of oral nonsteroidal anti-inflammatory drugs or acetylsalicylic acid  
BMI = body mass index; CHF = congestive heart failure; IHD = ischaemic heart disease; OR = odds ratio; CI = confidence 
interval 
 
The overall ORs of developing stroke or TIA associated with psoriasis were around 
one. Stratification of stroke cases into thrombotic or haemorrhagic stroke yielded 
overall adjusted ORs of 0.87 (95% CI 0.68-1.12) and 0.54 (95% CI 0.29-1.02), 
respectively. Patients with more intense oral psoriasis treatment (>2 
prescriptions/year) seemed to have lower risk estimates than those with less intense 
oral treatment, a similar observation as for MI (tables 3.5.7 and 3.5.8).  
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Stratification by age and psoriasis treatment yielded a higher risk of stroke and TIA 
for psoriasis patients receiving oral treatment who were ≥60 years of age (tables 
3.5.7 and 3.5.8). 
 
Table 3.5.7 Psoriasis and stroke risk stratified by age, duration, and severity, in the nested case-
control analysis 
 
Cases No (%) 
(n = 535) 
Controls No (%) 
(n = 2137) 
Adjusted OR* 
(95% CI) 
No Psoriasis 271 (50.6) 1054 (49.3) 1.00 (reference) 
Psoriasis 264 (49.4) 1083 (50.7) 0.93 (0.77 - 1.13) 
 <60 years 38 (7.1) 179 (8.4) 0.52 (0.29 - 0.93) 
 ≥60 years 226 (42.2) 904 (42.3) 0.99 (0.80 - 1.22) 
Short-term disease  87 (16.3) 479 (22.4) 0.69 (0.52 - 0.91) 
(<2 years)       
 Women 47 (8.8) 238 (11.1) 0.77 (0.53 - 1.13) 
 Men 40 (7.5) 241 (11.3) 0.65 (0.43 - 0.97) 
Long-term disease 177 (33.1) 604 (28.3) 1.14 (0.91 - 1.42) 
(≥2 years)       
 Women 82 (15.3) 325 (15.2) 0.94 (0.69 - 1.30) 
 Men 95 (17.8) 279 (13.1) 1.54 (1.10 - 2.15) 
Untreated psoriasis 15 (2.8) 58 (2.7) 1.02 (0.56 - 1.86) 
 <60 years 2 (0.4) 13 (0.6) 0.37 (0.06 - 2.35) 
 ≥60 years 13 (2.4) 45 (2.1) 1.18 (0.61 - 2.27) 
Topical treatment 240 (44.9) 997 (46.7) 0.91 (0.75 - 1.11) 
 <60 years 35 (6.6) 155 (7.3) 0.56 (0.31 - 1.02) 
 ≥60 years 205 (38.3) 842 (39.4) 0.95 (0.76 - 1.18) 
 Low intensity 127 (23.8) 541 (25.3) 0.87 (0.68 - 1.11) 
 High intensity 113 (21.1) 456 (21.4) 0.96 (0.74 - 1.23) 
Oral treatment  9 (1.7) 28 (1.3) 1.40 (0.64 - 3.08) 
(+/- topical)       
 <60 years 1 (0.2) 11 (0.5) 0.23 (0.02 - 2.23) 
 ≥60 years 8 (1.5) 17 (0.8) 2.24 (0.93 - 5.36) 
 Low intensity 4 (0.8) 10 (0.5) 1.98 (0.58 - 6.72) 
 High intensity 5 (0.9) 18 (0.8) 1.13 (0.41 - 3.16) 
* Adjusted for body mass index, smoking, hyperlipidaemia, hypertension, diabetes, other cardiac diseases, affective disorders, 
epilepsy, ischaemic heart disease, alcoholism, use of nonsteroidal anti-inflammatory drugs or acetylsalicylic acid 
OR = odds ratio; CI = confidence interval 
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Table 3.5.8 Psoriasis and transient ischaemic attack risk stratified by age, duration, and severity, in 
the nested case-control analysis 
 
Cases No (%) 
(n = 402) 
Controls No (%) 
(n = 1604) 
Adjusted OR* 
(95% CI) 
No Psoriasis 197 (49.0) 806 (50.3) 1.00 (reference) 
Psoriasis 205 (51.0) 798 (49.7) 1.00 (0.81 - 1.25) 
 <60 years 28 (7.0) 116 (7.2) 1.28 (0.61 - 2.68) 
 ≥60 years 177 (44.0) 682 (42.5) 1.02 (0.80 - 1.29) 
Short-term disease  67 (16.7) 331 (20.6) 0.81 (0.59 - 1.10) 
(<2 years)       
 Women 38 (9.5) 163 (10.2) 0.98 (0.63 - 1.52) 
 Men 29 (7.2) 168 (10.5) 0.62 (0.38 - 1.00) 
Long-term disease 138 (34.3) 467 (29.1) 1.15 (0.89 - 1.48) 
(≥2 years)       
 Women 75 (18.7) 263 (16.4) 1.16 (0.81 - 1.65) 
 Men 63 (15.7) 204 (12.7) 1.14 (0.78 - 1.67) 
Untreated psoriasis 11 (2.7) 48 (3.0) 0.93 (0.46 - 1.87) 
 <60 years 2 (0.5) 9 (0.6) 0.59 (0.07 - 5.09) 
 ≥60 years 9 (2.2) 39 (2.4) 0.97 (0.45 - 2.06) 
Topical treatment 186 (46.3) 735 (45.8) 0.99 (0.79 - 1.24) 
 <60 years 25 (6.2) 106 (6.6) 1.29 (0.60 - 2.82) 
 ≥60 years 161 (40.1) 629 (39.2) 0.99 (0.78 - 1.26) 
 Low intensity 112 (27.9) 405 (25.3) 1.12 (0.86 - 1.46) 
 High intensity 74 (18.4) 330 (20.6) 0.83 (0.61 - 1.12) 
Oral treatment  8 (2.0) 15 (0.9) 2.16 (0.87 - 5.35) 
(+/- topical)       
 <60 years 1 (0.3) 1 (0.1) NA NA  
 ≥60 years 7 (1.7) 14 (0.8) 2.56 (0.96 - 6.86) 
 Low intensity 4 (1.0) 7 (0.4) 2.90 (0.81 - 10.43) 
 High intensity 4 (1.0) 8 (0.5) 1.64 (0.47 - 5.78) 
* Adjusted for body mass index, smoking, hyperlipidaemia, hypertension, diabetes, other cardiac diseases, affective disorders, 
epilepsy, ischaemic heart disease, alcoholism, use of nonsteroidal anti-inflammatory drugs or acetylsalicylic acid 
OR = odds ratio; CI = confidence interval;  
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3.5.5 Discussion 
In our population-based study we quantified the risk of developing an incident 
diagnosis of MI, stroke, or TIA in association with psoriasis. In contrast to the study 
by Gelfand et al.,108 the follow-up period in our cohort study started at the first-time 
recording of a psoriasis diagnosis. While in our study there was no evidence for an 
overall increased risk of MI, stroke, or TIA associated with psoriasis, there was a 
suggestion of a slightly elevated risk associated with severe psoriasis. For MI, this 
effect was particularly elevated in younger patients. However, the absolute risk was 
low with 0.51 / 1000 py (patients 0-60 years of age).  
The MI incidence rate in our psoriasis-free comparison group (OR 1.47, 95% CI 1.29-
1.69) was similar to the MI incidence rates reported in a population-based study in 
the UK,211 while Gelfand et al.108 reported an MI rate in their psoriasis-free 
comparison group (OR 3.58, 95% CI 3.52-3.65) which was comparable with the 
(nonincident) MI rates reported in the above-mentioned study.211  
Several methodological differences can explain the different rates: Gelfand et al.108 
included all patients with a psoriasis diagnosis (prevalent or incident) between 1987 
and 2002, who contributed at least one day of observation time to the study, not 
excluding patients with a previous history of MI. In contrast, we only included patients 
with a documented first-time psoriasis diagnosis between 1994 and 2005 after having 
been in the database for at least 3 years, and we only included incident MI cases 
thereafter; thus, we excluded potential cases who had diagnosed ischaemic heart 
disease prior to the first psoriasis diagnosis. Due to these differences, our study only 
encompassed some 30% of patients included by Gelfand et al.108 As we only 
included patients with a first-time psoriasis diagnosis in or after 1994, the proportion 
of patients with early psoriasis was likely to be higher in our study population. Of our 
initial psoriasis cohort 2.3% received oral treatment as compared with 2.9% in the 
study by Gelfand et al.108  We assessed an IR for MI among patients with severe 
psoriasis only (defined as having had ≥1 prescription for an oral psoriasis treatment 
at some point in time; n = 946), and we found an overall crude IR of MI of 5.24 (95% 
CI 3.23-8.49) / 1000 py (data not shown).  
In contrast to the study by Gelfand et al.108 and another recently published study 
using the GPRD,110 we did not find an overall increased risk of MI in all psoriatic 
patients. This discrepancy may be explained by the different study designs. 
Consistent with the study by Gelfand et al.,108 we found the highest IRR of MI for 
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psoriasis patients compared with their comparison group in the age group 30-39 
years with an IRR of 5.48 (95% CI 1.24-24.2) (data not shown in table 3.5.1). In the 
nested case-control analysis restricted to patients below the age of 60 years, we also 
found a more than 60% increased MI risk for psoriasis patients compared with 
psoriasis-free patients and a relative risk estimate which was even higher for patients 
who additionally received oral treatment. Considering psoriasis patients across all 
age groups, the risk tended to be highest in patients who received UV/oral treatment 
(of whom 75% received methotrexate, 14% azathioprine, 11% UV/PUVA therapy, 
and none acitretin or ciclosporin). However, the risk was not related to the duration of 
psoriasis, a finding which has also been observed in a previous, although much 
smaller study.212 Interestingly, the OR tended to be higher for patients with less 
intense oral treatment (≤2 prescriptions/year) than for those with >2 
prescriptions/year. This may be a chance finding due to the wide CIs and the not 
statistically significant results, or it supports the current notion that disease-modifying 
antirheumatic drugs (DMARDs), mainly methotrexate, may reduce not only the 
disease activity in the skin (or in joints in rheumatoid arthritis), but also the risk of 
cardiovascular morbidity and mortality due to their systemic anti-inflammatory 
activity.213-215  
The overall stroke and TIA incidence rates found in our study population were similar 
to background rates from other UK-based analyses.211, 216 They did not materially 
differ between psoriasis patients and the psoriasis-free comparison group which is in 
contrast to other reports on the association between stroke and psoriasis using the 
same database.107, 109, 110 However, in two of these,107, 109 the same approach was 
applied as for MI discussed before, and the third one110 was a crude analysis without 
validation of stroke cases or adjustment for risk factors. As for MI, we found a 
tendency among severe psoriasis patients towards higher ORs in patients with less 
intense oral treatment.  
Our study has several limitations. In large observational studies one can never rule 
out a certain degree of misclassification which may have led to the inclusion of 
psoriasis or of MI, stroke, or TIA cases who in fact did not have such a diagnosis. 
However, in previous GPRD-based studies psoriasis had a high validity.115, 139, 147 
Additionally, we applied a stringent predefined algorithm and reviewed a large 
sample of case profiles so that we were confident that misclassification of MI, stroke, 
or TIA patients was not a major issue in this study. The first-time recording of a 
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psoriasis diagnosis by the GP may not be the onset of the disease but rather the first 
time the disease was brought to medical attention (due to some clinical 
manifestation). By starting follow-up at that point in time for all patients, we intended 
to increase the likelihood of beginning follow-up for all patients at a similar stage of 
the disease. Due to this study design, the number of psoriasis patients exposed to 
oral treatment was low in our study population, and thus we did not have much 
information on this subgroup which is thought to have the highest disease severity. It 
is further possible that some patients may have received some oral or injectable 
treatment from a specialist which was not recorded by the GP. Such misclassification 
may have diluted any possible risk differences caused by disease severity to some 
degree, if indeed any were present. Although we tested for a large number of 
potential confounding factors, we cannot exclude the possibility that unknown 
confounders or biases may have affected our results to some degree. The relatively 
short follow-up time (4.6 years) is also a limitation of the study, as chronic systemic 
inflammation may take longer to cause adverse cardiovascular outcomes.  
In summary, we conclude that by using a different study design than Gelfand et al.108 
we did not find an overall increased risk of MI, stroke, or TIA in all psoriatic patients. 
However, the MI risk was elevated in psoriatic patients under 60 years of age (mainly 
with severe psoriasis) independent of other cardiovascular risk factors. The observed 
trend for a risk reduction with longer-term systemic treatment may be the result of 
systemic anti-inflammatory effects of methotrexate and other DMARDs, but this 
observation needs further confirmation due to the limited information in this study. 
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3.6.1 Abstract 
Psoriasis has been associated with lymphohaematopoietic and solid cancers; 
however, reports have been inconsistent. 
Cancer incidence was compared between psoriasis and psoriasis-free patients and 
the roles of psoriasis duration and treatment explored in this observational study 
using the UK GPRD.  
Among 67,761 patients, 1703 patients had incident cancer; 54% had a history of 
psoriasis (IRR 1.13, 95% CI 1.02-1.24). IRRs for lymphohaematopoietic and 
pancreatic cancers were 1.81 (95% CI 1.35-2.42) and 2.20 (95% CI 1.18-4.09). In a 
nested case-control analysis, adjusted ORs for cancer overall were 1.50 (95% CI 
1.30-1.74) for psoriasis ≥4 years duration and 1.53 (95% CI 0.97-2.43) for patients 
receiving systemic treatment (marker of disease severity). Lymphohaematopoietic 
malignancy risk was highest in patients with systemic treatment (OR 10.17, 95% CI 
3.24-31.94). The OR for patients without systemic treatment was 1.59 (95% CI 1.01-
2.50) for psoriasis of <2 years and 2.12 (95% CI 1.45-3.10) for ≥2 years duration. 
Risks of bladder/kidney and colorectal cancers were increased with longer-duration 
psoriasis.  
Psoriasis patients may have an increased overall risk of incident cancer (mainly 
lymphohaematopoietic and pancreatic). Longer-term psoriasis and more severe 
disease may increase the risk of some cancers. 
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3.6.2 Background 
Psoriasis is a chronic inflammatory disease with an estimated prevalence in the 
general population of between 1% and 3%;139, 217 its impact on QoL is considerable.64 
The disease is characterised by T cell-mediated hyperproliferation of keratinocytes 
and inflammatory processes based on a complex genetic background. T cells and 
various other immune cells infiltrate the skin and activate each other and 
keratinocytes via cytokines, which appear to play a central role in the pathogenesis of 
psoriasis. This process leads to an increased proliferation of keratinocytes, as well as 
to the production of other cytokines and growth factors, thereby sustaining the 
inflammatory process.48 
A derailed immune response is believed to be involved in the pathogenesis of 
psoriasis-associated comorbidities. Psoriasis has classically been associated with 
high physical and psychological morbidity. Better understanding of the underlying 
immunopathogenesis and intensified epidemiological research suggest that psoriasis 
is linked to additional comorbid conditions, such as psoriatic arthritis, Crohn’s 
disease, atherosclerosis, myocardial infarction, and metabolic syndrome.82 The 
incidence of some cancers, in particular lymphoma, has been reported to be 
increased in patients with psoriasis. This is due, in part, to the use of immune- 
suppressive and potentially carcinogenic treatments, such as ciclosporin, 
methotrexate, and psoralen and ultraviolet A (PUVA) therapy.81  
Many published studies on the prevalence of cancer in patients with psoriasis have 
been hospital-based or conducted in patients with PUVA treatment, and results have 
been inconsistent or difficult to interpret.113, 114, 117, 119-121, 218-220 Among the population-
based studies reported to date, two studies conducted using the GPRD focused on 
the risk of lymphoma115, 116 and one using an American claims records database118 
evaluated the risk of all cancers combined, but did not stratify the results by type of 
cancer.  
The aim of the present population-based, observational study was to further elucidate 
the association between psoriasis and the risk of developing cancer and to provide 
baseline IRs of different types of cancer in patients followed for a maximum of 11 
years after the diagnosis of psoriasis. The effect of disease duration and treatment 
received was also evaluated. 
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3.6.3 Methods  
This observational study with a nested case-control analysis was conducted to 
quantify the risk of various cancer types in patients with early psoriasis and to 
compare results with a matched population without psoriasis. 
 
Data source 
We used data from the GPRD, a large UK-based database established in 1987 that 
includes approximately five million patients who are actively enrolled with selected 
GPs. These GPs provide data for research purposes; they have been trained to 
record medical information in a standard manner and to supply it anonymously. 
Patients enrolled in the GPRD are representative of the UK population with regard to 
age, sex, geographical distribution, and annual turnover rate. The information 
recorded includes patient demographics and characteristics (e.g. age, sex, height, 
weight, and smoking status), symptoms, medical diagnoses, referrals to consultants, 
hospitalisations, and all drug prescriptions, as the doctors generate prescriptions 
directly with the computer using a coded drug dictionary. This database has been the 
source for numerous epidemiological studies (including those of psoriasis) published 
in peer-reviewed journals and has been described in detail36, 38 and validated 
extensively.34 
The study protocol was approved by ISAC for MHRA database research. 
 
Study population 
We included all patients with a first-time diagnosis of psoriasis between 1 January 
1994 and 31 December 2005, along with a comparison group of the same number of 
patients without psoriasis. Patients in the control group were matched to the psoriasis 
patients on calendar time (follow-up for the matched patient started at the same date 
as for the psoriasis patient, i.e. at the date of the psoriasis diagnosis), age (same 
year of birth), sex, general practice, and years of history in the GPRD. Patients with 
<3 years of history in the database prior to the first-time psoriasis diagnosis (or the 
corresponding date in the comparison group) were excluded. The validity of psoriasis 
diagnoses in the GPRD has been documented to be high,115, 139, 147 and as a result, 
all patients with a recorded psoriasis diagnosis were included in the analyses, as in 
previous GPRD-based studies on psoriasis.155, 158, 221 
 
3 Psoriasis project  Psoriasis and risk of incident cancer 
 106 
Follow-up and identification of incident cancer cases 
We excluded patients if they had a history of cancer (malignant or in situ; except 
nonmelanoma skin cancer) or HIV prior to the psoriasis diagnosis or the 
corresponding date in the comparison group and followed all patients until one of the 
following events: a first-time diagnosis of cancer (malignant or in situ, other than 
nonmelanoma skin cancer); death; end of follow-up in the medical record; or end of 
the follow-up period. The date of the cancer diagnosis will be referred to as the index 
date hereafter. We validated all potential patients with a recorded code for incident 
cancer using both a computer-based algorithm and manual computer profile review. 
We included patients if they received cancer treatment (chemotherapy, endocrine 
therapy, or radiotherapy), were referred to a specialist, were hospitalised, underwent 
surgery, and/or died within 180 days after the diagnosis. We excluded patients if they 
did not fulfil these criteria or if there was evidence that the cancer may have been 
pre-existing rather than newly diagnosed. 
 
Nested case-control analysis 
Each patient with cancer was matched with four control patients chosen at random 
from the study population based on age (same year of birth), sex, and calendar time 
(same index date, i.e. the date when the patient was first diagnosed with cancer).  
We compared the prevalence of diagnosed psoriasis prior to the index date in 
patients with cancer (overall and stratified by type) and matched controls. Psoriasis 
patients were classified by duration of disease (<2, ≥2 years or <2 years, 2 to <4 
years, or ≥4 years) and treatment (no treatment, topical treatment alone [emollients, 
salicylic acid, calcipotriol, coal tar, dithranol or tazarotene preparations, or 
corticosteroids], and/or UV/oral treatment [azathioprine, ciclosporin, methotrexate, 
acitretin, hydroxyurea, mycophenolate mofetil, or UV/PUVA therapy]). Patients who 
received treatment were further classified by treatment intensity, defined as ≤4 or >4 
prescriptions per year for topical treatment and ≤2 versus >2 prescriptions per year 
for oral treatment.  
 
Statistical analysis 
In the follow-up analysis, we assessed person-years for all patients in the study 
population from the date of first psoriasis diagnosis (or the corresponding date in the 
comparison group) until a patient developed an outcome of interest or died, or 
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follow-up in the medical record ended. We assessed crude IRs of a first-time cancer 
diagnosis (overall and stratified by cancer type) in patients with or without psoriasis, 
stratified by age and sex; crude IRRs were calculated with the 95% CI.  
In the nested case-control analysis, we performed conditional logistic regression 
analyses using SAS (version 9.1, SAS Institute Inc, Cary, NC, U.S.A.) to calculate 
relative risk estimates as ORs with 95% CI. These analyses were controlled for the 
potential confounders age, sex, and calendar time by matching and were further 
adjusted for smoking status (none, current, past, or unknown) and BMI (<18.5, 18.5–
24.9, 25.0–29.9, ≥30 kg/m2, or unknown) in the multivariate model, as well as for the 
presence of benign cancer diagnoses before the index date. In addition, the analysis 
of digestive organ cancers was adjusted for gastro-oesophageal reflux disease and 
use of proton pump inhibitors (none, 1–9, or ≥10 prescriptions), the analysis of lung 
cancer was adjusted for COPD, and the analysis of breast cancer was adjusted for 
use of oestrogens, progestagens, or oral contraceptives (none, 1–9, or ≥10 
prescriptions). The presence of other potential confounding covariates (including 
alcoholism) not included in the final model because they were not materially 
associated with the exposure or the outcome was also investigated. A test for trend 
was performed in the conditional regression analysis to investigate the influence of 
psoriasis duration on the risk of the different types of cancer. We did not perform any 
sample size calculation because our main focus was on a high quality analysis by 
e.g. excluding psoriasis patients with less than three years of active history before 
the psoriasis diagnosis date, by excluding patients with a history of cancer before the 
psoriasis diagnosis, and by calculating cancer incidence rates only in patients with a 
first-time psoriasis diagnosis.  Hence, we took all the information we could get within 
this large database. 
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3.6.4 Results 
The study population consisted of 73,404 patients, including 36,702 with psoriasis 
(16,969 [46.2%] men and 19,733 [53.8%] women) and 36,702 matched psoriasis-free 
patients. Compared with those in the comparison group, psoriasis patients were 
more likely to be current smokers (23.9% vs. 18.8% for psoriasis and non psoriasis 
patients, respectively) and overweight (BMI 25–29.9 kg/m2 in 22.7% vs. 21.6% and 
BMI ≥30 kg/m2 in 13.3% vs. 10.6%, respectively). The average follow-up time was 
4.6 years. 
 
Incidence rates of cancer in the person-time analysis 
After excluding patients with a history of cancer or HIV, the remaining study 
population consisted of 67,761 patients, including 33,760 with psoriasis (46.9% men 
and 53.1% women) and 34,001 psoriasis-free patients (46.8% men and 53.2% 
women). Within this population, we identified 1703 patients with an incident cancer 
diagnosis. The IR was 5.83 (95% CI 5.47-6.22) per 1000 py in patients with psoriasis 
and 5.18 (95% CI 4.83-5.55) per 1000 py in patients without psoriasis. Among the 
1703 cancer cases, 927 (54%) had a history of psoriasis and 776 (46%) did not, 
resulting in a crude IRR of 1.13 (95% CI 1.02-1.24) for all cancers combined. IRs and 
IRRs for the different cancers are shown in table 3.6.1 and table 3.6.2, respectively. 
Overall, the risk of developing lymphohaematopoietic malignancies and cancers of 
the digestive tract (in particular pancreatic cancer) was statistically significantly 
increased for patients with psoriasis, although this was not the case for other types of 
cancer (table 3.6.2). Lymphohaematopoietic malignancies included leukaemia 
(including other myeloproliferative disorders) and lymphoma. All eight patients with 
cutaneous T cell lymphoma (CTCL) had psoriasis, therefore the IRR for lymphomas 
excluding CTCL was also calculated.  
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Table 3.6.1 Cancer incidence rates stratified by cancer type in patients with or without psoriasis  
 
Non Psoriasis Psoriasis 
 
Cases IR / 1000 py (95% CI) Cases IR / 1000 py (95% CI) 
All cancer 776 5.18 (4.83 - 5.55) 927 5.83 (5.47 - 6.22) 
Lymphohaematopoietic  62 0.41 (0.32 - 0.53) 119 0.75 (0.63 - 0.90) 
malignancies       
 CTCL 0 NA NA 8 0.05 (0.03 - 0.10) 
 Lymphoma (ex. CTCL) 36 0.24 (0.17 - 0.33) 59 0.37 (0.29 - 0.48) 
 Leukaemia / MD 26 0.17 (0.12 - 0.25) 52 0.33 (0.25 - 0.43) 
Lung  101 0.67 (0.55 - 0.82) 85 0.53 (0.43 - 0.66) 
Melanoma 33 0.22 (0.16 - 0.31) 29 0.18 (0.13 - 0.26) 
Breast  139 1.71 (1.45 - 2.02) 153 1.79 (1.53 - 2.10) 
Prostate  95 1.38 (1.13 - 1.69) 85 1.16 (0.93 - 1.43) 
Digestive organs 107 0.71 (0.59 - 0.86) 159 1.00 (0.86 - 1.17) 
 Pancreas 12 0.08 (0.05 - 0.14) 28 0.18 (0.12 - 0.25) 
 Oesophagus 16 0.11 (0.07 - 0.17) 23 0.14 (0.10 - 0.22) 
 Colorectal 55 0.37 (0.28 - 0.48) 79 0.50 (0.40 - 0.62) 
 Other digestive 24 0.16 (0.11 - 0.24) 29 0.18 (0.13 - 0.26) 
Female genital organs 35 0.43 (0.31 - 0.60) 51 0.60 (0.45 - 0.79) 
Bladder/kidney 43 0.29 (0.21 - 0.39) 57 0.36 (0.28 - 0.46) 
Brain 16 0.11 (0.07 - 0.17) 22 0.14 (0.09 - 0.21) 
Other cancers 97 0.65 (0.53 - 0.79) 126 0.79 (0.67 - 0.94) 
Metastasis 48 0.32 (0.24 - 0.42) 41 0.26 (0.19 - 0.35) 
CTCL = cutaneous T cell lymphoma ; ex. = excluding; MD = other myeloproliferative disorders; IR = incidence rate; py = person-
years; CI = confidence Interval; Other cancers: oral cavity, bone, male genital organs, parathyroid carcinoma, thymoma, and 
unspecified; Person times in non psoriasis patients: overall 149,900.2 py, men 68,843.7 py, women 81,056.6 py, <60 years 
104,108.4 py, ≥60 years 45,791.9 py; in psoriasis patients: overall 158,906.0 py, men 73,553.5 py, women 85,352.5 py, <60 
years 111,945.2 py, ≥60 years 46,960.8 py 
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Table 3.6.2 Incidence rate ratios of cancer, stratified by type, sex, and age (reference group: patients without psoriasis) 
Type overall men women <60 years ≥60 years 
 IRR  (95% CI) IRR  (95% CI) IRR  (95% CI) IRR  (95% CI) IRR  (95% CI) 
All cancer 1.13 (1.02 - 1.24) 1.11 (0.97 - 1.28) 1.14 (1.00 - 1.30) 1.19 (0.99 - 1.43) 1.13 (1.02 - 1.27) 
Lymphohaematopoietic  1.81 (1.35 - 2.42) 2.45 (1.67 - 3.59) 1.24 (0.79 - 1.94) 2.17 (1.25 - 3.78) 1.74 (1.24 - 2.45) 
malignancies           
 Lymphoma overall 
   Lymphoma (ex. CTCL) 
1.76 
1.55 
(1.19 - 2.58) 
(1.03 - 2.31) 
2.15 
1.76 
(1.27 - 3.63) 
(1.01 - 3.08) 
1.40 
1.35 
(0.79 - 2.48) 
(0.76 - 2.41) 
2.38 
2.07 
(1.19 - 4.75) 
(1.00 - 4.28) 
1.59 
1.41 
(1.00 - 2.53) 
(0.87 - 2.28) 
 Leukaemia + MD 1.89 (1.21 - 2.94) 2.88 (1.65 - 5.05) 1.02 (0.49 - 2.11) 1.86 (0.74 - 4.69) 1.95 (1.18 - 3.23) 
Lung  0.79 (0.60 - 1.06) 0.80 (0.56 - 1.13) 0.78 (0.48 - 1.29) 0.74 (0.35 - 1.58) 0.83 (0.61 - 1.13) 
Melanoma 0.83 (0.50 - 1.36) 0.73 (0.36 - 1.46) 0.95 (0.46 - 1.94) 0.83 (0.43 - 1.60) 0.84 (0.39 - 1.80) 
Breast  1.04 (0.83 - 1.31) NA NA 1.04 (0.83 - 1.31) 0.98 (0.68 - 1.40) 1.11 (0.82 - 1.49) 
Prostate  0.84 (0.63 - 1.12) 0.84 (0.63 - 1.12) NA NA 0.76 (0.32 - 1.83) 0.88 (0.65 - 1.20) 
Digestive organs 1.40 (1.10 - 1.78) 1.25 (0.91 - 1.71) 1.64 (1.14 - 2.38) 1.80 (1.00 - 3.25) 1.38 (1.06 - 1.79) 
 Pancreas 2.20 (1.18 - 4.09) 2.43 (0.97 - 6.13) 2.03 (0.88 - 4.69) NA NA 2.11 (1.12 - 3.99) 
 Oesophagus 1.36 (0.72 - 2.54) 1.40 (0.64 - 3.08) 1.27 (0.44 - 3.61) 2.48 (0.76 - 8.09) 1.13 (0.54 - 2.36) 
 Colorectal 1.35 (0.97 - 1.90) 1.30 (0.82 - 2.05) 1.42 (0.86 - 2.36) 1.21 (0.53 - 2.74) 1.43 (0.99 - 2.07) 
 Other digestive 1.14 (0.67 - 1.95) 0.80 (0.42 - 1.52) 2.85 (1.07 - 7.59) 2.79 (0.70 - 11.17) 1.02 (0.57 - 1.83) 
Female genital organs 1.38 (0.91 - 2.11) NA NA 1.38 (0.91 - 2.11) 1.93 (1.04 - 3.59) 1.06 (0.60 - 1.90) 
Bladder/kidney 1.25 (0.84 - 1.85) 1.11 (0.70 - 1.76) 1.71 (0.81 - 3.59) 0.78 (0.24 - 2.53) 1.37 (0.90 - 2.08) 
Brain 1.30 (0.69 - 2.45) 1.74 (0.72 - 4.18) 0.95 (0.38 - 2.39) 1.70 (0.66 - 4.41) 1.07 (0.46 - 2.52) 
Other cancers 1.23 (0.94 - 1.59) 1.14 (0.77 - 1.67) 1.31 (0.91 - 1.88) 1.06 (0.68 - 1.67) 1.35 (0.98 - 1.87) 
Metastasis 0.81 (0.53 - 1.22) 1.25 (0.64 - 2.42) 0.60 (0.35 - 1.03) 1.49 (0.50 - 4.42) 0.75 (0.48 - 1.17) 
ex. = excluding;  CTCL = cutaneous T cell lymphoma; MD = other myeloproliferative disorders; IRR = incidence rate ratio; CI = confidence interval 
Other cancers: includes oral cavity, bone, male genital organs, parathyroid carcinoma, thymoma, and unspecified 
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Nested case-control analysis – overall cancer risk 
We included all 1703 incident cancer cases and 6812 matched controls without 
cancer in the nested case-control analysis; patient characteristics are summarised in 
table 3.6.3.  
 
Table 3.6.3 Characteristics of cancer cases and controls in the nested case-control analysis 
Variable 
Cases No (%) 
(n = 1703) 
Controls No (%) 
(n = 6812) 
Adjusted OR* 
(95% CI) 
Sex** 
      
 Men 828 (48.6) 3312 (48.6) - - 
 Women 875 (51.4) 3500 (51.4) - - 
Agegroup (years)** 
      
<30 34 (2.0) 137 (2.0) - - 
30-59 418 (24.5) 1687 (24.8) - - 
≥60 1251 (73.5) 4988 (73.2) - - 
Smoking status 
      
 Non smoker 726 (42.6) 3232 (47.4) 1.00 (reference) 
 Current smoker 396 (23.3) 1361 (20.0) 1.31 (1.14 - 1.51) 
 Ex smoker 418 (24.5) 1498 (22.0) 1.26 (1.10 - 1.45) 
 Unknown 163 (9.6) 721 (10.6) 1.07 (0.85 - 1.35) 
BMI (kg/m2)       
 12-18.4 46 (2.7) 95 (1.4) 1.71 (1.18 - 2.48) 
 18.5-24.9 548 (32.2) 2092 (30.7) 1.00 (reference) 
 25-29.9 496 (29.1) 2173 (31.9) 0.87 (0.76 - 1.00) 
 30-60 313 (18.4) 1149 (16.9) 1.05 (0.89 - 1.23) 
 Unknown 300 (17.6) 1303 (19.1) 0.89 (0.75 - 1.07) 
Benign cancer 372 (21.8) 1072 (15.7) 1.53 (1.34 - 1.76) 
* Adjusted for all covariates listed in the table; ** matching variable; BMI = body mass index; OR = Odds ratio; CI = confidence 
interval 
 
The adjusted OR of developing cancer for patients with psoriasis was slightly over 
one relative to patients without psoriasis; this increased with duration of psoriasis 
(OR of 1.50, 95% CI 1.30-1.74 in patients with ≥4 years psoriasis duration), mainly 
among patients ≥60 years of age (table 3.6.4 and figure 3.6.1). A possible link with 
severity of psoriasis using treatment as a proxy was observed: the OR was 1.53 
(95% CI 0.97-2.43) for all patients receiving oral treatment and 2.48 (95% CI 1.08-
5.72) for male patients receiving high-intensity oral treatment (table 3.6.4). In total, 96 
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patients received oral psoriasis treatment, 72% of whom received methotrexate. In 
patients who did not receive oral treatment, the adjusted OR was 1.31 (95% CI 1.16-
1.48) for psoriasis patients with ≥2 years disease duration. The cancer risk also 
remained increased for patients with longer-term psoriasis duration in sensitivity 
analyses [1] excluding all patients with a prescription for biologicals, ciclosporin, or 
methotrexate at any time and irrespective of indication and [2] adjusting the main 
models for any use of ciclosporin, methotrexate, and biologicals. 
 
Table 3.6.4 Relative cancer risk stratified by age, sex, duration, and severity of psoriasis in the nested 
case-control analysis   
 
Cases No (%) 
(n = 1703) 
Controls No (%) 
(n = 6812) 
Adjusted OR* 
(95% CI) 
No Psoriasis 776 (45.6) 3394 (49.8) 1.00 (reference) 
Psoriasis 927 (54.4) 3418 (50.2) 1.13 (1.02 - 1.26) 
 Short-term disease  334 (19.6) 1517 (22.3) 0.91 (0.79 - 1.05) 
 (<2 years)       
 Women 168 (9.9) 802 (11.8) 0.84 (0.69 - 1.03) 
 Men 166 (9.7) 715 (10.5) 0.98 (0.80 - 1.20) 
 <60 years 112 (6.6) 387 (5.7) 1.29 (0.99 - 1.68) 
 ≥60 years 222 (13.0) 1130 (16.6) 0.79 (0.66 - 0.93) 
Long-term disease 593 (34.8) 1901 (27.9) 1.31 (1.17 - 1.48) 
(≥2 years)       
 Women 309 (18.1) 991 (14.5) 1.29 (1.09 - 1.53) 
 Men 284 (16.7) 910 (13.4) 1.33 (1.13 - 1.58) 
 <60 years 142 (8.3) 533 (7.8) 1.14 (0.90 - 1.45) 
 ≥60 years 451 (26.5) 1368 (20.1) 1.37 (1.19 - 1.57) 
Untreated psoriasis 48 (2.8) 245 (3.6) 0.81 (0.59 - 1.12) 
 Women 24 (1.4) 139 (2.0) 0.70 (0.45 - 1.09) 
 Men 24 (1.4) 106 (1.6) 0.95 (0.60 - 1.51) 
Topical treatment 853 (50.1) 3103 (45.6) 1.15 (1.03 - 1.28) 
 Women 440 (25.8) 1613 (23.7) 1.12 (0.97 - 1.30) 
 Men 413 (24.3) 1490 (21.9) 1.18 (1.02 - 1.38) 
Oral treatment  26 (1.5) 70 (1.0) 1.53 (0.97 - 2.43) 
(+/- topical)       
 High intensity 16 (0.9) 43 (0.6) 1.56 (0.87 - 2.80) 
 Women 13 (0.8) 41 (0.6) 1.25 (0.66 - 2.36) 
 High intensity 7 (0.4) 26 (0.4) 1.06 (0.45 - 2.46) 
 Men 13 (0.8) 29 (0.4) 1.99 (1.02 - 3.91) 
 High intensity  9 (0.5) 17 (0.2) 2.48 (1.08 - 5.72) 
 <60 years 7 (0.4) 21 (0.3) 1.56 (0.64 - 3.82) 
 ≥60 years 19 (1.1) 49 (0.7) 1.47 (0.85 - 2.54) 
* Adjusted for body mass index, smoking, benign cancers; OR = odds ratio; CI = confidence interval  
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In a further analysis including only case patients who developed cancer ≥6 months 
after the start of follow-up (n = 1539), an OR of 1.44 (95% CI 1.28-1.63) was 
observed for patients with psoriasis of ≥2 years duration compared with the psoriasis-
free comparison group. Among those who had no benign neoplasms before the index 
date (372 cases and 1072 controls), the OR was 1.30 (95% CI 1.13-1.49) for patients 
with psoriasis of ≥2 years duration compared with the psoriasis-free reference group. 
 
Nested case-control analysis – stratified by type of cancer 
Figure 3.6.1 shows the risks of different cancer types in patients with psoriasis in 
relation to duration of psoriasis and compared with psoriasis-free patients. The 
overall relative risk of developing a lymphohaematopoietic malignancy was increased 
by about two-fold for patients with psoriasis compared with the psoriasis-free control 
group. The risk was highest in patients who received oral treatment, resulting in an 
OR of 10.17 (95% CI 3.24-31.94) for any treatment and 16.79 (95% CI 3.23-87.22) 
for those with >2 prescriptions. An analysis restricted to patients without oral 
treatment yielded adjusted ORs of 1.59 (95% CI 1.01-2.50) for patients with psoriasis 
of <2 years duration and 2.12 (95% CI 1.45-3.10) for those with psoriasis of ≥2 years 
duration. Stratification by age yielded increased overall risks for both age groups (OR 
2.77, 95% CI 1.39-5.52 for patients aged <60 years and OR 1.84, 95% CI 1.24–2.73 
for those aged ≥60 years). When the risks of developing lymphoma or leukaemia 
were explored separately, the highest OR was 3.22 (95% CI 1.64-6.35) for leukaemia 
in patients with psoriasis of ≥4 years duration. The relative risk was increased for 
lymphoma already in patients with early psoriasis (figure 3.6.1), particularly among 
patients <60 years of age (data not shown). All eight patients with CTCL had a 
history of psoriasis, compared with only 34% of the 32 controls.  
For cancers of the colon/rectum, pancreas, and bladder/kidney, the risk increased 
with duration of psoriasis (see test for trend in figure 3.6.1). Furthermore, an analysis 
restricted to patients with a normal BMI yielded an OR of 6.10 (95% CI 1.27-29.32) 
for pancreatic cancer in psoriasis patients compared with psoriasis-free patients. The 
relative risk of melanoma tended to decrease in patients with psoriasis of longer 
duration (figure 3.6.1). A tendency towards an increased risk of brain cancer was 
observed in male patients with psoriasis duration ≥2 years (OR 3.38, 95% CI 0.92–
12.45), although the number of cases of brain cancer was low overall (data not 
shown). 
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Figure 3.6.1.Psoriasis duration and risk of cancer by specific cancer type 
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3.6.5 Discussion 
The findings of this large population-based study suggest that patients with psoriasis 
appear to be at an increased risk of developing certain cancers, especially patients 
with long psoriasis duration and possibly severe disease. Findings to date have been 
inconsistent, however, and, with the exception of evidence that is strongly suggestive 
of an increased incidence of lymphoma in this population,115, 116 no clear links 
between specific cancers and psoriasis have been identified. Some studies in which 
the overall cancer risk was not stratified by duration or severity of psoriasis reported 
an increased risk,113, 114, 117, 119 but not all.115, 218, 220 The findings of the present 
population-based study, based on a follow-up of a large group of patients, provide 
evidence of an association between psoriasis and specific cancers that increases 
with disease duration.  
There is a suggestion, in the present data, that the overall risk of developing cancer 
(excluding nonmelanoma skin cancers) is slightly increased in patients with psoriasis 
compared with psoriasis-free patients. Furthermore, patients with long-duration 
psoriasis appeared to be at increased risk for colorectal, bladder, and kidney 
cancers, as well as pancreatic and lymphohaematopoietic cancers. Patients 
receiving oral treatment, which can be considered a proxy for disease severity, were 
also at increased risk of developing cancer, with the greatest effect observed in men 
receiving high-intensity treatment.  
Other studies have reported that patients with psoriasis are at an increased risk of 
developing leukaemia86, 222, 223 and other myeloproliferative disorders, in particular 
lymphoma.115-118, 219, 224-226 In the present study, the increased risk was most 
prominent in male patients (as observed by Margolis et al.118) and, in the case of 
lymphoma, in patients with psoriasis of shorter duration. Similar results were seen 
when all lymphomas and lymphoma excluding CTCL were considered, allowing for 
the possibility of misclassification of psoriasis and CTCL. One explanation for the 
increase in these cancers may be the antigen-driven proliferation of lymphocytes in 
chronic inflammation caused by psoriasis (antigenic stimulation hypothesis).223 
Previous studies have identified associations between psoriasis and a range of 
cancers, including those of the lung,86, 113, 114, 117, 119 liver,113 oropharynx,113, 114, 117, 119 
colon,114, 119, 120 kidney,113, 119, 219, 220 breast,113, 120, 121, 220 central nervous system,120, 
121
 pancreas,113 genital organs,113 and thyroid.121 The results of the various studies 
were conflicting, possibly due to differences in study designs. With the exception of 
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pancreatic and lymphohaematopoietic cancers, we did not find an increased risk for 
these cancers in the overall psoriasis population. In the case of smoking-related 
cancers, this may be due, at least in part, to the fact that we adjusted for smoking, 
whereas similar adjustment was not undertaken in earlier studies. The risk of cancers 
of the colon/rectum, pancreas, bladder, and kidney significantly increased in patients 
with psoriasis of long duration. As chronic inflammation influences initiation and 
progression of neoplastic growth,227 it is conceivable that the chronic inflammation 
sustained with psoriasis of longer duration may play a role in the development of 
cancer in patients with severe psoriasis. Like psoriasis, lupus erythematodes and 
rheumatoid arthritis are also chronic inflammatory diseases, and they have also been 
associated with certain types of cancer.228, 229 
In this study, there was a tendency of an increase in the risk of cancer with 
increasing disease severity. Other studies have also shown an association between 
the severity of psoriasis and increased cancer. In a study performed using the 
Medicaid databases,118 patients with severe psoriasis had an increased cancer risk 
of 78% compared with the reference group of hypertensive patients. As patients with 
severe psoriasis may receive drugs, such as methotrexate, ciclosporin, or PUVA 
therapy, all of which have been associated with lymphoproliferative disorders230-233 
and malignancies (particularly nonmelanoma skin cancers),59, 234-236 we conducted a 
number of sensitivity analyses in which patients with these treatments were 
excluded. A longer-term history of psoriasis (≥2 years) remained associated with an 
increased relative cancer risk in this subset of patients, indicating that this effect was 
independent of treatment received. 
Our study has several limitations. First, in large observational studies, a certain 
degree of diagnosis misclassification cannot be ruled out. However, in previous 
GPRD-based studies on psoriasis or cancer, the validity of these diagnoses has 
been high.115, 139, 147, 237 The epidemiology of psoriasis in the GPRD is similar to other 
population-based studies in the UK, 92% of patients with a psoriasis code received 
psoriasis treatment, and, of a random sample of GPs, about 90% confirmed the 
psoriasis diagnosis after four years of follow-up. Furthermore, the incidence rate of 
psoriasis in our study population (not shown) is closely similar to the rate of another 
study on the GPRD with validated psoriasis patients.66 In contrast to the USA, most 
psoriasis patients in the UK are diagnosed and managed in primary care and are not 
referred to a specialist.54, 66 Second, the initial recording of a psoriasis diagnosis by 
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the GP is not the date of onset of the disease but rather the point in time when the 
disease was brought to medical attention for the first time. Follow-up was started at 
the first recorded psoriasis diagnosis to increase the likelihood of beginning follow-up 
for all patients at a similar stage of the disease. Third, the number of psoriasis 
patients exposed to oral therapies was low in our study population, and therefore 
information on this subgroup, which may have the greatest disease severity, is 
limited. It is possible that some patients may have received oral or injectable 
treatment from a specialist that was not recorded by the GP; such misclassification, if 
indeed present, may have diluted differences in risk caused by disease severity. 
Fourth, although we tested for a large number of potential confounding factors, we 
cannot exclude the possibility that unknown confounders or biases may have 
affected our results. 
On the other hand, this study has an important strength: it reports the findings of a 
follow-up of a large population of people with psoriasis whose medical information 
was recorded prior to the cancer diagnosis, thereby eliminating concerns about 
biased reporting of date of psoriasis diagnosis, treatments, and other potential 
confounders.  
In conclusion, this observational study conducted on a large population-based data 
resource explored the association between early psoriasis and the risk of incident 
cancers. Patients with psoriasis had an increased risk of developing 
lymphohaematopoietic or certain types of solid cancers. The risk for solid cancers 
was increased primarily in psoriasis patients with a longer-term disease history. 
Further investigation into common mechanisms underlying psoriasis and the cancers 
identified in this study is warranted. 
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4 DISCUSSION, CONCLUSIONS, AND OUTLOOK 
4.1 DISCUSSION 
In past years, an increasing number of epidemiological research on psoriasis has 
been published, in parallel with the investigation of new drugs for the treatment of this 
skin disorder and their introduction on the market (primarily biologicals). The aim of 
this work was to contribute to the current knowledge of the natural history of psoriasis 
by addressing uncertain issues due to conflicting results in the literature or due to 
weak or lack of data. 
Detailed evaluations of the results of Studies 3.1 – 3.6 are presented in the 
discussion sections of the respective studies. In appendix 5.3 the aims and the main 
results of the six studies are briefly summarised. In the following, some general 
aspects which these studies may have raised will be discussed. 
 
Use of beta-blockers or lithium and the risk of psoriasis (Study 3.1 / 3.2) 
The fact that Study 3.1 did not suggest a materially altered risk of a first-time 
psoriasis diagnosis after exposure to beta-blockers, emphasises the importance of 
not taking an observation for granted, but to re-evaluate a hypothesis upon 
availability of new data. Beta-blockers are, along with lithium and antimalarials, the 
drugs which have been most commonly related to the induction or exacerbation of 
psoriasis. They are mentioned in most standard dermatology textbooks as risk 
factors for the skin disease. However, evidence of a potential association was 
primarily based on case reports and case series, which have a low level of evidence 
according to the Oxford Centre for EBM.13 Although case reports are important to 
indicate early a rare adverse event to a drug or to raise hypotheses, it is difficult to 
rule out that an observed event did not happen by chance, especially if the latency 
period was long, if the event happens quite frequently independent of drug exposure 
(e.g. psoriasis with a prevalence between 2% - 3% in northern Europe87), if the event 
was not pharmacologically predictable (type B reactions; in contrast to type A 
reactions which are pharmacologically predictable), or if the reaction was not 
confirmed by dechallenge and rechallenge. Furthermore, the chance that an event is 
reported in relation to exposure to a certain drug increases once such an association 
has become public. Several articles have warned against publication bias and 
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overinterpretation of case reports in the literature.2 A review published 1982 in the 
British Medical Journal238 elucidated this problem. The author showed that of 47 
anecdotal reports published in four highly ranked journals of internal medicine, 
causality was doubtless or reasonable for 28 (60%), while the 19 (40%) remaining 
required verification which was done for 7 (15%). In total, 12 (25%) had not been 
verified within approximately 20 years. While 8 reported rare clinical syndromes with 
no further published associations with the suspected drugs, the other 4 reactions 
were relatively common clinical syndromes. Although there had been further reports 
for two of them, this was not enough for verification; this is an epidemiological 
problem238 and would require investigation with sound epidemiological methods. The 
purpose of Study 3.1 was to investigate the reported (in case reports and case 
series) association between beta-blockers and induction of psoriasis, and it could not 
be confirmed. Apart from this observation, the alternating theory on the pathogenesis 
of psoriasis as described in the introduction (chapter 1.2.2) is another example in the 
research history of psoriasis which should have taught researchers not to establish 
dogmas and to be open to new hypotheses.239 
One could argue that the results of Study 3.1 were distorted because for some 
patients in the study the psoriasis diagnosis may not have been incident, or it may 
have been misclassified first as another skin disorder. Due to the notion of a possible 
association between beta-blockers and psoriasis (and other skin reactions), these 
patients may have received another drug instead of a beta-blocker to treat the 
underlying disease (= protopathic bias, a type of selection bias1). However, three 
points contradict this argument: First, sensitivity analyses only including subgroups of 
patients with a high probability of incident psoriasis or without any skin reactions 
before the first recording of psoriasis left the results virtually unchanged. Second, 
past exposure to beta-blockers did not show an increased risk of psoriasis either. 
Third, Study 3.2 could show an increased risk of psoriasis after mainly long-term 
exposure to lithium, and this drug had also been associated with psoriasis (and other 
skin reactions) in several case reports.  
The association between antimalarial drugs and psoriasis was not studied because 
recording of the exposure to this drug class may be incomplete in the GPRD, and this 
could lead to biased results. 
 
 
4 Discussion, Conclusions, and Outlook  Discussion 
 123 
Use of thiazolidinediones, other antidiabetics, and psoriasis (Study 3.3) 
Study 3.3 shows that observational epidemiological studies can also have a place in 
identifying or confirming potential new indications of a drug or of drug classes. An 
early example was a study conducted by the BCDSP in 1974240 with the finding of a 
protective effect of acetylsalicylic acid on the development of acute MI. By studying 
the potential mechanism of action of such a drug in relation to the disease, it may be 
possible to learn more about the pathomechanism and the risk factors of this disease 
or to get ideas for predictive tests.241 However, one can measure such a protective 
effect of a drug on an outcome that can be expected only as long as this effect is not 
known yet because afterwards, future case patients may receive the drug in an 
attempt to prevent the disease or to treat first signs of the disease not (yet) confirmed 
(= protopathic bias1). A protective effect can then not be measured anymore. 
While randomised controlled trials deliver primarily results of efficacy, observational 
studies provide effectiveness data. In combination they can improve the 
understanding of the outcomes associated with certain therapies. An example of 
such a ‘synergism’ was the understanding of the value of cholesterol control in the 
prevention and treatment of coronary heart disease.2 However, observational 
effectiveness studies may be prone to confounding by indication if they focus on 
expected drug effects. Confounding by indication refers to ‘an extraneous 
determinant of the outcome parameter that is present if a perceived high risk or poor 
prognosis is an indication for intervention’,242 i.e. the drug of interest is prescribed 
selectively depending on the severity or prognosis of the underlying disease to be 
treated, and this influences the outcome of interest. The use of propensity scores is a 
relatively new statistical approach for a better control of such selective prescribing in 
observational research. The probability or propensity of receiving a treatment 
depending on an individual’s covariates or risk factors is determined for each 
individual, and this score can be considered in the analysis (by matching, adjusting, 
or stratification).1 In Study 3.3, confounding by indication was not an issue because 
effectiveness of thiazolidinediones was investigated before the patients developed 
psoriasis, i.e. it was tested if the drugs could prevent the disease, and a protective 
effect could not be anticipated by the GPs. The effectiveness data of Study 3.3 
together with the partly favourable results of thiazolidinediones in the treatment of 
psoriasis may strengthen the hypothesis that this drug class influences the 
pathophysiology of psoriasis in a positive way. 
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Psoriasis and diabetes (Study 3.4) 
Several published studies reported an increased prevalence of diabetes in patients 
with psoriasis. However, most of them were cross-sectional.243 A major disadvantage 
of this design is that exposure and outcome data are collected at the same time. 
Hence, the temporal relation between the two measures (in this case psoriasis and 
diabetes) cannot be determined, i.e. it is hardly possible to tell which came first. 
Cross-sectional studies belong to the descriptive observational studies (see figure 
1.1.3 in the introduction section) and are primarily useful for the generation of 
hypotheses, not for testing them.2, 16 With Study 3.4, a cohort study with a nested 
case-control analysis, incidence rates of diabetes in patients with or without psoriasis 
could be determined and psoriasis, particularly severe psoriasis of longer-term 
duration, be identified as a risk factor for diabetes. Additionally, the results of Study 
3.3 suggested that patients with psoriasis did not have an increased prevalence of 
diabetes before the first-time recorded diagnosis of their skin disorder. This 
observation was confirmed by another case-control study investigating the medical 
history of patients with psoriasis.244 
 
Psoriasis and cardiovascular diseases (Study 3.5) 
There has been much discussion about the association between psoriasis and 
cardiovascular diseases recently, mainly also after Gelfand et al.108 had published a 
population-based cohort study using GPRD data in the Journal of the American 
Medical Association concluding that psoriasis patients, primarily those of young age 
and with severe disease, had an increased risk to develop MI. In the past, there had 
been conflicting results about this association in the literature. Study 3.5 was 
designed to investigate this association by using a different approach than the one by 
Gelfand et al.108 (The differences between the two approaches are pointed out in the 
discussion section of Study 3.5.) In Study 3.5, the incidence rates of MI in patients 
with psoriasis and the control group were lower than in the approach by Gelfand et 
al.108 Furthermore, there was no overall increased risk of MI in patients with 
psoriasis, but only in subgroups, mainly of young patients and patients with severe 
disease, as reported by Gelfand et al.108 In his article on interventional and 
observational studies JP Vandenbroucke15 emphasised the importance of replicating 
findings from observational studies with different methods and of discussing the 
differences due to the potential of bias, confounding, or multiple analyses in 
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observational research. This was done in this case: While both studies showed an 
increased risk of MI in subgroups of patients with psoriasis, Study 3.5 slightly 
attenuated the association in that sense that patients with mild psoriasis may be less 
worried (if at all) to develop an MI. 
The different incidence rates of MI found with the two different study designs, may 
point to an emerging caveat in the reporting of observational studies in the future: 
While the rates provided by Gelfand et al.108 may not be incidence rates in the stricter 
sense due to inclusion of patients with a potential history of an MI in the study, they 
are useful for the comparison of rates of spontaneous MI reports in relation with a 
drug because the ‘real life situation’ is reflected; spontaneous reports are generated 
irrespective of a patient’s MI anamnesis. The rates in Study 3.5 are first-ever 
(incident) rates of MI in patients with psoriasis and may be rather valuable for an 
analytical (or causal) evaluation of the association between psoriasis and MI.  
The different findings of two nested case-control studies on the association between 
PPIs and fracture risk may reflect a similar situation. While the first study,245 in which 
all potential confounders of the association were adjusted for in the analyses, yielded 
an increased fracture risk after long-term exposure to PPIs, the second one,246 which 
excluded all patients with potential confounders in their characteristics, could not 
confirm this association. The latter study may have been more an analytical 
approach to study a potential relation between exposure and outcome by trying to 
exclude as many potential confounders as possible (comparable to the strict in- and 
exclusion criteria of interventional trials), while the first study may rather reflect the 
‘real life situation’.  
In future, it may be important to report more accurately the exact purpose of the 
study, i.e. rather reflection of the ‘real life situation’ or a more analytical investigation 
to learn more about a potential causal association between exposure and outcome 
(bearing always in mind that causality cannot be proven with observational research 
alone).  
 
Psoriasis and cancer (Study 3.6) 
The medical literature encompasses several studies on the association between 
psoriasis and cancer, often with conflicting results (appendix 5.4). Looking at these 
studies in detail, one realises that different study designs were applied or different 
study populations investigated. This underpins the statement by JP Vandenbroucke15 
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that systematic reviews of observational studies may be difficult, and that the 
advantages and disadvantages of the different studies should be discussed. The aim 
of Study 3.6 was to analyse a potential association between psoriasis and cancer by 
including only patients with a first-time recording of a psoriasis diagnosis and 
following them for a potential incident cancer diagnosis. The findings suggest 
duration of psoriasis as a risk factor for the development of solid cancers. This may 
explain some of the conflicting results of this association in the literature because in 
most previous studies follow up of patients with psoriasis began at different stages of 
the skin disease.  
 
Incident psoriasis, validation of diagnoses, and severity of psoriasis 
The study population of the three case-control and the three cohort studies consisted 
of patients with a first-time diagnosis of psoriasis. To increase the likelihood of only 
including patients with a first-time diagnosis, patients had to have at least three years 
of active history in the database. One could argue that for psoriasis, being a chronic 
and not an acute disorder, the disease may have begun already before the first-time 
recording in the medical records. In a cohort study, however, the study population 
should by definition be followed from the beginning of the exposure2 (here 
‘psoriasis’). The start of follow-up at the first recording of a psoriasis diagnosis was 
probably a good solution to consider this requirement in database research; follow-up 
started for all patients when the disease was first brought to medical attention which 
increased the likelihood that patients were in a similar stage of the disease. In the 
case-control studies, sensitivity analyses including only patients who did not have 
quite specific treatment for psoriasis or who did not have skin disorders before the 
first recording of psoriasis were conducted to confirm the results.  
An advantage of selecting patients with a first-time recording of psoriasis and looking 
back in time with a case-control design and forward in time with a cohort design was 
the possibility to learn more about the temporal sequence of the association between 
psoriasis and other diseases or risk factors. 
In general, research in pharmacoepidemiology seems to move more and more from 
infectious diseases or acute events to chronic diseases. Defining the beginning of 
such a chronic state may always be a challenge, also due to genetic predisposition, 
and one should accept that the optimal solution can only be approached at the 
moment. 
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Misclassification of diseases can be an issue in observational database research. For 
psoriasis however, Gelfand et al.115, 139, 147 could show a high validity of the diagnosis 
in the GPRD. Furthermore, the incidence rates of psoriasis in our study population 
(chapter 1.2.5.1, figure 1.2.3) were similar to the rates of another study conducted 
with data from the GPRD.66 The authors of that study only included validated patients 
and conducted sensitivity analyses to confirm the results in patients with a high 
likelihood of having an incident psoriasis diagnosis. In the case-control studies of this 
thesis, sensitivity analyses in a subgroup of patients with quite specific treatment for 
psoriasis after the diagnosis were done in addition to the sensitivity analyses in 
patients with highly probable incident psoriasis diagnoses. In the cohort studies, the 
patients for the outcomes studied (i.e. diabetes, MI, stroke, TIA, and cancer) were 
selected with a stringent predefined algorithm based on precedent profile review and 
blinded with regard to the exposure status. 
 
For the studies of this thesis, severity of psoriasis was primarily defined by treatment 
of the disease. This approach was chosen in previous studies by other groups as 
well, but is only an approximation to the optimum. Even in clinical practice the 
definition of severity of psoriasis has proven to be difficult (chapter 1.2.3). The 
number of patients classifying for having severe psoriasis in the studies of this thesis 
was low, probably due to selection of only patients with a first-ever recording of 
psoriasis in the database. 
 
Major advantages and disadvantages of database research  
Database research permits the generation and analysis of hypotheses within a 
usually large study population, and - depending on how long the database has been 
in place - effects with long latency periods can be studied. Studies can be conducted 
at a relatively low cost and often within a short time because data are already 
available (although not always in the format required). Timing may be an important 
aspect in the evaluation of an adverse drug reaction. Furthermore, certain databases, 
such as the GPRD, are representative of the population and hence, allow the 
execution of population-based studies. 
Bias is inherent in observational study designs and can influence the validity of these 
studies. Information / observation bias results from systematic differences in the way 
data on exposure or outcome are obtained from the various study groups, e.g. 
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differences in patients’ recall on exposure (= recall bias) or differences in collecting or 
recording of information from the patients (= interviewer bias).16 As data from the 
GPRD result from medical records, they are collected independent of any research 
question, and thus the likelihood of such a bias in Studies 3.1 – 3.6 is small. Other 
biases1, 2 such as selection bias, which results from different criteria applied to enrol 
cases and controls in a study, misclassification bias, which results from error in 
classifying study participants with regard to their exposure or disease status, or 
confounding (in particular residual confounding) may be of concern also in database 
research. For Studies 3.1 – 3.6 these types of biases are discussed in the respective 
manuscript or in the discussion sections above. Finally, in database research, 
information on drug use is usually based on prescription data. Hence, it is not sure if 
and when the patient took the drug.  
In summary, when doing this type of research, it is important to understand the 
database used in great detail to be able to decide what is feasible and what is not 
and to critically discuss the findings. 
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4.2 CONCLUSIONS 
Pharmacoepidemiology plays an increasing role in the development process of drugs 
and is an important tool for the constant risk-benefit analysis and the risk 
management of drugs. Apart from the traditional studies on adverse or beneficial 
drug reactions, studies on disease epidemiology to gain (more) information on the 
burden of a disease (incidence, prevalence data), on risk factors and comorbidities, 
or on drug utilisation are more and more conducted because such information helps 
in the risk-benefit analysis of a drug developed or marketed for that particular 
disease. Furthermore, increased knowledge of diseases helps healthcare 
professionals to make decisions in their daily clinical practice. 
Psoriasis exemplifies this trend. It is a common chronic disorder, and a couple of 
innovative drugs (mainly biologicals) have emerged on the market recently or are in 
the development stage. Hence, much research is currently being conducted in this 
area, and, as mentioned above, epidemiological data play an important role. One 
focus of this thesis was on two areas of the natural history of psoriasis which may 
have been neglected so far: (1) Drugs as potential risk or protective factors to 
develop psoriasis and (2) the temporal sequence of the association between 
psoriasis and other diseases or risk factors. In the following, the main findings of the 
six studies are briefly summarised. 
 
 In contrast to the current proposition in the literature, use of beta-blockers as well 
as of other antihypertensive drugs was not associated with a materially altered 
psoriasis risk. The data, however, do not allow inferences on the relation between 
these drug classes and the exacerbation of pre-existing psoriasis. 
 Consistent with the literature (case reports and case series), exposure to lithium, 
mainly long-term, increased the risk of developing psoriasis by 70 – 100%. This 
seemed to be the case mainly in older and female patients. 
 Long-term use of atypical antipsychotics, primarily olanzapine, may have a 
protective effect on the development of psoriasis, primarily in young and male 
patients. The effect of atypical antipsychotics on cytokines could explain this 
observation and merits further investigation. 
 The risk of diabetic patients with long-term exposure to thiazolidinediones to 
develop psoriasis was decreased yielding an OR of 0.33 (95% CI 0.16-0.66). This 
finding was intriguing despite the low number of patients exposed. The 
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observation of a reduced psoriasis risk after long-term exposure to metformin 
needs further investigation. 
 Several factors may lead to a small increased psoriasis risk, such as smoking, 
high BMI, alcoholism, skin infections, or a psychiatric diagnosis in close proximity 
to the psoriasis diagnosis date. 
 A precedent diagnosis of diabetes did not seem to alter the psoriasis risk, but 
patients with psoriasis had an overall increased diabetes risk of about 30% which 
increased to about 150% for patients with long-term psoriasis receiving oral 
treatment. This risk seemed independent from high BMI alone.  
 The overall risk of MI, stroke, and TIA was not elevated in patients with early 
psoriasis. In subgroups of patients <60 years of age and with severe psoriasis, 
however, the MI risk was increased. Cardiovascular diseases did not seem to 
alter the risk of a first psoriasis diagnosis. 
 The proposition that longer-term treatment of psoriasis with methotrexate or other 
DMARDs may decrease a potential cardiovascular risk in patients with psoriasis 
needs further investigation. 
 Duration of psoriasis seemed to increase the risk of developing certain solid 
cancers in patients with psoriasis. While psoriasis patients had an overall 
increased risk of lymphohaematopoietic and pancreatic cancers, the risks of 
bladder/kidney and colorectal cancers were only increased in patients with longer-
term psoriasis duration. Severity of psoriasis was also suggested to alter the risk 
of developing cancer, mainly lymphohaematopoietic cancers. 
 The proposed dependency of the risk of certain solid cancers from duration of 
psoriasis may partially explain the conflicting results in the literature due to 
different study designs and start of follow-up at different stages of the psoriasis 
disease. 
 Severity of psoriasis seemed to increase the risk of diabetes, cardiovascular 
diseases, and cancer while duration of psoriasis only appeared to alter the risk of 
diabetes and cancer, but not of cardiovascular diseases. A hypothesis might be 
that cardiovascular diseases develop only under severe inflammatory processes, 
diabetes and cancer also under less severe processes if they are enduring. This 
suggestion would need further investigation. 
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4.3 OUTLOOK 
4.3.1 Psoriasis project 
In this thesis, the influence of beta-blocker and lithium use on the risk of induction of 
psoriasis was studied in a large number of patients. In a further step, it would be 
interesting to investigate if these drugs can exacerbate pre-existing psoriasis. This 
was also already postulated based on weak data. However, it is difficult to study this 
aspect on the GPRD because of the uncertainty of correct recordings of 
exacerbations of a disease. Additionally, the current notion that beta-blockers or 
lithium exacerbate psoriasis may lead to confounding, meaning that severity of 
psoriasis, patient attitude, or location / phenotype of psoriasis may lead to selected 
prescribing of these drugs to the patients; patients with more severe or more 
unstable psoriasis may be less likely to receive such a drug. The best way would be 
to conduct a randomised clinical trial, but, as this may ethically not be possible, one 
could consider a prospective cohort study with careful control for confounding, e.g. by 
using propensity scores.  
The findings of Study 3.3 have shown that potential protective effects of drugs on 
psoriasis can be shown with GPRD data. There are indications247-249 in the literature 
that statins may improve psoriasis. Hence, in a further study it would be interesting to 
investigate the association between this drug class and induction of psoriasis. 
Protective effects on the induction of psoriasis have been suggested for atypical 
antipsychotics (mainly olanzapine) and metformin. In a next step, it would be 
interesting to study if these drugs may be useful treatment options for psoriasis. One 
could conduct randomised controlled trials or prospective observational cohort 
studies (with careful control for confounding) in patients with psoriasis and psychiatric 
disorders or diabetes who need antipsychotics or oral antidiabetics.  
There are now quite a lot of consistent data showing an increased risk of diabetes in 
patients with psoriasis, and the association may be causal. Common inflammatory 
mechanisms have been suggested in the pathomechanism of both diseases. It would 
now be interesting to study the mechanism in greater detail in laboratory research. 
Genetics should also be further investigated; like diabetes type I, psoriasis is a 
complex HLA-associated disease,250 but there are also data which suggest a genetic 
overlap with type II diabetes.251 Furthermore, (bio)markers should be searched for 
which identify the psoriasis patients most at risk to develop diabetes.  
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The observed effect of methotrexate to decrease the cardiovascular morbidity in 
patients with rheumatoid arthritis213-215 should also be studied in patients with severe 
psoriasis, but with a larger number of patients than in Study 3.5. One could conduct a 
retro- or prospective cohort study with a nested case-control analysis comparing 
severe psoriasis patients who receive methotrexate with severe psoriasis patients 
who do not receive this drug.  
The observed dependency of the risk of certain types of cancer from psoriasis 
duration should be confirmed in a study with longer-term follow-up. 
 
4.3.2 In general 
Safety surveillance of drugs has shifted from a rather passive to an active approach.  
Additionally, regulatory actions such as the accelerated approval process in the US 
and the conditional marketing authorisation in the European Union (EU) make high 
demands on the monitoring of such drugs. Hence, it is important that new methods 
are being developed which allow the surveillance of newly marketed drugs and a fast 
recognition of a safety issue. Two methods were described in the introduction section 
(chapter 1.1.7), namely the use of registries, which, e.g. in the case of natalizumab, 
allowed the drug to be re-introduced onto the market despite safety issues (chapter 
1.1.2), and prescription-event monitoring. Another interesting approach252 was 
presented at the 24th annual international conference on pharmacoepidemiology and 
therapeutic risk management (2008). Patients who filled their first prescription for a 
recently marketed drug in a pharmacy in the Netherlands were asked to participate in 
a program and received a questionnaire via e-mail four times during six months, in 
which they were asked regarding any adverse events. The three approaches can 
only generate hypotheses because a control group is usually lacking. However, data 
from such programs could for example be compared to data from studies on the 
natural history of the disease to be treated with the drug under surveillance, and 
relative risks could be approximated. A prerequisite would be a high participation in 
the programs and a high response rate to the questionnaires.  
Programs as described above may be part of a risk management program for a drug. 
Risk management is a growing field, and pharmacoepidemiology can make valuable 
contribution (as shown in the introduction section). New methods have to be 
developed for this field, and the benefit of entire risk management programs may 
have to be evaluated in future. 
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Since 2007, pharmaceutical companies in the EU have to submit a paediatric 
investigation plan for a drug in development and, if feasible, studies have to be 
conducted to show the efficacious and safe use of these drugs in this patient 
population. However, data on the use of older drugs in children are often missing, 
and over half of the pharmacological interventions in hospitalised children are off-
label or unlicensed drugs.253 Although awareness has increased and clinical trials 
involving paediatric patients will be conducted, it may take time until useful data are 
available. Furthermore, even if trials will be conducted in the paediatric population, 
these may be underpowered to detect safety signals (especially in the case of 
uncommon adverse events) due to a smaller target population.254 UK clinical 
databases, in particular also the GPRD, are suitable to conduct studies in the 
paediatric population,255 and one should benefit more from this potential in the future.  
 
In the following, three areas will be briefly mentioned where pharmacoepidemiology 
could contribute if availability of the necessary data was guaranteed. 
1) In clinical practice, it is rather common to use drugs off label (e.g. in dermatology). 
If this usage was recorded in databases as off label, the extent to which a certain 
drug is used off label could be quantified. Based on such data, pharmaceutical 
companies could then decide on label extensions of their products. 2) The 
population’s interest in herbal and other alternative medications (e.g. chinese 
medicine) has been increasing in recent years.1 However, several examples have 
shown that the use of such products is not unproblematic (e.g. drug drug interaction 
between Hypericum perforatum and ciclosporin256 or potential bleeding due to ginkgo 
biloba257). If exposure to such products was recorded in large databases in a 
standardised manner and almost completely, the safety of such medicines could be 
better evaluated. 3) With the development of new, noninvasive methods to collect 
DNA (e.g. with buccal swabs),1 interest has grown to link databases with genetic 
information of patients (also in the GPRD). If such information as well as complete 
laboratory parameters and environmental factors were recorded in databases or 
clinical notes, pharmacoepidemiology may contribute to the concept of personalised 
medicine (defined as ‘a form of medicine that uses information about a person’s 
genes, proteins, and environment to prevent, diagnose, and treat disease’258) by e.g. 
defining patients most at risk to develop adverse events to drugs. 
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There are many efforts in resource poor settings to increase the access to effective 
drugs. However, less than 27% of lower middle and low income countries have 
national pharmacovigilance systems registered with the WHO programme, which is 
mainly due to lack of resources, infrastructure, and expertise.259 
Pharmacoepidemiologists and experts in pharmacovigilance and public health should 
draw attention to the issue that the availability of drugs in these countries should be 
linked to an – at least minimal – risk-benefit plan. Healthcare professionals in these 
regions should be educated on drug surveillance, and national solutions should be 
elaborated on with the government. Data from the high income countries are often of 
limited value due to other environmental and genetic influences. The only 
contribution may be the conduct of studies in immigrants from such low or middle 
income countries which might at least indicate if there are genetic influences on the 
safety of a drug.  
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5 APPENDIX 
5.1 STUDY DESIGNS OF THE THESIS 
 
Case-control design 
 
 
 
 
Follow-up design with nested case-control analysis 
 
Cohort study 
 
 
 
 
Nested case-control study 
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5.2 EXAMPLE OF A CASE REPORT 
 
A fatal tick bite occurring during the course of 
tick-borne encephalitis vaccination 
 
Yolanda B. Brauchli, MSc1, Matthias Gittermann, MD2, Marc Michot, 
MD3, Stephan Krähenbühl, MD, PhD1, Hanspeter E. Gnehm, MD2 
 
Division of Clinical Pharmacology & Toxicology, University Hospital 
Basel1, Paediatric Clinic2 and Intensive Care Unit3, Kantonsspital Aarau, 
Switzerland 
 
ABSTRACT 
In Western Europe tick-borne encephalitis virus infections 
with fatal outcome are rare, especially in children. We 
report the case of an adolescent who died of 
meningoencephalitis after a tick bite that occurred between 
the first two tick-borne encephalitis vaccinations. The case 
demonstrates the difficulty of differentiating possible 
adverse events associated with the immunization from 
symptoms of simultaneous infection with tick-borne 
encephalitis virus.  
 
INTRODUCTION 
In Europe, tick-borne encephalitis (TBE) is the commonest 
viral infection of the central nervous system (CNS) 
transmitted by ticks. Vaccines on the basis of an 
inactivated virus are available from two manufacturers and 
both products have been shown to be effective and safe.1 
The seroconversion rates are ≥97% 21-35 days after the 
second vaccination and ≥99% 21-28 days after the third.2 
Data from a surveillance system in Austria, where the 
majority of the population has been vaccinated, indicate 
that the protection rate after two and three doses of the 
vaccine is between 96% and 100%.1 The manufacturers 
suggest to start with the first two vaccinations of the three-
step vaccination schedule (0 months, 1-3 months, (5) 9-12 
months) in the winter months to provide protection in the 
peak season for ticks (spring and summer). To avoid 
difficulties in differentiating possible adverse events 
following immunization from symptoms of a simultaneous 
infection with tick-borne encephalitis virus (TBEV) the 
preferential vaccination during the cold months may offer 
an additional benefit. This case report demonstrates the 
above-mentioned difficulties and, in addition, discusses a 
possible role of an antibody-dependent enhancement of 
infection (ADEI). 
 
CASE REPORT 
A 15-year-old girl from an endemic area for TBEV was 
admitted to our hospital with a presumptive diagnosis of 
meningitis. She had suffered from fever and headache for 
one day. Two weeks before, she had had a tick bite 
(without informing her general practitioner) and four days 
before hospitalization she had received the second 
vaccination against TBEV (first dose had been 
administered one month earlier). The patient had no 
relevant medical history. On admission, her body 
temperature was 38.8°C, she was well oriented but 
somnolent (Glasgow Coma Score, 14-15) and suffered 
from neck stiffness and photophobia. The cerebrospinal 
fluid (CSF) revealed pleocytosis (189 polynuclear 
cells/mm3, 26 mononuclear cells/mm3), normal glucose, 
and slightly elevated protein and lactate. Serum C-reactive 
protein and blood leukocyte count were normal. Cultures 
for bacteria remained negative in CSF, and acute 
infections with Borrelia burgdorferi, herpes simplex virus, 
enteroviruses, Epstein Barr Virus, measles, and mumps 
virus were ruled out. Enzyme-linked immunosorbent assay 
(ELISA) IgG and IgM antibodies against TBEV were 
positive in the serum but negative in the CSF. The patient 
became increasingly somnolent (Glasgow Coma Score, 
13-14). The following day a cranial computed tomography 
(CT) demonstrated signs of brain edema, and the patient 
was transferred to the intensive care unit. During the night 
from day 4 to 5 of hospitalization she complained of 
drowsiness and experienced seizures. A second and third 
CT confirmed increasing cerebral edema. Decompression 
was not possible, and the patient died on day 5. 
The brain autopsy revealed cerebral edema with 
herniation, and histology showed the picture of severe 
lymphocytic meningoencephalitis. Further investigations 
revealed high titers of TBEV-neutralizing antibodies, which 
had increased from 1:20 on day 1 to 1:320 on day 5, and 
TBEV ELISA IgG and IgM antibodies, which had risen from 
2,660 Vienna units (VIEU) to 220,000 VIEU and from 
borderline to >1000 VIEU, respectively. RNA-polymerase 
chain reaction (PCR) for TBEV was negative in CSF, but 
positive in the brain stem, cortex, and cerebellum. 
Immunohistochemically, visualization of TBE viral antigen 
was successful in the dentate nucleus (Fig.1), while tests 
for herpes simplex virus (HSV), varicella zoster virus 
(VZV), cytomegalovirus (CMV), measles, and 
toxoplasmosis were negative. These findings 
demonstrated the presence of a multifocal encephalitis 
compatible with TBE. Culture of the virus was 
unsuccessful, but sequencing of a PCR fragment from the 
conserved region NS5 revealed differences at several 
locations when compared with the virus used for the 
vaccine applied in this patient. These results confirm an 
infection with a wild-type TBEV, transmitted most probably 
by the tick bite between the first and the second 
vaccination.  
 
DISCUSSION 
Symptom onset occurred two-to-three days after the 
second TBE vaccination and about two weeks after the 
patient experienced a tick bite in an area endemic for 
TBEV and B.burgdorferi. Possible causes for the 
symptoms were: an adverse reaction to the vaccine; tick-
borne infection of the central nervous system (CNS), and 
other acute CNS infections or diseases. Infection with 
TBEV is mainly diagnosed by clinical and laboratory 
findings. During the viremic phase, which usually begins a 
few days to two weeks after the tick bite, the virus can be 
isolated from the blood, or it can be detected by reverse-
transcriptase-polymerase chain reaction (RT-PCR). During 
this period patients may be asymptomatic or present non-
specific symptoms.3 Our patient was hospitalized with 
neurologic symptoms, and the viremic phase had probably 
already passed. In such cases the diagnosis of TBE relies 
mainly on the identification of specific serum antibodies. At 
the onset of disease, specific antibodies in CSF are only 
detectable in about 50% of patients, they can, however, be 
identified in almost all patients within 10 days of disease 
progression.3 The presence and rapid increase of serum 
IgM and IgG antibodies against TBEV are considered to be 
indicative of an infection with TBEV. In our case, however, 
vaccination could also have been responsible for the 
presence of serum TBEV antibodies. Post mortem brain 
biopsies allowed the identification of viral RNA in several 
parts of the brain by RT-PCR. Using sequencing 
techniques the virus could be differentiated from the virus 
used in the vaccine, confirming an infection with a wild-
type virus. 
Permanent morbidity and case fatality rates after 
infection with the Western European TBEV subtype are 
low, especially in children.4  One fatal case has been 
reported: an 11-year-old boy who was operated on for a 
suspected appendicitis.5 Postexposure prophylaxis with 
hyperimmunoglobulin has been associated with an 
unfavorable course in a few pediatric patients.4, 6 A 
possible ADEI, which is supposed to be responsible for a 
serious course of Dengue fever after reinfection with 
another serotype,7 was put forward by the authors.6 This 
phenomenon was demonstrated in vitro for TBEV in 
mouse macrophages exposed to mouse monoclonal 
antibodies against TBEV and polyclonal antisera against 
six other flaviviruses.8 Subneutralizing concentrations of 
neutralizing antibodies were proposed to play a 
potentiating role in viral infection, either by virus-antibody 
complex binding via the Fc portion to cells bearing Fc- type  
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FIGURE 1. A: Haematoxylin and eosin stain 
showing patchy mononuclear inflammatory 
infiltrates in dentate nucleus (H&E x40). B: 
Multinodular aggregates of macrophages/ 
microglia in inferior olives of medulla 
oblongata (anti-CD68 x20). C: Anti-TBEV 
immunostaining reveals diffuse cytoplasmic 
labeling of single neurons in dentate nucleus 
(anti-TBEV x200). D: Abundant CD8-positive 
T-lymphocytes, some of them in direct 
contact with morphologically intact neurons in 
dentate nucleus (anti-CD8 x200). Inset, 
granzyme-B-releasing cytotoxic T cells in 
close contact with neurons (antigranzyme-B 
x600).  
 
receptors (macrophages, monocytes, B-cells, neutrophils 
and granulocytes) or by binding to complement receptor 
type 3 (CR3).7 
In vivo, however, ADEI could not be demonstrated in a 
mouse infection model, although the same antibodies 
enhanced the infection of macrophages.9  
Epidemiologically, the large number of fully or only partially 
vaccinated children and adults in Austria, together with the 
nonexistence of severe or lethal TBE cases after active 
immunization, contradicts a possible ADEI. 1, 10 However, 
ADEI cannot be excluded completely in our patient due to 
the possibility of a low concentration of neutralizing 
antibodies in the time period between the tick bite and 
shortly after the second vaccination. 
During the course of active immunization against 
TBEV vaccine should be withheld for up to four weeks 
after a known tick bite, as the incubation period for TBE 
lasts up to 30 days. To be well protected a vaccine series 
with at least two doses should be completed before the 
spring season.  
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5.3 BRIEF SUMMARY OF ALL STUDIES OF THIS THESIS 
 Study Aim Main results 
3.1 To explore further the association between use beta-blockers and 
other antihypertensives and the risk of a first-time psoriasis diagnosis 
because the current knowledge is based on weak data (as for lithium) 
- Adjusted OR for current use of ≥20 prescriptions for beta-blockers 1.10 
(95% CI 1.01-1.20); no increasing risk with duration of use.  
- Risk estimates for the other antihypertensives also close to one 
- No increased psoriasis risk due to cardiovascular diseases/risk factors  
3.2 To explore further the association between use of lithium and 
antipsychotics and the risk of a first-time psoriasis diagnosis  
- Adjusted OR for current use of 5 prescriptions for lithium 1.68 (95% 
CI 1.18-2.39) and for olanzapine 0.50 (95% CI 0.28-0.89) 
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3.3 To evaluate the association between use of thiazolidinediones and 
other oral antidiabetics and the risk of a first-time psoriasis diagnosis 
- Adjusted OR for current use of 5 prescriptions for thiazolidinediones 
and 15 prescriptions for metformin 0.33 (95% CI 0.16-0.66) and 0.77 
(95% CI 0.62-0.96), respectively 
- Prevalence of diabetes not increased in patients before the first-time 
psoriasis diagnosis 
3.4 To elucidate further the association between psoriasis and the risk of 
new-onset diabetes mellitus 
- Incidence rate of diabetes in patients with psoriasis 4.06 (95% CI 3.75-
4.39); about 35% higher than in patients without psoriasis  
- Diabetes risk highest in patients receiving oral treatment and with a 
long-term psoriasis history; independent of BMI 
3.5 To investigate the reported association between psoriasis and 
myocardial infarction (MI), stroke, or transient ischaemic attack (TIA) 
using primary care data from the UK and applying a slightly different 
study design than the earlier reports 
- Overall IRs of MI, stroke, and TIA similar among patients with and 
without psoriasis 
- Increased risks in younger psoriasis patients (MI OR <60 years of age: 
1.66, 96% CI 1.03-2.66) and with severe disease   
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3.6 To further elucidate the association between psoriasis and the risk of 
developing cancer, and to provide baseline incidence rates (IR) of 
different types of cancer in psoriatic patients  
- Overall risk of incident cancer may be increased in patients with 
psoriasis (mainly lymphohaematopoietic (LC) and pancreatic cancers) 
- Overall cancer risk increased with duration of psoriasis (OR for 4 
years duration 1.50, 95% CI 1.30-1.74) and severity (OR for patients 
with systemic treatment 1.53, 95% CI 0.97-2.43; mostly for LC) 
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5.4 SUMMARY OF STUDIES ON THE ASSOCIATION PSORIASIS AND CANCER 
Study Design Data from Follow up from Increased cancer risk of: 
Lindegard B.86 
1986 
Cross-sectional; diagnoses at 
hospital discharge 
Population register Sweden NA Lung, Haematological 
Stern RS et al.120 
1988 
Cohort study: psoriasis patients with 
PUVA treatment; 
Comparison with expected rate 
from SEER* program 
Photochemotherapy follow up 
study 
Entry into cohort All noncutaneous, gastro-
intestinal tract, breast, central 
nervous system 
Lindelof B et al.220 
1990 
Cross-sectional; Comparison with 
expected cancer rate in Sweden 
Linkage: Swedish Psoriasis 
Association membership registry / 
Swedish Cancer registry 
NA Male breast, female kidney 
Olsen JH et al.119 
1992 
Follow up after hospital discharge; 
Comparison with expected rate in 
Denmark 
Linkage: National Hospital 
Discharge Register Denmark / 
Danish Cancer Registry 
From hospital 
discharge 
Nonmelanoma skin cancer, lung, 
larynx / pharynx, colon, kidney 
Bhate SM et al.218 
1993 
Cross-sectional case-control 
analysis 
General practitioner notes NA Skin cancer  
Stern RS et al.121 
1997 
See Stern RS et al. 1988 See Stern RS et al. 1988 See Stern RS et al. 
1988 
Thyroid, breast, central nervous 
system 
Frentz G et al.114 
1999 
See Olsen JH et al. 1992 See Olsen JH et al. 1992 See Olsen JH et al. 
1992 
All sites, nonmelanoma skin 
cancer, oral cavity, larynx / 
pharynx, colon, lung, connective 
tissue, mycosis fungoides 
Hannuksela-Svahn A 
et al.117 2000 
Follow up after hospital discharge; 
Comparison with expected rate in 
Finland 
Linkage: Finnish Hospital 
Discharge Register / Finnish 
Cancer Registry 
From hospital 
discharge 
All sites, nonmelanoma skin 
cancer, Hodgkin und non-
Hodgkin lymphoma, larynx, 
pancreas, lung, bronchus 
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Study Design Data from Follow up from Increase cancer risk of: 
Bofetta P et al.113  
2001 
Follow up after hospital discharge; 
Comparison with expected rate in 
Sweden 
Linkage: In-patient Register 
Sweden / Swedish Cancer 
Registry 
From hospital 
discharge 
All sites, oral cavity, oesophagus, 
liver, pancreas, lung, squamous 
cell carcinoma, breast, male 
genitals, bladder, kidney / pelvis, 
mycosis fungoides 
Margolis D et al.118 
2001 
Population-based controlled cohort 
study; psoriasis patients classified 
into mild or severe psoriasis 
according to treatment 
Medicaid database From point of time 
when patients classified 
for study group (e.g. 
severe psoriasis) 
All sites, lymphoproliferative 
cancers, nonmelanoma skin 
cancer, other cancers (in severe 
psoriasis patients) 
Gelfand JM et al.115 
2003 
Population-based controlled cohort 
study (patients age ≥65 years) 
General Practice Research 
Database 
Maximum of patient 
registration, practice 
up-to-standard, or 
psoriasis diagnosis 
date 
Lymphoma 
Gelfand JM et al.116 
2006 
Population-based controlled cohort 
study; psoriasis patients classified 
into mild or severe according to 
treatment 
General Practice Research 
Database 
Maximum of patient 
registration, practice 
up-to-standard, or 
psoriasis diagnosis 
date 
Lymphoma (mainly Hodgkin 
lymphoma and cutaneous T cell 
lymphoma) 
* SEER = Surveillance Epidemiology and End Results (US National Cancer Institute) 
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